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Abstract 
Lung cancer is the leading cause of cancer-related deaths in China, with over 690 000 lung cancer 
deaths estimated in 2018. The mortality has increased about five-fold from the mid-1970s to the 
2000s. Lung cancer low-dose computerized tomography (LDCT) screening in smokers was shown to 
improve survival in the US National Lung Screening Trial, and more recently in the European 
NELSON trial. However, although the predominant risk factor, smoking contributes to a lower 
fraction of lung cancers in China than in the UK and USA. Therefore, it is necessary to establish 
Chinese-specific screening strategies. There have been 23 associated programmes completed or still 
ongoing in China since the 1980s, mainly after 2000; and one has recently been planned. Generally, 
their entry criteria are not smoking-stringent. Most of the Chinese programmes have reported 
preliminary results only, which demonstrated a different high-risk subpopulation of lung cancer in 
China. Evidence concerning LDCT screening implementation is based on results of randomized 
controlled trials outside China. LDCT screening programmes combining tobacco control would 
produce more benefits. Population recruitment (e.g. risk-based selection), screening protocol, nodule 
management and cost-effectiveness are discussed in detail. In China, the high-risk subpopulation 
eligible for lung cancer screening has not as yet been confirmed, as all the risk parameters have not as 
yet been determined. Although evidence on best practice for implementation of lung cancer screening 
has been accumulating in other countries, further research in China is urgently required, as China is 
now facing a lung cancer epidemic. 
Key words: lung cancer; China; screening; recommendation; low-dose computerized tomography; 
risk factor; tobacco control; pulmonary nodule management. 
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Introduction 
Lung cancer has an extremely high incidence and mortality rate, thus it is recognised as a major 
public health problem all over the world, increasingly so in developing economies that have not 
heeded the dangers associated with smoking uptake. China, the most populous country in the world,  
has approximately 20% of the world population but has over one-third of the newly diagnosed lung 
cancer cases and lung cancer deaths worldwide, which were projected at over 774 000 and 690 000 in 
2018 by GLOBCAN1 (Table 1). Lung cancer is the most frequently diagnosed cancer in Chinese men 
and the second in Chinese women2. During 2000-2010, there was a slight but insignificant decrease in 
incidence rate in males of 0.2% per year, but an annually significant upward change of 0.9% in 
females2. The male-to-female incidence ratio decreased from 1.56 to 1.35 in the period of 1989-20083. 
Mortality had an increasing trend observed over the last decades, that is, 5.47/100 000 in the mid-
1970s, 17.27/100 000 in the early 1990s, and 30.83/100 000 in the 2000s2, 4. Since then, lung cancer 
became the leading cause of cancer-related deaths for both genders2 (Figure 1A).  
Attributable Risk Factors  
Internationally, smoking is considered to be the predominant risk factor for lung cancer. However, in 
China, the proportion of lung cancer cases attributable to smoking was  57.5% in males and 11.5% in 
females in 2013, respectively5, which is much lower than that reported in the United Kingdom (UK, 
85% in males and 80% in females in 2010)6 and the United States (US, 84.4% in males and 78.9% in 
females in 2014)7. Lung cancer incidence among male and female non-smokers estimated from the 
2010 national data was over three times the 1990 US never-smokers8. The attributable fraction of lung 
cancer cases and deaths to smoking are similar5, 7. Therefore, other risk factors, including outdoor as 
well as indoor air pollution (i.e. second-hand smoking exposure), prior lung diseases (i.e. tuberculosis 
infection, COPD), family history of cancer are considered to have a more important role in China, 
especially in never-smokers, than other regions or populations6, 7, 9.  
Second-hand smoking exposure was estimated to contribute to 3.0% of male and 22.0% of female 
lung cancers in never-smokers aged ≥ 30 years in China (2013)5. The attributable fraction of lung 
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cancer cases in Chinese never-smoking females is much higher than their counterparts in the UK 
(15.4% in all ages in 2010)6 and the US (2.3% in ages ≥ 30 years in 2014)7; similarly, lung cancer 
deaths5, 7.  
Use of coal for household heating and cooking - another component of indoor air pollution - is also a 
significant risk factor in China9. The lung cancer mortality in Xuanwei County, Yunnan Province, 
ranking among the highest in China is the best example: 2-3 times and 4-7 times higher in local men 
and women residents, respectively, than other contemporary rural areas (in the early 1990s, mid-
2000s and early 2010s)10. Using smoky coal and unimproved domestic stoves is the main reason10. 
Outdoor air pollution (i.e. particulate matter [PM]) becomes increasingly significant in China11, with a 
lung cancer risk ratio of 1.03, 1.04 and 1.03 per 10 µg/m3 in relation to PM2.5, SO2 and nitrogen 
oxides, respectively11, 12. Occupational history (i.e. construction)13, radiation (i.e. residential radon 
radiation)9 and unhealthy diet (i.e. low fruit/vegetable intake)5 also have a significant influence on 
lung cancer risk or death in China.    
Recent data has demonstrated that genetic factors modulate cancer pathogenesis. Genome-wide 
association analysis has revealed susceptibility loci for lung cancer, e.g. the 15q25 14, 15 or 5p15 16, 17 
locus yet with different profiles of genetic variants between Chinese and Caucasians. Evidence also 
shows significant gene-smoking interactions in lung cancer, e.g. rs1316298 and rs4589502 in the 
Chinese population, which may shed light on the lung cancer aetiology18. Investigations into familial 
lung cancers have indicated a number of predisposing germline mutations, e.g. EGFR T790M (mostly 
Caucasians), EGFR V843I and HER2 G660D (East Asians)19.  Furthermore, somatic mutation 
profiles have differed between lung cancer subgroups in terms of smoking status, ethnicity and 
histological subtypes20-22; e.g. EGFR mutations are more likely present in non-smokers (vs smokers: 
67.2% vs 27.0% in Chinese non-small cell lung cancers [NSCLCs])20, East Asians (vs other 
ethnicities: 30% vs 8%)21, 22 and lung adenocarcinomas (vs squamous cell cancer: 40.4% vs 2.5% in 
smoking lung cancers in China)20.  These results demonstrate that lung cancer is not a single disease20, 
23. The nature of lung cancer in China is therefore not only attributable to environmental factors but 
further complicated with genetic influences. 
 5 
 
Tobacco Use  
Epidemiology 
China is the largest tobacco producer and consumer in the world.  It manufactured over 2.9 million 
tons of tobacco in the year 201624, 25. There was estimated to be over 300 million current smokers 
aged ≥15 in China including 288.1 million males and 12.6 million females in the 2010 Global Adult 
Tobacco Survey (GATS)26.  
In the China Health and Nutrition Surveys during 1991 - 2011, the prevalence of current smoking in 
individuals aged ≥15 has reported a successively decline from 60.6% to 51.6% in males and 4.0 to 
2.9% in females27(Figure 1A). However, the ever-smoking prevalence in both genders did not alter 
greatly during that time27. Specifically, females’ smoking uptake rate decreased in generations who 
were born during the 1930s - 1970s28, but increased in the younger generations born in the 1980s and 
thereafter29. The prevalence of smoking in females aged 12-17 during 1981-2010 multiplied from 
2.47% to 19.72% for ever-smokers and from 0.29% to 3.26% for current smokers29. Collapse of 
“cultural prohibitions against smoking among young women” due to socio-economic and political 
changes29 (i.e. probably reform and opening up in China since 1978) might be responsible for the 
uptake increase in Chinese young women, which was similarly witnessed in the US and UK during 
and after World War II30 (Figure S1). Overall, the current smoking prevalence in both genders has 
slightly declined over the last 20 years27; however, a slight increase in the younger female subgroup 
has been reported29. Given China as the most populated country in the world, the number of smokers 
is strikingly high.   
In contrast, the UK and the US observed a very different trend from China in smoking prevalence 
(Figure 1B, 1C). In the UK, the tobacco-uptake rate peaked at 82% in 1948 among males and 45% in 
the mid-1960s among females, respectively31, 32. However, it saw a continuous decline in both men 
and women in the following decades32 (Figure 1B). In 2017, the UK now has an overall current 
smoking prevalence of 15.1%33, which is among the lowest prevalence rates in Europe34; although 
there are still significant gaps in smoking uptakes in specific regions within the UK (e.g. 22.0% in 
Manchester vs 6.4% in Chiltern located in South West England in 2017)33, which is closely related to 
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deprivation status35. The smoking trend in the US36, 37 is very similar to the UK (Figure 1C). One has 
to be cautious when comparing these data, as differing definitions for smoking rates and statistical 
methods have been used in reporting smoking cessation rates in different countries. 
Smoking-related mortality  
It is perceived that there would be a long delay between the peak of smoking prevalence and its full 
impact on mortality.  Cigarette epidemiology was first described by Lopez et al. as a four-stage model 
in 199438(Figure 1D). The model precisely described the relationship between smoking and smoking-
related deaths in males and females in economically developed countries, such as the UK and the US. 
It was largely reflected in the interaction between smoking and lung cancer mortality since smoking 
was attributed to over 80% of lung cancer deaths in these countries7, 39. Both countries may be 
currently experiencing the fourth stage when smoking prevalence in both genders decreased in recent 
years yet with their mortality converging38 (Figure 1B, 1C).      
As for China, the situation seems more complicated. The earliest nationally representative prevalence 
survey on smoking in China was in 1984, only a little over 30 years ago (Figure S1-S2)40, while there 
are over 60 years of records in the UK 31, 32 and US 36, 37. China has made great efforts to move 
forward in cancer surveillance, especially after 2002 when National Central Cancer Registration 
(NCCR) was launched41, 42. It has witnessed a surge in the number of both cancer registration points in 
total and those included in the reports of Cancer Incidence in Five Continents (CI5), the latter taken as 
an indicator of data quality41. The latest version of CI5 (CI5 Vol. XI) released in 2017, has included 
data from 35 points collected during 2008-2012, almost three times the previous version, indicating a 
significant improvement in data quality (Figure S2) 41, 43. However, concerns arise regarding the 
population coverage by cancer registry, data quality control and data representativeness, etc.41, 42. 
Cancer registries providing data with good quality are more established in eastern, developed and 
urban areas 2, 44, which compromises data representativeness nationally41, 42. Most of the rural cancer 
registries are established in high-risk regions of cancer 41, 45 and have a lower level of population 
coverage 41. Furthermore, the overall cancer mortality estimated from rural cancer registries was 13% 
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higher than the estimate of the third National Death Survey, indicating overestimation; the difference 
was even more significant in some specific cancer types45.  
Substantial healthcare disparities exist across China, as indirectly evidenced by geographical 
variations in all cancer mortality and its 5-year survival in 2015: the estimates for rural areas were 
considerably worse than the urban (149.0 vs 109.5 per 100 000 [age-standardised by world 
population] and 30.3% vs 42.8%, respectively); similarly Southwest China was worse than  East 
China (170.2 vs 115.6 per 100 000, and 24.9% vs 40.3%, respectively)2. In contrast to the urban, the 
rural population more likely underutilise healthcare resources (e.g. less likely to choose self-care, 
outpatient and inpatient care vs no care) due to inferior health insurance coverage and reimbursement 
procedures associating with the two-class social insurance system 46.  Unbalanced health service 
supply 46 and a lack of qualified primary healthcare providers 47 impede rural individuals’ equitable 
access to healthcare46 and induce a high rate of misdiagnosis and/or inappropriate treatment thus poor 
management of chronic diseases47.  Factors, which potentially increase financial risks are also non-
negligible46, e.g. travelling distance46 and low annual household income (rural vs urban: US$2587 vs 
US$4761 on average in 2011) 48. Western and central China have experienced similar healthcare 
inequalities, where the economy is less developed than eastern China 48. Encouragingly, the gaps 
between regions has been shrinking since continuous efforts made in healthcare reforms by the 
government46, 48, 49.  
Thus, cautions can never be overemphasized in data interpretation due to its potentially poor 
representation of what the rural and underdeveloped areas are currently experiencing. From current 
data, China is most likely experiencing the ‘third stage’ of the four-stage model at this time50. In Stage 
III, males’ smoking prevalence starts to decline; while females’ could rise first, due to a resurgence of 
uptake in the younger generation29 and peak at a later time. Both genders would have a continuous 
increase in mortality in Stage III38. It’s worth noting that the smoking patterns are changing in 
younger generations, regarding an earlier age of initiation (e.g. before 20 years old) and consuming 
more cigarettes daily28. Moreover, the attributable fraction of smoking has probably not reached its 
full impact to date 30, considering the lower smoking attributable fraction to lung cancer in China5.  
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Hence, one is more likely to witness severe health consequences in China in the upcoming decades. 
However, these are only assumptions based on limited data, and the exact time smoking and mortality 
in both genders will peak or decrease is not yet defined (this information can only be revealed from 
national tobacco surveys/cancer registries in future years).  
Social changes and historical events are also responsible for these different trends of smoking and 
mortality between China and the UK & US (Figure S1), and these differences continue even today. 
Interventions have been encouraged to reduce the growth in tobacco consumption and risk of death 
from tobacco-related diseases.   
Interventions for Lung Cancer  
More than one-half of lung cancer cases were diagnosed at a very late stage throughout these years, as 
evidenced by the retrospective data from West China Hospital51 and the US national cancer registries’ 
statistics52. These late-stage lung cancer patients have a minimal chance of a successful therapeutic 
intervention, thus resulting in an inferior prognosis. The 5-year survival rate in this subgroup is only 
5% in the US52 or well below 5% in the UK53. It is now agreed that one requires an integrated 
programme of tobacco control with earlier detection through low-dose computerised tomography 
(LDCT) screening, which would facilitate an improvement in lung cancer survival.   
Tobacco control  
The protective effect of smoking cessation increases with the quitting duration in ex-smokers who 
stopped smoking either by choice (while still healthy) or due to illness28, 54, 55. However, the mortality 
risk is still somewhat higher than never-smokers28, 54, 55. Quitting before the age of 40 years would 
avoid over 90% of the excess deaths due to regular smoking54, 55; and adults who had quit smoking 
early enough would gain ten extra years of life expectancy compared with those who continued to 
smoke55.  
In 2005, China ratified the World Health Organisation Framework Convention on Tobacco Control 
(WHO FCTC)56. The framework aims to reduce tobacco use among countries worldwide. It has six 
elemental compositions called MPOWER, including Monitoring, smoke-free Policies, Offer help to 
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cessation, health Warnings, Enforcing advertising bans and Raising taxes56. The enforcement of these 
measures in China is still weak, compared to the UK, who has adopted comprehensive MPOWER 
measures at a best-practice level56. The major obstacle remains the state-owned tobacco industry40, 50. 
The state tobacco monopoly in China is in charge of both tobacco manufacturing and selling, and 
tobacco control in the WHO FCTC40.  “The tipping point” was a documentary by the Party School in 
2013, which discussed the historical and philosophical perspectives on tobacco and tobacco control in 
China, including conflicting interests of the Chinese tobacco monopoly40. Since then, tobacco control 
initiatives have been conducted one after another including the tax readjustment in 201540 (Figure 
S1). Although the percentage of tax in the retail price (56%) is still lower than the WHO’s 
recommendation of at least 70%57, some early positive impacts have been reported in 201858. 
Cigarette sales have dropped from 127 billion packs in 2014 to 117 billion in 2016; and a decline of 
0.2%-0.6% estimated in adults’ smoking prevalence during this period, i.e. 2.2-6.5 million fewer 
smokers, could be related to the increased cigarette prices58. China is moving forward in tobacco 
control albeit slowly. It is crucial for China to take further action in comprehensive legislation, 
taxation, education and tackling the current dual identity of the state tobacco monopoly40.  
Lung cancer screening outside China 
A number of lung cancer screening trials were undertaken since the 1980s, but none of them showed 
mortality reductions by utilising chest X-rays (CXR) with/without sputum cytology59, 60. However, 
LDCT was found to be more sensitive than CXR in detecting lung cancers in observational studies59, 
61 and also potentially improve survival by detecting lung cancer at an early stage, i.e. in ELCAP 61 
(later in I-ELCAP as well 62). After that, lung cancer screening trials, mainly randomised controlled 
trials (RCTs), have been undertaken in the US (NLST)63, Europe (eight RCTs) 64-71 and lately in Japan 
(JECS) 72 to investigate benefits of screening by LDCT (Table S1).  
Briefly, NLST was the first RCT to report mortality reduction by LDCT screening. In 2011, it 
demonstrated a 20% reduction in lung cancer mortality and 6.7% reduction in all-cause mortality in 
the LDCT arm when compared with the CXR arm after a median follow-up of 6.5 years post 
randomisation63. Since then, multiple organisations in the US have approved annual screening for 
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high-risk individuals based on the NLST results73-77. Four European trials (DLCST, DANTE, 
ITALUNG and MILD) reported on mortality, despite not having sufficient study power to test this, 
and none of them demonstrated a protective role of LDCT concerning mortality reduction65-68 
However, NELSON, the only fully powered trial in Europe, reported at the WCLC 2018  a 26% 
decrease of lung cancer mortality in males and an even higher reduction in its smaller-sized 
population of females, which ranged from 39% to 61% depending on the length of follow-up of 8 to 
10 years64. 
Lung Cancer Screening in China 
We have searched four Chinese databases (China National Knowledge Infrastructure database 
[CNKI], Wanfang Data, Chongqing VIP database and Chinese Clinical Trial Registry Centre Library) 
and four English databases (PubMed, Embase, Web of Science Core Collection Library and Cochrane 
Library) as of September 10, 2018 from the earliest dates available. Other sources (e.g. references in 
reviews/articles, policies/news from government websites and personal communication with principal 
investigators) were also used (Supplementary). Generally, most of the publications concerning 
LDCT and/or CXR were retrospective cohorts (e.g. in a population undergoing regular physical 
examinations), case-control studies (e.g. comparison in the performance of LDCT versus CXR in 
selected populations) or cross-sectional studies (e.g. with one-time LDCT/CXR screening). Therefore, 
we only considered prospective cohorts and RCTs here. There have been 23 associated programmes 
completed or ongoing in China since the 1980s, the majority after 2000; and one has recently been 
planned (Figure 2, Table 2; Supplementary). 
Generally, studies in earlier times targeted occupational populations and applied CXR and/or sputum 
examination for lung cancer screening78-83. They mainly investigated the effectiveness of screening 
and lung cancer-associated risk factors (e.g. The Yunnan Tin Corporation [YTC] cohort 82 and the 
Kailuan cohort 83). Municipal or city-level screening programmes84-92 have been accumulating 
especially after the central government-led programmes (RuraCSP 93, 94 in 2009 and CanSPUC 95, 96 in 
2012). Most of the programmes referred above are pilot or feasibility studies to investigate the 
effectiveness of LDCT screening.  
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Some institutes have built collaborative relationships with international organisations (i.e. Zhuhai I-
ELCAP 97, Beijing I-ELCAP 98, NELCIN-B3 99), to help to clarify characteristics and to accumulate 
evidence of lung cancer screening in China. NELCIN-B3 99, a Netherlands-China collaborative, multi-
centre study, will focus on the three major diseases of the thorax – lung cancer, cardiovascular disease 
and chronic obstructive pulmonary disease – by using one-stop CT imaging technology in the context 
of LDCT screening. NELCIN-B3 would be expected to provide more evidence on the management of 
both nodules and other thoracic diseases99. 
Notably, the majority of the programmes are funded by central or local government, which is argued 
as unsustainable and unaffordable for a larger-scale programme in the long run92. The Guangzhou 
Financing demonstration project in planning will investigate the potential financing models which 
could be viable to cope with costs during the screening implementation92.  Charity foundations and 
supports of companies could also play a role in the financing (i.e. Guangzhou GMU-1stHosp 
programme 91, 92 and Qinghai SH-Renji programme 100, 101). The reader has to be aware of the 
limitations of the references to many of the Chinese CT screening programmes, which are only based 
on web pages or conference abstracts, thus one has to be cautious with the interpretation. 
To date the majority of the studies have only reported their preliminary results, suggesting possible 
benefits of LDCT in detecting early lung cancers. However, concerning high-risk definition, nodule 
management and mortality outcomes, evidence in China is quite limited at this time. There is a 
different risk profile for lung cancer in China, as indicated by the baseline/preliminary results from 
Beijing I-ELCAP 98, Tianjin CancerHosp 84, Shanghai CancerHosp cohort 86  and Shanghai 
ChestHosp RCT 87: females and non-smokers could have a lung cancer detection rate comparable to 
or even higher than males and smokers in China. Therefore, risk stratification based on exotic 
guidelines or entry criteria could result in a significant misdiagnosis in the Chinese population.  
Utilising microsimulation modelling, Sheehan et al.102 compared eligibility criteria of Centres for 
Medicare & Medicaid Services in 2015 (CMS 2015: ages 55-77 and smoking ≥30 pack-years, quitting 
≤15 years if former smokers) 77 and the 2015 China National lung cancer screening (CNS 2015: ages 
50-74 and smoking ≥20 pack-years, quitting ≤5 years if former smokers)103 in Chinese population if 
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annual LDCT screening was applied from 2016 to 2050. Applying CNS 2015 criteria would have a 
lower mortality reduction in males (6.30% vs 6.58%), but a higher one in females (2.79% vs 1.97%), 
namely 2.9% more lung cancers prevented when compared to CMS 2015 criteria. However, more 
screens would be needed when using CNS 2015 criteria (1.43 billion vs 998 billion if CMS 2015 
criteria applied)102. In a decision analysis way, Wang et al.104 simulated a cohort of 100,000 Chinese 
urban smokers aged 45-80 who would receive a one-off screening. They found there would be a lung 
cancer mortality reduction of 17.2% and 24.2% by LDCT screening when compared to CXR 
screening and no screening, respectively. In the LDCT screening scenario, there would be 9387 false 
diagnosis and seven deaths attributed to false diagnosis; in CXR screening, the number would be 2497 
and two, respectively. Lung cancer prevalence, LDCT sensitivity and proportion of early stage in lung 
cancers detected by LDCT would influence mortality reduction the most in the LDCT screening arm 
when compared to no screening104. These results demonstrate the possible benefit of mortality 
reduction in China and also the urgent necessity of better definition in high-risk eligible individuals.      
Many hospitals establish their independent programmes, but now need to collaborate to work to 
consensus protocols and data collection methods, to provide data which can be utilised throughout the 
whole of China. A good example of international collaboration is the European Position Statement on 
lung cancer screening 105, where a consensus approach throughout Europe has been agreed. Evidence 
specific to China is awaited as the majority of the programmes are still ongoing. It is essential to 
consider what other countries have done and combine with Chinese conditions; thus, we can better 
aim to curb lung cancer sufferings in this specific population in the long run.  
Integrating tobacco control into screening programmes  
It is considered that on-going lung cancer screening programmes would create a ‘teachable moment’ 
for the participating smokers, thereby motivating smoking cessation and maximising overall cancer 
prevention benefit, as had been introduced first and assessed in ELCAP in 2001106. Subsequently, a 
positive effect of the screening programmes per se on quitting107-109, and CT abnormality-dependent 
smoking cessation108, 110, 111 have been illustrated in other trials. Researchers also found consistently 
negative scans were not necessarily related to a lower rate of smoking abstinence or a higher 
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percentage of relapse112.  Quitting smoking has also been reported to benefit participants’ outcomes 
within the frame of lung cancer screening programmes, where the mortality reduction could be 
comparable to or even exceed that achieved by LDCT screening alone 113, even in late quitters who 
stopped smoking during follow-up after baseline scan114.  In 2018, a group of researchers launched a 
statement of the Smoking Cessation within the Context of Lung Cancer Screening (SCALE) 
collaboration in order to determine the optimal implementation strategy from this specific 
integration115.  
Planning for Lung Cancer Screening Programme 
High-quality medical research is necessary for prioritising health needs. Regarding real-world 
evidence, Sun et al.117 concluded a desperate lack of pragmatic clinical trials in China, in total, only 
amounted to 16, of which nine were on traditional Chinese medicine and most featured moderate 
sample sizes and short follow-ups. Undoubtedly, more efforts are demanded on population-specified 
and highly reliable medical research in China. We reviewed current evidence on lung cancer LDCT 
screening both in and out of China and discussed them below in the hope of facilitating its 
implantation in the Chinese population.  
Population Recruitment 
Most of the lung screening trials (Table S2) applied combined recruitment strategies to enrol 
participants. The detailed information on recruitment yields has been reported in a limited number of 
the screening trials (i.e. NELSON, ITALUNG, LUSI and UKLS). The overall yield of participation in 
all the approached population ranged from 1.4% to 4.5%. All the four trials approached the population 
by mailing. The recruitment rate was mainly dependent on the recruitment methods (closely related to 
the response rate) as well as the stringency of the selection process (i.e. risk-based selection).  
Recruitment methods 
Current smoking stigma and deprivation are the common factors compromising uptake in a lung 
cancer screening trial118, 119. Younger individuals are less likely to respond to the first invitation 
approach118. Conversely, after assessing lung cancer risk and when approaching the eligible high-risk 
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cohort, older people are more likely refuse119.  Differences in risk perception can also impact 
participation119, 120.. Practical barriers including travel and comorbidities, along with emotional 
barriers, were the most reported reasons for non-uptake119.  
The minorities or underserved, who may be more vulnerable to morbidity and mortality121, 122, were 
underrepresented in the screening trials121. It would impede generability of lung cancer screening 
programmes. These people are more likely to be less-educated, economically disadvantaged, 
uninsured123 and also smokers122. The barriers to their participation include lack of awareness, lack of 
opportunity/access, individual beliefs123, economic obstacles and weakness in study designs124. 
Targeted strategies have been suggested for this subgroup123, 125, e.g. the more intensive face-to-face 
recruiting method123, 124. A second or third contact126, or using mobile CT scanners and one-stop lung 
health checks near local shopping centres127 were also demonstrated beneficial for uptake in deprived 
areas. Some tactics are probably helpful, including cooperation with community-based clinics or 
organisations who have built trust in local people, employment of coordinators who are proactive and 
knowledgeable in programmes, complimentary transportation assistance and personalized post-
screening navigation125. Current evidence on the efficacy and effectiveness of recruitment strategies 
are limited, mostly because recruitment targeting the underserved was issued in the midway of a 
study123, 128 and data collection on recruitment methods were incomplete123, 128, 129. It suggested a 
considerate preparation of trial design, population approach and cost estimation be needed. 
Additionally, reporting the nature and effectiveness of recruitment strategies in screening trials is an 
essential requirement, as it is useful for later evaluation and comparisons in different settings. 
Risk-based selection 
How to define the high-risk population remains unanswered. Most of the screening trials defined their 
entry criteria on a solo combination of age and smoking exposure (Table S2). Specifically, NELSON 
selected its participants based on lung cancer mortality risk estimated from 2 large-scale cohorts, US 
Cancer Prevention Study I and II (CPS I/II)130. UKLS and PanCan were the only RCT and cohort, 
respectively, to apply a risk model for such a selection. However, as for Chinese screening studies, 
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other risk factors (e.g. passive smoking, occupation, family history of cancer, kitchen fume, et al.), 
parallel to smoking exposure, were also considered in entry criteria (Table 2). 
 Age  
The age eligibility in screening trials varies greatly, with the lower limit between 40 and 60, and the 
upper ranged from 69 to no limit (Table S2). Whereas the median age of the enrolled participants in 
all studies was normally around 60 years, ranging from 56 to 67 years old (Table S3). A lower age 
limit is not necessarily associated with an accordingly lower median age in enrolees of the trials. 
Conversely, younger individuals are less likely to participate due to a lower affective risk 
perception118, or to be eligible because of a generally lower predicted risk if any prediction models 
were applied that included age131, 132. The lower cut-off point for age eligibility of at least 58 has been 
suggested by the UKLS researchers because the positive response rate in the high-risk population ≥58 
was much higher than those below this age (≥4.3% vs 1.0%)118.  
As for the upper age limit, discordance widely exist in recommendations73, 133: 74 in ACCP, ASCO, 
ATS74 , ACS76 and NCCN134 (all based on the NLST results),  74 in the CNS 2015/2018135 and 79 in 
AATS75 (based on the NLST results, age-specific incidence and life expectancy in the specific 
nations) and 80 in USPSTF73 (based on data modelling). USPSTF modelled data from NLST, PLCO, 
the Surveillance, Epidemiology, and End Results program (SEER) and the U.S. Smoking History 
Generator. They selected the most advantageous screening scenario by maximizing lung cancer 
mortality reduction and reducing over-diagnosis as much as possible73, 136.  
However, it is widely presumed that older individuals would be not eligible for inclusion due to their 
existing comorbidities. In this subpopulation, harm from screening might outweigh the benefits, but 
this can be difficult to measure due to the competing causes of death. In another microsimulation 
modelling, Han et al.133 incorporated over-diagnosis into the outcome measures (including lung 
cancer deaths prevented and life-year gained due to screening). They found that stopping screening at 
a younger age of 75 would have higher efficiency in maximizing the benefits (mainly life-years 
gained per over-diagnosed case) than at 80, and there was no gender difference.  
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In a trend analysis of national cancer registries-based lung cancers in China during 1989-2008, the 
average age in male and female patients significantly increased from 65.32 to 67.87, and from 65.14 
to 68.05, respectively3. The change may be explained by our ageing population with time3. However, 
In West China Hospital, the average age at diagnosis in hospital-based lung cancer cases was 59.22 
during 2008-201451. The difference might be attributed to data sources, geographical factors et al. 
Therefore, it’s better for us to comprehensively consider age- and geographical-specific lung cancer 
incidence, participation rate and also benefit-to-harm ratios before determining the age at entry.  
Smoking status 
Smoking is the other basic entry criteria after age. Heavy current and former smokers are the targets 
in most of the trials, except the Asian studies (Table 2 and S2). JECS in Japan only targets non- or 
light smokers. The Chinese ones (e.g. Shanghai Cancer Hosp cohort 86, Shanghai Chest Hosp RCT 87 
and China FeasiRCT  137, 138) also recruited individuals exposed to other risk factors, not restricted to 
heavy current/former smokers only. Although PanCan and UKLS used a risk model for high-risk 
assessment and recruitment, the final studies included participants who were practically all ex- or 
current smokers (Table S3).  
There are two types of smoking exposure criteria in the trials: cumulative pack-years, or smoking 
duration and intensity (average number of cigarettes per day), separately (Table S2). In the LLP 
model used by UKLS as a selection tool, smoking duration was demonstrated as the strongest 
predictor instead of other smoking-related factors, e.g. smoking status, intensity and time since 
quitting139, 140. While ten Haaf et al.141 concluded little difference between the two criteria in the 
aspect of cost-effectiveness in their microsimulation modelling; the scenario with stringent smoking 
criteria, annual screening for persons aged 55-75 who smoked >40 pack-years and who currently or 
quit ≤ 10 years ago, were optimal141.  
Most of the Western World trials and nearly all the screening guidelines concentrated on the smoking 
subpopulation. Additionally, both Ten Haaf et al.142 and Tammemagi et al.143 demonstrated most 
never-smokers wouldn’t benefit from lung cancer screening; notably, the two studies were based on a 
US dataset. Since there are different smoking profiles in lung cancer patients from the US and China 
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as discussed above, whether Chinese never-smokers could gain more significant benefits than harm, 
from early screening, is still unknown. Given other predisposing factors, it may indicate totally 
distinct entry criteria for lung cancer screening in China. This is somewhat evidenced by the baseline 
results from Shanghai Chest Hosp RCT 87 and Shanghai Cancer Hosp cohort86, which had a less 
stringent smoking eligibility criteria86, 87. The former had a similar prevalence rate of lung cancer 
between the NLST-ineligible males (1.1%) and females (1.4%) in the LDCT arm87, which was 
comparable to NLST (1.0%) 144. In the latter, the incidence in never-smokers was two-fold that of 
smokers at baseline screening 86(Table 2, Table S3). Some lessons could be learned by comparison 
with other Asian studies, where never-smoker lung cancer incidence is more comparable to China. 
However, this is difficult because of limited data.  
Thus favourably, a pre-evaluation of lung cancer risk in the local population, and pre-estimation of 
cost-effectiveness for different scenarios of screening criteria in the setting of the corresponding 
economic structure would assist in the selection of the optimal eligibility criteria. Moreover, 
establishing a specifically optimised Chinese risk model would preferably simplify recruitment in 
China and could lead to a more effective screening program on the basis of an individual’s risk. 
Modelling for risk prediction in the population outside China 
Many publications have implied the outperformance of risk models in improving screening 
effectiveness and efficiency over current eligibility criteria, used in the trials or recommended in 
guidelines143, 145-149. UKLS and PanCan applied risk models (the LLP model and PanCan model, 
respectively) in selecting high-risk individuals for eligibility entry. The high-risk cut-off threshold 
was defined as the risk estimation of LLPv2 risk model ≥ 5% in 5 years in UKLS122, 132, and PanCan 
model (a prototype of PLCOm2012) > 2% in 6 years in PanCan131. Generally, studies using models had 
a higher lung cancer detection rate 122, 131 and cost-effectiveness 122 than their counterparts (Table S2-
S3).   
There had been a large number of risk models established for predicting lung cancer risk150, 151. The 
predictors in the models varied a great deal, from the simplest combination of age and smoking to 
more complicated models (integrated medical conditions, medical history, ethnicity and socio-
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economic factors)150, 151. Although with good discrimination (and calibration) in development datasets, 
the performance of most models in external validation was generally limited150, 151.  
A few studies146, 147, 152, 153 assessed and compared different risk models in respect to discrimination, 
calibration and clinical utility. However, wide variations exist in their performances. In a UK case-
control dataset: Spitz and LLP were comparable in discrimination and positive/negative predictive 
values, both of which were better than Bach; LLP showed a better sensitivity but lower specificity 
than Spitz and Bach152. Ten Haaf, et al.146 demonstrated that PLCOm2012, Bach and the Two-Stage 
Clonal Expansion (TSCE) incidence model had the best overall performance with an AUC of 0.68-
0.71 in NLST and 0.74-0.79 in PLCO for 6-year lung cancer incidence, superior to the other models 
(including LLP, Knoke and two versions of the TSCE model for lung cancer death). Katki, et al.153 
arrived at the conclusion that PLCOm2012, Bach, the Lung Cancer Risk Assessment Tool (LCRAT) and 
the Lung Cancer Death Risk Assessment Tool (LCDRAT) outperformed the other five models, 
including Spitz, LLP, the LLP incidence (LLPi) Risk model, Hoggart and the Pittsburgh Predictor, in 
three US population-based datasets. However, in a German cohort, Li et al.147 demonstrated only a 
modest superiority of PLCOm2012 over Bach and LLP in selecting high-risk population for screening. 
On reflection, there may be a number of reasons for the varied performance. Firstly, some models, 
e.g. LLP and Spitz, were derived from case-control datasets, while others, e.g. PLCOm2012, Bach and 
TSCE, were from cohorts150, 153. Risk models developed from case-control datasets may lack 
generalizability in the population due to selection bias in cases and controls; they may also have the 
bias in risk estimations because recall bias exists in data collection153. Secondly, all the models were 
derived from a specific ethnicity or region. This population-dependent feature would impair their 
performance in populations from other ethnicities and regions, e.g. PLCOm2012 under-rated lung cancer 
risk in Hispanics153. Thirdly, some risk factors may be unavailable in another independent dataset, 
which may weaken the prediction. However, the impact may be limited. Ten Haaf and colleagues146 
found that full version and simplified version (only including age, gender and smoking) of risk 
models performed similarly, i.e. full PLCOm2012 and simplified PLCOm2012, full LLP and simplified 
LLP. It indicated that the three variables in simplified models contributed to lung cancer risk the most.  
 19 
 
Evidence of long-term benefits and harms, such as trade-offs between life-years gained, mortality 
reduction and over-diagnosis are limited. The optimal threshold for risk models, at which lung cancer 
screening programs or clinical practice should gain maximum benefits over harms, is still 
undetermined146, 150. Thus, no preferential risk model and risk threshold have been recommended in 
risk prediction for screening eligibility across different populations. The European position 
statement105 suggested that “either the PLCOm2012 or the LLPv2 would suffice if screening were to be 
implemented immediately” given their high level of prediction.  
There are emerging models integrating clinical factors, e.g. molecular biomarkers from blood, 
pulmonary function and genetic biomarkers (e.g. single-nucleotide polymorphisms), which potentially 
are alternative ways to improve risk models’ overall performance. Some of them are extensions of the 
original existing models, which have only epidemiological factors, but the improvement was found to 
be generally moderate150, 151. Specifically, the extended LLP model has been successively integrated 
with different SNPs twice, whose performance in discrimination increased from 0.72 to 0.75 154 and 
from 0.73 to 0.79155, respectively, when compared with the original epidemiological model. However, 
a modest enhancement in the performance of the risk models would still be significant and 
meaningful, since the ‘improvement space’ is limited. It is also important to note that genetic risk is 
already captured to some extent in the LLP risk model through the inclusion of personal and family 
cancer history. 
Risk models for participant selection in China  
In mainland China, four studies explored this topic156-159 (Table S4). Among them, three models had 
good discrimination (AUC: 0.7037-0.885)157-159. Specifically, Lin et al.157 constructed a model by 
using the first-degree pedigrees of patients and their spouses as cases and controls (633 proband 
pedigrees vs 565 spouse pedigrees). The higher the risk threshold was, the more accurate the 
prediction in clinical use: cut-off value <5, an accuracy of 68.3%; 5-10, 84.0%; ≥10, 91.9%. But no 
external validation was performed. Yang et al.159 developed a model from a retrospective cohort; 
when the risk probability was calculated at ≥ 0.65, the model’s sensitivity and specificity was 14.9% 
and 94.5% in the development dataset, 13.0% and 98.3% in the external validation dataset, 
 20 
 
respectively. The model built by Wang et al.158 performed well in the aspects of discrimination and 
clinical use, but it had no external validation either. All the four models were derived from hospital-
based data156-159, which potentially would introduce bias in data analysis. Further optimisation is 
desperately needed to produce new models. A prospective cohort to observe lung cancer incidence 
within a specific timeframe and validate the models is also worth consideration but may cause 
significant delay unless performed alongside CT screening, using the best current model. 
In the future, a comprehensive, systematic reporting standard in the development and validation of 
screening would be helpful for comparisons between models from similar or different backgrounds, 
enabling extensive validation of various models in a unified cross-border dataset. Undoubtedly, 
further research is important and should be an integral part of any screening programme. 
Screen protocols and related issues 
Screening interval 
There were only six screening trials which applied biennial LDCT screening in their intervention 
arms, including PanCan, NELSON (only once), MILD and the three Chinese trials (the China 
FeasiRCT 137, 138, the Shanghai ChestHosp RCT 87 and Tianjin CancerHosp programme 84). Others, 
except JECS with a 5-year screening interval, used annual screens for their enrolees (Table 2, Table 
S1). 
In NELSON160, there were an increasing number of interval cancers (5 vs 19 vs 28, respectively) and 
higher proportions of stage IIIB/IV in screen-detected lung cancers (6.8% vs 5.2% vs 17.3%, 
respectively) after a corresponding 1, 2 and 2.5-year interval160. These results indicated that an 
interval of 2.5 years is most likely too long for a population screening programme.  
No significant difference between annual and biennial screening in MILD has been found in respect to 
interval lung cancers, specificity, sensitivity and positive/negative predictive value161. Note that the 
population in MILD was much smaller than NELSON. In the UKLS modelling, annual screening 
would prevent more lung cancer deaths (956 vs 802), but induced more over-diagnosis (457 vs 383) 
and screening episodes (330,000 vs 180,000)162. By microsimulating NLST, the biennial screening 
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gained similar quality-adjusted life-years (QALYs) to the annual screening over 20 years (24,000 vs 
23,000); but the former was more cost-effective regarding both incremental cost-effectiveness ratios 
and CT scans saved163. Therefore, a 2-year interval might be a cost-effective alternative for screening. 
The risk of screen-detected lung cancer depended strongly on the results of the first scan: 1.0% with a 
baseline-negative scan, 5.7% with an indeterminate result and 48.3% with a positive result over a 5.5-
year follow-up164. When compared to individuals with a nodule at the baseline scan, those without 
would possess a much lower risk in 2 years (0.2% vs 4.6%)131. Thus, a tailored screen interval is 
needed. For such a low-risk probability, the subpopulation with a negative baseline result might be 
safely screened every two years or even a longer interval; other subpopulations with distinct baseline 
nodule results might be managed according to their specific risk probabilities. The risk probabilities of 
the individuals with nodules could be implied by the cut-off value of nodule risk prediction models 
(discussed below). Evidence from the Chinese studies is limited because the results of interval 
screening rounds are still awaited. 
Over-diagnosis  
Over-diagnosis is always a critical issue disputed in the context of screening. It is defined as the 
detection of a cancer that would not have been clinically apparent if there were no screening165. With 
over-diagnosis, unnecessary treatment, psychological problems and economic burdens would result165. 
An upper bound of about 18% - 25% of all the cancers detected in the LDCT screening were 
estimated indolent, thus probably over-diagnosed165, 166. The over-diagnosed lung cancers are more 
likely to be adenocarcinoma since it has a higher proportion in the LDCT arm than the control arm66, 
165 and also a longer volume doubling time (VDT) than other lung cancer subtypes 166. 
A contradictory indicator to over-diagnosis is stage shift. The primary aim of screening is to detect 
lung cancer at an earlier stage; thus we aim for a corresponding reduction in advanced lung cancers. It 
is therefore not expected that tumours detected might appear to be indolent. Over-diagnosis will be 
caused if there is no reduction in advanced lung cancers but only an accumulation of indolent cancers 
categorised into early stages65. Only NLST63 (Stage IV: 0.9% vs 1.3%) and DLCST65 (T4N3M1: 0.4% 
vs 1.0%) showed a significantly lower proportion of advanced lung cancers in the intervention arm 
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than the control arm. There was no evident stage shift in DANTE66 (stage IV: 2.1% vs 2.8%) and 
ITALUNG67 (stage IV: 1.7% vs 2.2%). The reasons could be the larger study size, differing approach 
methods used for NLST and DLCST or some degree of over-diagnosis existed in these trials.  
Additionally, the effects of over-diagnosis could be mixed with lead time. The latter is defined as “the 
difference between the time when diagnosis would have been made without screening and the time 
that the diagnosis was actually made as a result of early detection by screening”165. A longer follow-
up may be helpful to distinguish between over-diagnosis and lead time. There were a mean lead time 
of 3.6 years estimated for non-bronchioloalveolar carcinoma (BAC) NSCLCs and 32.1 years for 
BACs, to when they naturally become clinical significance without screening interventions. 
Specifically, over 25% of the non-BAC NSCLC cases would have a lead time of >5 years, and a very 
low proportion of 6.3% would exceed more than one decade. However, for BACs, 73.2% would have 
a lead time of ≥10 years, and approximately 50% would be over-diagnosed throughout the whole 
life165.  
In ITALUNG, the cumulative number of lung cancers in the usual care group caught up with the 
LDCT group after a follow-up of 6 - 7 years from randomisation67. However, in DANTE, after a 
median follow-up with 8.35 years since randomisation, there was still a lung cancer excess rate of 
30.76% in the LDCT arm compared with the usual care arm66. Apart from over-diagnosis, the 
difference in-between may also be explained by one more screening round in DANTE and the 
possibly different subtype distribution in the diagnosed lung cancers.  
The results above indicated that certain screening rounds accompanying a specific and long enough 
follow-up timeframe might minimise over-diagnosis. Moreover, over-diagnosis would be affected by 
the possibly different distribution of lung cancer subtypes in screening participants.  
Length of screening 
As discussed above, screening length is closely associated with over-diagnosis; comparing with the 
usual care group, the LDCT group managed with three annual screens would have an over-diagnosis 
rate of 31% within a complete 7-year follow-up after baseline165. Given the evidence from 
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ITALUNG67 and DANTE66 extended follow-ups (as above), it is better to estimate screening length, 
follow-up duration and corresponding over-diagnosis rate before a trial is started. 
When compared with the unscreened Beta-Carotene and Retinol Efficacy Trial (CARET) cohort, the 
mortality reduction due to two annual screening rounds in the New York ELCAP cohort became 
apparent in the 4th year and reached the maximum in the 6th-8th year after enrolment. The overall 
mortality reduction would be 36% when standardised by the CARET entry criteria167; the mortality 
would be reduced further if the screenings continued167. In the COSMOS pilot cohort of 1035 
individuals, a lung cancer mortality reduction of 31%-61% would be expected after seven years of 
annual screening when compared with the extrapolation from an age- and sex-matched unscreened 
CPS II smokers168. Despite a lack of statistical significance in mortality reduction after a 9-year 
follow-up in ITALUNG, the researchers found a significant mortality reduction in the post-screening 
period67. Therefore, extensions of screening and follow-ups could enhance mortality reduction. 
In summary, for planning the screening length of a trial or national programme, some factors to 
consider are: 1) the mortality reduction expected in screening population; 2) cost-effectiveness ; 3) 
limiting over-diagnosis; 4) minimising other potential harms, e.g. radiological exposure, 
psychological impact. 
Nodule management 
The nodule management protocols of most screening trials largely follow or are modified from the 
ELCAP/I-ELCAP (Table S5). Henschke and colleagues published the protocols consecutively in 
199961, 2004169, 2011170 and 2016171 when new evidence accumulated. When comparing the modified 
versions with the 1999 protocol, the significant changes are as follows: 1) nodule cut-off value 
increased; 2) volumetric analysis and VDT introduced to define growth; 3) management differed 
among solid, part-solid and nonsolid nodules; 4) non-solid nodules managed less aggressively; 5) 
management differed in baseline nodules and new nodules detected at intervals (the latter managed 
more aggressively); 6) endo-bronchial solid nodules also specified. 
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The NELSON protocol was derived from the 2004 I-ELCAP protocol172. It was the first lung cancer 
screening trial to use volumetry as a nodule assessment method. It developed two classification 
systems for nodules detected at either baseline or interval scans: NODCAT (nodule categories) and 
GROWCAT (growth categories). Generally, the solid component, either in solid or part-solid nodules, 
is measured in volume (mm3); while, the overall size of the part-solid, non-solid and pleural-based 
solid nodules are measured in diameter (mm). NODCAT is applied to all nodules detected on CT 
scans, assisting decision-making on follow-up; GROWCAT is applied when there are follow-up scans 
for assessing VDT or a new solid component growth in a nonsolid lesion172.  
The UKLS trial nodule management largely followed that of the NELSON. The main difference 
between UKLS and NELSON categories is that UKLS picked 15-49 mm3 nodules as a separate 
category to ensure the inclusion of  cancers in nodules <50mm3 to the largest degree in a single screen 
design173.  
A variety of guidelines about pulmonary nodule management have also emerged in different countries 
tailored to their own circumstances103, 135, 174-177. Specifically, several risk models for nodule 
malignancy prediction have been recommended in these guidelines: the Mayo Clinic model by the 
American College of Chest Physicians (ACCP)176 and the Fleischner Society178, or the Herder model 
and Brock model by the British Thoracic Society (BTS)175. As its guidelines are applicable to clinical 
practice, the Fleischner Society recommended adherence to the existing American College of 
Radiology Lung CT Screening Reporting and Data System (Lung-RADS) guidelines for lung cancer 
screening178.  
Associated guidelines have also been developed in Asia or China in the clinical174 or screening 
setting103, 135. Remarkably, evidence supporting these recommendations is predominantly from the 
Western countries. It is possible that they are inappropriate to the East whose features are distinct in 
demographic, geographic and genetic aspects, but unclear if this variation in the aetiology of lung 
cancer in the East is limited to the initiation of lung cancer, or extends to the biological features that 
influence nodule behaviour. In the absence of any large-scale LDCT trials in China and other Asian 
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countries, the slight modifications made in the Asian guidelines were basically from experts’ 
opinions103, 135, 174. Herein we discussed some crucial issues related to nodule management. 
Measurement: diameter or volumetry? 
There are several ways to evaluate nodule size in the screening trials: maximum axial diameter, the 
average of length and width, and three-dimensional (3D) volumetric computer-aid assessment179. 
Specifically, amongst all the screening trials, NELSON, MILD and UKLS used volumetric-based 
measurement for nodule assessment; others mostly followed a diameter-based protocol (e.g. NLST), 
with some applying a computer-aided system at follow-up scans for nodule growth and VDT 
assessment (e.g. DLCST, LUSI) (Table S5). 
Mean axial diameter (using the average of the long-axis diameter and that taken at right angles to it) 
for nodule risk assessment was first adopted in ELCAP61. The Fleischner Society statement in 2017179 
It commented that, due to substantial inter- and intra-observer variability, using the maximum 
dimension would lead to misclassification of nodules, especially in small nodules, thus resulting in a 
high false-positive rate179. Large variance of intra-nodular diameters also existed in indeterminate 
nodules; it could reach up to a median value of 2.8mm, higher than the growth threshold of 1.5mm 
recommended by LUNG-RADS180. Hence, nodule size represented by diameter is concluded as poor. 
Calculation of volumes based on the diameter was also used. However, compared with volume 
measured semi-automatically in a 3D software, a mean over-estimation of volume by 85.1% and 
47.2% could occur in volume calculation by the maximum and mean axial diameter, respectively180. 
Therefore, the European position statement105 and BTS 2015175 recommended volumetry as preferred 
assessment method.  
Cut-off values 
NLST defined ≥4mm as its threshold of positive results; while most of the others applied the cut-off 
value of ≥5mm (Table S5). With rising thresholds, the frequency of positive results and further work-
ups decreases successively, thus saving medical resources. Precisely, when increasing the threshold 
from 6mm to 9mm in I-ELCAP181, the screening-positive rate dropped from 10.2% to 4.0% and the 
work-up would be reduced from 63% to 25%. The disadvantage was the corresponding increased rate 
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of lung cancer diagnostics delayed up to 9 months from 0% to 6.7%. Similar results have been 
concluded in the NLST LDCT-arm dataset182, 183. The ≥6mm threshold has performed well in other 
aspects, including the avoidance of false positivity183, 184 and more positive predictive findings185, but 
it impaired the sensitivity185 when compared with the cut-off of ≥4mm. There was no statistically 
significant effect on survival or mortality in different nodule sizes183. Currently, the nodule-positive 
threshold of 6mm has been recommended by I-ELCAP (2016) 171, the Fleischner Society (2017)178 
and LUNG-RADS 186. BRELT1 also increased its threshold from the original 4mm to 6mm during the 
implementation187.   
The lung cancer probabilities in different nodule sizes at baseline are also an essential factor when 
determining the appropriate threshold. In NELSON, the risk increased with the volumes (or 
diameters) of baseline non-calcified nodules: a low risk of 0.6% (or 0.4%) in nodules of <100mm3 (or 
<5mm, respectively), comparable to those without nodules (0.4%); intermediate risk of 2.4% (1.3%) 
in 100-300mm3 (5-10mm); high risk of 16.9% (15.2%) in ≥300 mm3 (≥10mm)188. No additional CT 
scans or work-up are needed for low-risk nodules, while the high-risk should undergo diagnostic 
examination immediately.  For intermediate-risk nodules, they should be risk-stratified by VDTs and 
managed differently. The authors concluded that lung cancer risk increased with reduced VDTs: 0.7% 
for VDTs ≥600days, 4.0% for VDTs of 400-600 days, and 9.9% for those ≤400 days188. Therefore, the 
management strategies should be tailored to risk stratification accordingly, to detect the most lung 
cancers whilst limiting the required resources. 
The I-ELCAP researchers found non-solid nodules featuring a slow growth and a 100% curative rate 
by surgery189. In MILD, only 16.7% of the non-solid nodules progressed after a mean follow-up of 
over 55 months190. Annual follow-up for non-solid nodules of all sizes  (except those with a new solid 
component at following CT scans) has been recommended in the I-ELCAP protocols170, 171. The 
perifissural nodules have also been found as low malignancy191, 192. In PanCan, perifissural nodules 
have been excluded from its nodule positive definition 131.  
Another issue is concerning de novo nodules, which are first detected at interval scans. It is 
demonstrated that lung cancers derived from de novo nodules have more aggressive features and a 
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poorer prognosis than those diagnosed from baseline-positive nodules193. Lung cancer probabilities 
increased with the volumes (and diameters) of de novo nodules; in NELSON, the risk is 0.5% in 
nodules of <27 mm3 (3.7mm), 3.1% in 27-206 mm3 (3.7-8.2mm), and 16.9% in ≥206 mm3 (8.2mm)194. 
A cut-off value of ≥27 mm3 would achieve a sensitivity of 95.8% and specificity of 38.3% for lung 
cancer194. Therefore, new nodules at incidence rounds and those from the prevalence round should be 
managed separately. The 2011170 and 2016171 I-ELCAP protocols has suggested a diameter threshold 
of 3mm for these de novo nodules. Meanwhile, the European position statement recommended a cut-
off value of >30mm3.105 
Number of nodules   
Generally, the radiological features of the largest nodule detected on CT have been assessed in trials. 
In I-ELCAP and Mayo LDCT study, the number of nodules required to be recorded was up to 6; In 
UKLS, the number reached 20; and in NELSON, all non-calcified nodules are measured (Table S6).  
It is very frequent to find two or more nodules in lung cancer screening participants, about 48.5% in 
all NELSON baseline participants195. 97.0% of the malignancies were diagnosed in the largest nodule 
at baseline195. However, lung cancer probability in an individual is not necessarily associated with the 
nodule count at baseline: 3.6%, 4.1%, 4.8%, 6.3% and 3.3% in those with 1, 2, 3, 4 and >4 nodules, 
respectively. For this reason, assessing each nodule separately is suggested195.  
In short, nodule count does not necessarily indicate for a benign or malignant lesion, but the specific 
features of each nodule are important. 
Modelling for risk prediction of nodule malignancy outside China 
The aim of modelling is to reduce biopsy rate and increase malignant-to-benign ratio. BRELT1 is the 
only screening trial that used a risk model, namely The Mayo Clinic model, for malignancy prediction 
of pulmonary nodules (Table S5). The Mayo Clinic model was also the first one to be introduced for 
pre-test prediction by ACCP since 2007196. It was initially developed and internally validated in a 
retrospective unscreened cohort of 629 patients with indeterminate solitary pulmonary nodules on 
CXR (malignant rate: 23%)197. However, the model did not show superior performance in the baseline 
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biopsy rate and malignant-to-benign ratio in BRELT1 when compared to other trials187 (Table S3), 
indicating future efforts in optimising. 
The Brock model198 was derived from the PanCan prospective cohort (malignant rate: 5.5%) and 
externally validated in the British Columbia Cancer Agency (BCCA). Both datasets were in the CT 
screening context and included ever and never smokers. It displayed great discrimination of over 0.89 
in all settings and calibrated very well. Specifically, it could also perform well in individuals with 
nodules ≤ 10mm. The Herder model199 was modified from the Mayo Clinic model by integrating 
positron emission tomography (PET) results. It was developed from a hospital-based unscreened 
cohort of 106 patients with indeterminate solitary nodules from Netherlands (malignant rate: 57.5%), 
the same dataset that the Mayo Clinic model used for external validation. It improved the AUC by 
13.6% when compared with the Mayo Clinic model. When validated in a hospital-based unscreened 
cohort from UK, there was a similar performance of the Brock model (AUC 0.902) and the Mayo 
model (AUC 0.895) in predicting nodule malignancy, but a higher accuracy of the Herder model 
(AUC 0.916) than the other two models above in patients undergoing PET-CT200. Therefore in the 
2015 BTS guideline, the Brock model would be used for risk assessment in nodules ≥8mm or ≥300 
mm3, and the Herder model used following PET-CT if malignancy risk is ≥10% in the Brock 
model175.  
Additionally, the Brock model has shown its excellent performance in heterogeneous populations, 
including LDCT screening trials, e.g. NLST (AUC 0.963)201, DLCST (AUC 0.826–0.870)202, a LDCT 
screen-detected sub-solid nodule cohort from Australia (AUC 0.89)203 and a multicentre unscreened 
cohort from Netherlands (AUC ≥0.90)204. Nonetheless, it may be suboptimal in other aspects, such as 
differentiating invasive lesions from sub-solid lesions (AUC: 0.671 in non-solid, 0.746 in part-solid 
nodules in a Korean unscreened cohort)205. The Herder model also had a good discriminatory power 
of 0.757 in an Italian retrospective cohort206, albeit inferior to the value previously reported in its 
development and external validation datasets199. However, the Brock and the Herder model were 
derived from and confirmed only in post-hoc analysis (i.e. applied retrospectively in pulmonary 
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nodule data). Whether they could perform well within an ongoing LDCT screening trial, is still 
unknown.  
Modelling for risk prediction of nodule malignancy in China 
A great many risk models for predicting malignancy in nodules were developed in China (Table S4). 
All of them were constructed from hospital-based retrospective cohorts. Most do not specify 
calibration. The two models developed by Li et al., 2012207 and Yang et al., 2018159, respectively, 
have spatially external validation. The model built by Li et al.207, also called the Peking University 
People’s Hospital (PKUPH) model, discriminated quite well (AUC 0.810) when evaluated externally. 
At a risk threshold of 0.471, the sensitivity and specificity of the PKUPH model were 83.3% and 
75.9%, respectively. For the model established by Yang et al., the discriminatory power was very 
limited in the external validation dataset (AUC 0.584)159. Additionally, three other risk models 
focused on sub-solid nodules208, 209 or ground glass opacities210.  
Notably, almost all the development datasets had a very high malignancy prevalence (except the 
Brock model) 151, especially those in China (malignancy prevalence >50%)  (Table S4). It may be 
mainly because only participants undergoing surgical procedures or biopsies were eligible for the 
analysis. The accuracy of a model is likely to depend on the lung cancer prevalence in a target 
population. Hence, these derived models may not be well calibrated in other datasets with a different 
prevalence151. However, because the decisions for invasive management in these datasets were often 
combined with the clinical experiences of doctors, models from these datasets may be more useful in 
the real world clinical practice. Still, it is unclear how these Chinese models would perform when 
applied in LDCT screen-detected nodules and ongoing screening trials.  
Other Screening-related Issues  
Significant other findings 
It is believed that significant other findings on CT scans would maximise the benefits of screening 
programmes. 19.6% of the NLST population who were screened in LSS centres had potentially 
significant extra-pulmonary abnormalities after three screening rounds211. Some would bear 
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significant clinical implications and need further clinical assessment; this accounted for 1% of the 
NELSON baseline population212. Extra-thoracic cancers were diagnosed in 0.39% of the screened 
participants during the screening period in NLST, including kidney (0.26%), thyroid (0.08%) and 
liver (0.05%) cancers211. Once found, these clinically significant abnormalities could be managed 
immediately and systematically. In this case, the specific individual may benefit from the screening in 
a ‘by-product’ way, although dangers of over-diagnosis are relevant to incidental findings.  
Moreover, some conditions, e.g. idiopathic pulmonary fibrosis are rare in the general population, but 
highly lethal. It is impossible to implement an independent screening trial for this kind of disease, so 
detection within a cancer trial is valuable. In 884 smokers from the NLST, the prevalence of 
interstitial lung abnormalities (ILA) was 9.7%, with fibrotic accounting for 2.1% and non-fibrotic for 
5.9%. Among them, 37% of the fibrotic and 11% of non-fibrotic ILA progressed in a 2-year follow-
up214. This epidemiological and clinical information provided through the screening would allow us to 
optimise our current ILA management strategies.  
The benefits of incidental findings are not limited to rare diseases, detection of common ones such as 
cardiovascular diseases and emphysema can also be provided to assist clinical management, e.g. 
significant role of coronary artery calcium score in predicting all-cause mortality and cardiovascular 
events215, quantification of emphysema extent 216 and its potential implication on lower bone 
density217.  
However, regarding the cost-effectiveness of management for these extra findings in screening, the 
evidence is very limited. Given that some abnormalities in the context of screening might be clinically 
non-significant or indolent in nature, such as mediastinal masses218, it’s better for us to manage these 
findings distinctively according to their characteristics.      
Cost-effectiveness 
Cost-effectiveness analysis could be used to evaluate if one trial design is superior to another 
concerning value for money and also investigate impact factors attributable to cost-effectiveness 
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improvement. Generally, related measures in the health-economic analysis include costs, quality-
adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs).  
Comparing to no screening, LDCT screenings in NLST provided an additional 0.02 QALYs per 
person and a corresponding ICER of $81, 000 per QALY gained219. Although with similar QALYs 
gained per person, UKLS had a mean ICER of $12,106, much lower than NLST122. By comparing 
UKLS with NLST, researchers concluded some possible ways for cost-effectiveness improvement: 1) 
higher lung cancer prevalence in a target population; 2) lower unit costs for management; 3) more 
effective selection of the high-risk population recruited; 4) fewer screens arranged in protocols; and 5) 
more true-positive results throughout the protocol of nodule management122.  
Cressman et al.220 analysed the factors driving program efficiency by comparing different scenarios 
applied to the NLST datasets. They found mortality reductions had the greatest impact on cost-
effectiveness, followed by long-term improvements to the quality of life in lung cancer-free 
participants. Considering non-lung cancer outcomes in screening participants may be necessary in the 
cost-effectiveness analysis 220. Using the same NLST dataset, Kumar et al.221 stratified the participants 
into different deciles according to their pre-screening risk of lung cancer mortality. Although lung 
cancer deaths prevented per 10 000 person-year increased from the lowest to the highest risk deciles 
(extreme decile ratio: 7.9), the gradients across deciles were attenuated in the aspects of life-years, 
and QALYs gained (extreme decile ratio: 3.6 and 2.4, respectively). ICERs across risk strata were 
similar221. The conflicting results may be explained by comparable roles between lung cancer and 
other diseases in the high-risk groups since they are more likely to be older and have more 
comorbidities220, 221. Therefore, some scholars argued that all-cause mortality reduction should be the 
benchmark for cancer screening222.  However, to date, none of the CT screening trials really have 
sufficient power to provide all-cause mortality data. 
In a post-hoc analysis of NLST screening participants, Young et al.223 demonstrated that smokers with 
higher lung cancer risk predicted by the PLCOm2012 model would have a COPD prevalence and 
likelihood of non-lung cancer deaths in a linearly increasing fashion. Limiting those of intermediate 
risk (predicted by PLCOm2012) to screening eligibility would achieve a greater reduction in lung cancer 
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mortality compared with those of risks just over the cut-off value (28% vs 17%). Similar conclusions 
could be drawn from those with normal lung function or only mild-to-moderate COPD when 
comparing to those with severe or very severe COPD. Regarding lung cancer mortality reduction, it is 
better to exclude those with high risk and severe or very severe COPD who are presumed to negate 
the benefit from screening due to other competing causes of death and inoperability223. 
Smoking cessation may be a good alternative for cost-effectiveness improvement at the population 
level, as indicated in a previously US health-economic analysis224, but does not address earlier 
detection of lung cancers in those currently at high risk. 
In summary, cost-effectiveness varies widely in different settings. Short-term or long-term outcomes, 
and lung cancer per se or other health conditions, should be considered in the analysis. Overall 
mortality reduction may be more critical than lung cancer-specific mortality reduction in assessing the 
effectiveness of screening. Considerations should be taken when recruiting people who would 
potentially die from other causes, e.g. the effect of COPD in lung cancer screening223. Some 
interventions, such as smoking cessation, managing cardiovascular risk in advance and 
screening/clinical strategy optimisation, may be anticipated to improve cost-effectiveness in those 
screened. 
Psychological impact 
Four trials including NELSON, NLST, DLCST and UKLS had reported their results on psychological 
impacts. Generally, there was a temporarily increased lung cancer-specific distress in participants 
with a high affective risk perception225 or those with positive results122, 226; but, it dropped with a long-
term follow-up, e.g. 6 months225, 2 years226, or when individuals were reassured with a negative 
result227.   
The psychological impact is presumed to be screening result-dependent. Those with false-positive 
scans, significant incidental findings or negative scans in NLST had no significant increase in anxiety 
228. Participants with true-positive scans who developed lung cancer within 1 year had a higher 
anxiety and lower health-related quality of life at 1 and 6 months after screening in NLST228, but this 
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is to be expected (and anxiety is likely to be less than if the subjects were diagnosed later with a 
higher stage disease).  
There was no difference in psychological impact across the LDCT and CXR screening arms in 
NLST228. However in DLCST229, compared to the LDCT arm, the usual care arm experienced more 
negative psychological consequences229. These may be explained by the reassurance in those with 
normal screening results in the LDCT arm227, 229. 
In short, lung cancer screening would exert certain short-term, yet generally minimal long-term 
psychological harm on participants. The impacts are usually not severe225 or not to clinical levels226. 
However, special attention should be paid to those with positive scans and help should be provided if 
necessary after regular psychological assessment. Those who do not receive the reassurance of an 
early diagnosis or a negative LDCT scan (e.g. those randomised to usual care in a trial, or unable to 
have a screening scan) may also need help. 
Radiation exposure 
New CT scanners have a much lower level of radiation, e.g. in NLST, the effective dose was 
estimated at about 2mSv for LDCT but 8mSv for full-dose chest CT230.  However, extra radiation 
exposure associated with screening is still a concern230. It is estimated that if a person aged 55 was 
followed up according to the Fleischner guidelines over 20-30 years (3 full-dose CT follow-ups over 
two years if nodules >4mm), he would experience a cumulative radiation dose of 280-420 mSv, a 
dose exceeding that of nuclear workers and atomic bomb survivors230. As a result, lung cancer risk 
would increase230. A male and female smoker would observe an increase of lung cancer risk induced 
by radiation about 0.23% and 0.85%, respectively, if he or she undergoes annual LDCT screening 
from 50 years-old until 75231.  
In ITALUNG, when assuming a lung cancer-specific mortality reduction of 20%-30% in current 
smokers, the potential fatal cancers associated with radiation exposure were 10 -100 times lower than 
the expected lives saved by screening in number, indicating a favourable benefit over the risk232. 
However, never or former smokers would benefit less in the same scenarios than current smokers232. 
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In a secondary analysis of the COSMOS data, lung cancers and major cancers induced by ten years of 
LDCT screening were 1.5 and 2.4 in number, respectively. The additional risk of induced cancer was 
extremely low, namely one induced major cancer for every 108 screen-detected lung cancers233. 
Therefore, we could expect a very low and acceptable risk of cancers induced by LDCT screening per 
se232, 233, but cancers would occur if screening is conducted long enough230. Protocols for screening 
should be optimised to attenuate the possible increased cancer risk by modifying the screening 
frequency and age range in line with individualised lung cancer risks and emerging evidence on 
screening-induced cancers. A mortality reduction considerably over 5% 231 is required to outweigh the 
radiation-induced cancer risk, and this should be estimated before screening is conducted, especially 
for individuals aged <50 years234.    
Recommendations on Chinese Lung Cancer Screening Programmes 
Herein, we reproduced the figure from Field’s review235 to conclude current evidence status in China 
(Figure 3). Most of the evidence in the 12 aspects are from outside China, thus requiring further 
research in the context of China taking population CT screening forward. We note several issues 
which require caution or further investigation and give our recommendations (Table 3).  
Participation - recruitment of hard-to-reach  
There are substantially health and healthcare disparities across different regions of China. The 
underserved are more likely to suffer from morbidities and mortalities, yet less likely to participate in 
the screening programmes. Some targeted recruitment methods have been suggested as efficient 
currently. In China, most of the programmes have targeted urban areas which are possibly featured 
with higher socio-economics. The Guangzhou GMU-1stHosp programme focused on underprivileged 
individuals, yet with low uptakes due to low awareness of preventive health care among the targeted 
population 91.  
In China, people have free access to any hospital, which leads to ‘medical migration’236. Selection 
bias and more dropout could be anticipated when recruiting participants based on hospital catchment 
areas as these are not fixed and people ‘migrate’. Community-based enrolment may be a favourable 
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alternative for lung cancer screening, by which people could be organised as a whole more 
effectively.  
A significant number of the lung cancer screening programmes in China only have references, which 
are based on web pages or conference abstracts, thus the detailed protocols and results are 
unavailable. In order to harmonise the CT screening programmes in China, it would be beneficial to 
facilitate cooperation between the lung cancer screening groups, which would increase awareness and 
also provide consistency, governance control and transparency of all the programmes. 
Risk-based selection  
Risk-based selection is presumed to focus on individuals who are most likely to be at higher risk of 
developing lung cancer and minimise unnecessary scans in the low-risk population, thus more likely 
to be cost-effective. However, such high-risk populations are also more likely to be older and suffer 
from non-lung cancer deaths, thus questioning the net benefits237. The high-risk profile for lung cancer 
screening is still undetermined in China. The proportion of lung cancers attributed to smoking is much 
lower in China than the UK & US. Other risk factors may play more critical roles in lung cancer 
incidence in China. The preliminary results of various programmes in China indicated a different risk 
profile from US and European countries.  
Risk models play a crucial role in lung cancer prediction in either general population screening or 
management of detected nodules, yet much work on optimisation is needed. Most of the risk models 
developed in China gave relatively poor discrimination, no calibration or no external validation.   
Since there are different risk profiles for lung cancer in China, we need to consider to what extent 
these differences will influence the optimal Chinese lung cancer risk model. Whether risk models 
should be developed separately in males and females, or different thresholds should be set in different 
genders or those with different smoking status, are questions that remain to be answered (and might 
not be fully addressed until implementation based on the best model at the time and further data 
gathered as part of the screening effort).  
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Moreover, one needs to consider in the Chinese context, is that science is rapidly advancing on an 
exponential scale. Current lung cancer prevalence may reflect exposure levels of risk factors many 
years ago, similar to the delayed impact of smoking on mortality; or mis-represent the real status quo 
in China due to potential bias in data collection, i.e. from current incomplete cancer registries. A 
recent publication has illustrated a higher lung cancer incidence in young women compared to young 
men, noting that both genders were born after the mid-1960s in the US238. Different smoking 
behaviours between the genders could not fully explain this phenomenon 238. Given the changing 
situations, the entry criteria into lung cancer screening programmes should be reconsidered.  
Screening age range  
Disputes exist in different microsimulation modelling studies; these studies often applied distinct 
outcome measures to assess the benefits and harms. In China, Lung cancer incidence is quite low in 
individuals aged ≤ 45, but it increases with ages in those over 50103, 135. Individuals in younger 
generation (i.e. <50 years) would suffer more harm from screening, e.g. excess cancer risk induced by 
radiation exposure234. While an older individual would not benefit from screening due to existing 
comorbidities and competing deaths of other causes. After combining the evidence above and life 
expectancy in China, the CNS 2015/2018 have recommended ages at 50 -74 for screening 
feasibility103, 135. Optimal screening age range has not yet been specified in China. 
Nodule measurement  
Accumulating evidence has demonstrated that volumetrics and VDT are less variable and more 
sensitive in detecting nodule sizes and growth. NELCIN-B3 will help to define it. It is also preferable 
to apply volumetry software to help optimizing nodule management strategies during implementation.  
Identify ‘Indeterminate’ nodules  
Different cut-off values would possess different lung cancer risks. By risk stratification, nodules 
would be managed accordingly. However, it is unclear if variations in the aetiology of lung cancer in 
the East would extend to the biological features that influence nodule behaviour.  Risk models for 
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malignancy prediction of nodules were derived from post-hoc analysis. It is unsure if these models 
would perform well in an ongoing LDCT screening trial. 
Mortality data  
The two largest studies - NLST and NELSON - reported a benefit of mortality reduction by LDCT 
screening. In China, a microsimulation modelling study indicated a favorable role of LDCT screening 
over CXR and no screening in mortality reduction among urban smokers at 45-80 years-old104. It is 
uncertain in China that to what extent LDCT screening would help to reduce mortality, either lung 
cancer-specific or all-cause, in the real world. Whether nonsmokers in China would benefit from 
screening is also undetermined.  
Cost-effectiveness    
Whenever it comes to real-life practice, cost-effectiveness should always be seriously considered. We 
should consider not just the health benefit provided by screening, but the associated financial benefits 
of reduced costs for cancer treatment and the improved economic output of those living longer and 
healthier lives. 
The ageing population in China would be more vulnerable to both lung cancer and other causes of 
death. The latest papers indicated that it would be better to take into consideration the long-term 
outcomes and non-lung cancer outcomes of participants during the assessment220, 221. There would 
always be compromises during the process, e.g. more screening rounds would lead to more lung 
cancer mortality reduction but result in more over-diagnosis and radiation exposures. Management 
should be individualised in screened participants according to their baseline scan results and nodule 
risk stratification, to reduce unnecessary scans in the low-risk and maximise the benefits. Currently, 
using a mathematical method to simulate different scenarios is a favourable alternative, and it may 
provide us with additional information which could not be obtained in real life because of limited 
research resources.  
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Screening intervals  
Lung cancer risk is baseline result-dependent. Nodule size and nodule attenuation (solid, part-solid, 
non-solid) will also affect the risk of malignancy. Similarly, cost-effectiveness analysis leads the way. 
Data from the real practice is needed in China.    
Smoking Cessation  
Tobacco control can provide more benefit than we have seen so far. Apart from lung cancer, smoking 
is closely related to morbidities such as COPD, cardio-vascular diseases and ischemic stroke, et al. 
Smoking exposure is positively associated with mortality risks of these morbidities. Quitting would 
help to decrease the risks28. Thus, tobacco control could save lives not only from lung cancers but also 
from other highly life-disabling conditions, thus improving the quality of life. When integrating 
tobacco control, lung cancer screening could achieve more cost-effectiveness. However, evidence of 
efficient and effective strategies of the combination is still limited.  
In conclusion, lung cancer and smoking prevalence in China are very different from other countries. 
Increasing trends for lung cancer mortality are expected following a lag from smoking exposure. 
Other risk factors may play a significant role alongside smoking for lung cancer risk in China; broader 
entry criteria might be more expedient in China to accommodate non-smokers. Evidence from 
Chinese lung cancer screenings is limited, but the success of screening programmes and evidence 
from other countries could pave the way. Risk models should be optimised, and a prespecified 
analysis would be helpful for initial trials, adopting a re-iterative, adaptive approach as screening 
programmes develop.  
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Figure Legends  
Figure 1  Trends in smoking prevalence, lung cancer incidence and mortality in China, UK and 
the US, by sex.   
(A) China: Current smoking prevalence data (Chinese population-adjusted) extracted from the China 
Health and Nutrition surveys (1991-2011) 27. Lung cancer incidence (world population-adjusted) from 
the World Health Organisation (1993-2007) 239 and annual reports of cancer statistics in China (2010-
2014) 4, 44, 240-242. Lung cancer mortality (world population-adjusted) from the First National Death 
Survey in China (1973-1975) 243, World Health Organisation (1987-2000) 244 and annual reports of 
cancer statistics in China (2006, 2010-2014) 4, 44, 240-242, 245.  (B) United Kingdom (UK, European 
population-adjusted): All data from the Cancer Research UK website (1948-2016) 53. (C) United 
States (US): Smoking prevalence from the International Smoking Statistics (web edition) (1935-
2014); nationally representative surveys included if possible; data with the highest value included if 
several prevalence rates are available (in many cases, more brands of tobacco products in a survey 
always contribute to a higher prevalence rate). Lung cancer incidence (world population-adjusted) 
from the WHO Cancer Incidence in Five Continents Time Trends (CI5plus) (1975-2007) 239. Lung 
cancer mortality (world population-adjusted) from the WHO Cancer Mortality Database (1950-2014) 
244. (D) Lopez’s model of cigarette epidemic (Lopez et al, 1994)38.  
Note: Because there were different definitions/metrics of smoking, different methods and sources 
used for analysis in the reported investigations, thus direct comparison may not be applicable. One has 
to be cautious when interpreting these figures.  
 
Figure 2 The landscape of lung cancer screening programmes in China since the 1990s.  
The programmes are displayed as ‘the programme name plus the initiation year’. In order to prepare 
this figure for publication in English language, all of the Chinese trials and projects are referenced by 
the trial names. In many cases, it was not possible to translate the Chinese into English. For the 
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purpose of this review, the English name for each of the trials is linked to the Chinese city or region 
and the responsible hospital, unless there is already an international name available (i.e. ELCAP or 
NELCIN-B3). Please refer to Table 2 and Supplementary for details. The coloured areas are the 
regions covered by the corresponding national programmes 93-96. Abbreviations: CanSPUC, Cancer 
Screening Program in Urban China; China FeasiRCT, China Lung Cancer Screening Feasibility RCT;  
CICAMS, Cancer Institute & Hospital Chinese Academy of Medical Sciences; GMU-1stHosp, 
Guangzhou Medical University First Affiliated Hospital; Guangzhou Financing, a demonstration 
project targeting Guangzhou to expand lung cancer screening and test innovative financing models; 
NELCIN-B3, Netherlands-China Big-3 screening; RuraCSP, Rural China Screening Programme;  
Shanghai Baoshan, lung cancer screening programme in old people in Baoshan District, Shanghai; 
Shanghai CancerHosp, Fudan University Shanghai Cancer Centre; Shanghai ChangzhengHosp, 
Shanghai Changzheng Hospital; Shanghai ChestHosp, Shanghai Jiaotong University affiliated 
Shanghai Chest Hospital; SH-RenjiHosp, Shanghai Jiaotong University Affiliated Renji Hospital; 
Tianjin CancerHosp, Tianjin Medical University Cancer Institute and Hospital; Tianjin 4-cancer, 
screening of the four common cancers (lung cancer, breast cancer, liver cancer and stomach cancer) in 
Tianjin; WCH, West China Hospital; YTC, Yunan Tin Corporation cohort.  
* NELCIN-B3 99 has three study centers in China: two in Shanghai (Shanghai Changzheng Hospital 
and Shanghai General Hospital) and one in Tianjin (Tianjin Medical University Cancer Institute and 
Hospital).  
§ Including three separate programmes sponsored by central government246, 247: one in 2017 and 
another two (including a multicentre RCT) in 2018. 
¶ The Guangzhou Financing project 92 was proposed in 2017 and is still being discussed currently. 
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Figure 3 Levels of evidence for the implementation of lung cancer CT screening in China 
(permitted by and adapted from Field et al.).  
The colour codes are similar to Field et al. 235. They refer to the current status in China in 2018, where 
green indicates we have sufficient evidence, orange is borderline evidence, and red requires further 
evidence (Chinese-specific). MDT, multi-disciplinary team; NCCN, National Comprehensive Cancer 
Network; CSCO, Chinese Society of Clinical Oncology; NLST, National Lung Screening Trial; 
NELSON, Nederlands Leuvens Longkanker Screenings Onderzoek (Dutch-Belgian randomised lung 
cancer multi-slice CT screening trial); UKLS, United Kingdom Lung Cancer Screening Trial; QALY, 
quality-adjusted life-year. 
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Tables  
Table 1 Estimated incidence and mortality rate (World population age-standardized, per 100 000) of lung cancer in China, the UK and the US, all 
ages.  
 Incidence Mortality 
 Total Male Female Total Male Female 
China 35.1 47.8 22.8 30.9 43.4 19.0 
UK 32.5 35.5 30.2 22.2 25.2 19.7 
US 35.1 40.1 30.8 22.1 25.9 19.0 
Data extracted from GLOBCAN 2018 1. UK, United Kingdom; US, United States. 
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Table 2 Lung cancer screening programmes in China.  
Time Trial/Study Name 
used in the 
manuscript (Ref.) * 
 
Initiation 
Year 
Targeted region/population Study 
design 
Interventions Entry criteria Population 
(recruiting time) 
Before 
the 1990s 
Mass photofluorograhy 
in early detection of 
peripheral lung cancer  
78 
 
1979 N/A Prospective 
cohort 
Annual CXR for 5 years Workers from 54 factories; no other 
restrictions 
211 811 person-years 
(1979-1983) 
 Mass screening in  
Hunan orpiment miners  
79 
 
1986 Hunan orpiment miners Prospective 
cohort 
Baseline: sputum cytology + CXR; 
follow-up according to sputum atypia: 
If moderate or severe sputum atypia:  
sputum + CXR at 3 months, 6 months, 1 
year and 3 years. 
-If no or mild atypia: sputum + CXR 3 
years later. 
 
Orpiment miners in Hunan; aged > 35. 601 (baseline) 
 Screening lung cancer 
by Sputum Occult 
Blood Test (OBT) 
Study 80, 81 
 
 1988 
 
 workers in Changchun 
automobile industries, Tangshan 
and  Yunnan tin mines, Xuanwei 
and Beijing steel factories 
 Cross-
sectional 
study  
 
 Sputum OBT and cytology with/without 
CXR  
 
High-risk Workers from various 
manufacturing and mining factories, 
including some famers/cadres; aged ≥ 40 
years 
14 431 (1988-1990)  
 
 2007  Laibing County, Xuanwei 
(Yunnan) 
 
prospective 
cohort 
 Baseline CXR (CT for CXR positive);  
sputum OBT at 4 months later (sputum 
cytology and HRCT if OBT positive) 
Residents aged 35-70 years about 30, 000 at 
baseline (Jan, 2007 – 
Jul, 2007) 
1990s The Yunnan Tin 
Corporation  (YTC) 
cohort ¶  82   
1992 Around Gejiu City, Southern 
Yunan. 
Prospective 
cohort 
Annual sputum sampled + annual CXR Current/retired YTC workers, aged ≥ 40 
years-old, with a history of underground 
mining/smelting  ≥10 years 
9143 (1992 - 1999 ) 
2000s Zhuhai I-ELCAP 
cohort 97  
 
2003 Zhuhai, Guangdong province Prospective 
cohort 
Annual LDCT Asymptomatic participants aged ≥40 years. 3582 (2003-2009) 
 Beijing I-ELCAP 
cohort 98  
 
2006 Beijing, China Prospective 
cohort 
Annual LDCT Asymptomatic participants aged ≥40 years, 
no history of malignancy (except basal cell 
carcinoma and  
cervical carcinoma in situ) within 5 years 
4690 (2007- 2012) 
 Kailuan  cohort ¶ 83   
 
2006  Kuailuan Group Company, 
Tangshan City, Heibei Province 
Prospective 
cohort 
biennial CXR ; annual follow-up in 11 
hospitals affiliated to the Kailuan 
Company 
Current or retired Employees aged ≥18 
years in the Kailuan Group Company 
(mining industry) 
133 273(2006-2011) 
2010s Rural China Cancer 
Screening Programme 
(RuraCSP) *  93, 94 
 
2009 Dagang Oilfield (Tianjin), 
Xuanwei (Yunnan), Gejiu 
(Yunnan), Beijing, Chengdu 
(Sichuan) and Shenyang 
(Liaoning).. 
Prospective 
cohort  
Annual LDCT and sputum cytological 
examination (for 3 years). 
Inclusion criteria are region-dependent: 50-
74 years (in Tianjin), 45-69 years (in 
Yunnan), staff aged 50-74 years and 
smoking history of ≥20 pack-years (in the 
Dagang Oilfield). The Xuaiwei centre 
included indoor air pollution as a risk 
factor. 
.  
19 068 (2010-2017, 
baseline participants) 
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Time Trial/Study Name 
used in the 
manuscript (Ref.) * 
 
Initiation 
Year 
Targeted region/population Study 
design 
Interventions Entry criteria Population 
(recruiting time) 
 Cancer Screening 
Program in Urban 
China (CanSPUC) ¶ 95, 
96  
2012 20 provincial/municipal-level 
regions in China by 2018 
Prospective  
cohort 
Annual LDCT for 5 years Urban residents (residing >3 years) aged 
40-69 (some areas defined ages at 40-74) 
with high risk of lung cancer; high-risk 
criteria are region-dependent. 
210 000 (planned in 
the first stage during 
2012-2016) 
 The China Cancer 
Screening Trial 
Feasibility Study 
(China FeasiRCT) * 137, 
138    
 
2014 3 cities (Changsha[Hunan]; 
Lanzhou[Gansu]; 
Haining[Zhejiang] 
RCT Arm 1: Annual LDCT for 3 years (T0, T1, 
T2) and baseline colonoscopy (T0); 
Arm 2: 2 LDCT (T0, T2) plus annual 
faecal immunochemical test (T0, T1, T2); 
Arm 3: Annual InSure-faecal 
immunochemical tests combined with 
Septin 9 test (T0, T1, T2). 
Local permanent residents; Aged 50-74 
years; smoking >30 pack-years， quit ≤15 
years if former smokers (or second-hand 
smoke exposure in females: living with a 
regular daily smoker for > 20 years); no 
previous history of lung cancer or colorectal 
cancer. 
2700 (as of  March 31, 
2015)  
 Beijing CICAMS 
programmes §, §§  246, 
247 
2017, 
2018 
Beijing N/A N/A N/A N/A 
 Tianjin CancerHosp 
cohort  84 
 
2012 Tianjin Prospective 
cohort 
LDCT at Baseline and 1 or 2 years later  Asymptomatic, of ≥40 years-old, tolerant of 
possible invasive procedures and not 
screened by CT within 1 year.  
650 (2014-2016) 
 Tianjin 4-Cancer 
programme * 85 
 
2017 Selected districts in Tianjin: 
Hexi and Jinzhou in 2017; will 
cover up to 7 districts planned in 
2018  
Prospective 
cohort 
LDCT screening; and then follow-up for 
LDCT result- positive participants 
Healthy Residents will undergo risk 
assessment first and the high-risk ones 
undergo LDCT screening 
52 092 risk assessed;  
992 LDCT 
screened(2017) 
 Shanghai CancerHosp 
cohort  86   
 
2013 7 selected communities In 
Minhang District, Shanghai. 
Prospective 
cohort 
Annual LDCT; community-based, LDCT 
+ CAD for screening.  
Asymptomatic individuals aged 50-80, and 
eligible to ≥ 1 risk factors:  
1) smoking ≥20 pack-years, and if former 
smokers, quit smoking < 5 years; 2) passive 
smokers; 3)never smokers with other risk 
factors, including lung cancer family 
history, kitchen fume or dust exposure. 
 
11332 (2013 -2014) 
 Shanghai  ChestHosp  
RCT 87   
 
2013 6 selected communities in Xuhui 
District, Shanghai. 
RCT Biennial LDCT vs Usual care arm (for 
three rounds) 
Asymptomatic residents aged 45–70 years, 
with ≥ 1 risk factors: 1) a smoking history ≥ 
20 pack-years, and if former smoker, quit 
≤15 years; 2) family history of cancer; 3) 
personal cancer history; 4) occupational 
exposures; 5) long-term exposure of passive 
smoking (>2h/day at home/indoor 
workplaces for ≥10 years); 6) long-term 
exposure to cooking oil fumes (>50 dish-
years). 
6717 (2013 -2014):  
 Shanghai-
ChangzhengHosp 
cohort 88, 89 
 
2013 Physical examination centres in 
7 tertiary hospitals and their 
surrounding communities 
Prospective 
cohort 
Baseline LDCT + CAD; interval scans 
were not specified. 
Asymptomatic; any age;  14506 (2013-2016) 
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Time Trial/Study Name 
used in the 
manuscript (Ref.) * 
 
Initiation 
Year 
Targeted region/population Study 
design 
Interventions Entry criteria Population 
(recruiting time) 
 Netherlands-China Big-
3 screening (NELCIN-
B3) ¶, §§ 99 
2016 Shanghai Changzheng Hospital, 
Shanghai General Hospital and 
Tianjin Medical University 
Cancer Institute & Hospital. 
N/A LDCT screening N/A N/A 
 Shanghai Baoshan 
Programme * 90, 248 
2018 Baoshan District, Shanghai Prospective  
cohort 
one-time CT; referral to a hospital for 
further assessment if with positive results; 
and follow-up 
Ages ≥75 years-old, or ≥65 years-old yet 
with cough/expectoration ≥2 weeks and 
abnormal CXRs. 
1 4005  (as of 
September 2018) 
 Chengdu WCH cohort 
§§  
 
2013 Chengdu, Sichuan Province Retro-
prospective 
cohort 
Annual CXR or LDCT Workers of specific industries/ enterprises/ 
organisations undergoing annual physical 
examinations (CXR or LDCT) (records 
back to the year 2006) 
Baseline: 46 317 (by 
CXR); 15 996 (by 
LDCT)  
 Guangzhou GMU-
1stHosp Programme   
91, 92 
2015 Guangzhou, Guangdong  
Province 
Prospective 
cohort 
Annual LDCT Low-income residents aged ≥50 years;  or 
residents in Yuexiu district, aged 50-74, 
with high risk; or volunteered  residents 
aged ≥40 years in the whole province (the 
former two will get a free screening; but the 
latter a 1/5 discount on screening costs ). 
808 (as of Dec 2017) 
 
 Guangzhou Financing 
project (in planning) * 
92 
N/A Guangzhou, Guangdong  
Province  
Prospective 
cohort 
N/A 40-80 years; residents undergoing health 
checks through their employers’ health 
insurance or out-of-pocket payments, or 
occupational workers at higher risk of air 
pollution in working environment. 
10 000 (planned) 
 Qinghai SH-RenjiHosp  
programme 100, 101 
 
2016 Deprivation areas in Qinghai 
(would be expanded to Henan, 
Xinjiang and Shandong 
Province) 
N/A N/A Aged 50-74; or aged ≥35 but with ≥ 1 risk 
factors including long-term smokers, long-
term exposure to severe air pollution, 
radiation, coal smoke and kitchen fume, 
with a family history of lung cancer, a 
personal history of cancer or pulmonary 
diseases. 
N/A 
Most of the CT trial/programme (since 2010) names have been provided in the above table to identify the targeted region and the hospital in which they are undertaken otherwise stated for the purpose of this review. * 
Named after the studies’ characteristics by the author: RuraCSP - Rural China Screening Programme; China FeasiRCT - China Lung Cancer Screening Feasibility RCT; Tianjin 4-cancer programme - screening of the 
the four common cancers (lung cancer, breast cancer, liver cancer and stomach cancer) in Tianjin; Shanghai Baoshan programme - lung cancer screening programme in old people in Baoshan District, Shanghai; 
Guangzhou Financing project – a demonstration project targeting Guangzhou to expand lung cancer screening and test innovative financing models.  ¶ Yunan Tin Corporation cohort, Kailuan cohort, CanSPUC and 
NELCIN-B3 are formal names of the programmes, respectively. § Including three separate programmes funded by central government: one in 2017 and another two (including a multicentre RCT) in 2018. §§, personal 
communication with the corresponding principal investigators Professor Wu Ning, Professor Ye Zhaoxiang, Professor Li Weimin, respectively. Please see the Supplementary for details.   
Abbreviations: LDCT, low-dose computerised tomography; CAD, computer-aided diagnosis system; N/A, not applicable or not available; CICAMS, Cancer Institute & Hospital Chinese Academy of Medical Sciences; 
GMU-1stHosp, Guangzhou Medical University First Affiliated Hospital; RCT, randomised controlled study; Shanghai CancerHosp, Fudan University Shanghai Cancer Centre; Shanghai ChangzhengHosp, Shanghai 
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Changzheng Hospital; Shanghai ChestHosp, Shanghai Jiaotong University affiliated Shanghai Chest Hospital; SH-RenjiHosp, Shanghai Jiaotong University Affiliated Renji Hospital; Tianjin CancerHosp, Tianjin 
Medical University Cancer Institute and Hospital; WCH, West China Hospital;
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Table 3 | Recommendations for implementation of lung cancer screening in China. 
 Screening programme coverage to be expanded to underserved areas. Recruitment criteria 
suggested by other countries should be considered. The involvement of international 
investigators in lung cancer screening trials in China should be considered. 
 Community-based recruitment may be a more favourable approach in China: utilising face-
to-face clinical appointments and trustworthy collaborations with local clinics/ 
organisations. 
 To make cohort profiles or study protocols public is suggested. Collaboration between lung 
cancer screening trial groups should be considered. Developing consensus protocols and 
also the agreement to utilise common databases and minimum datasets would enable 
pooling of data from different trials in China. 
 In China, consider adapting the entry criteria, i.e. a lower threshold of smoking exposure; 
consider including other risk factors: second-hand smoke, family history of cancer, 
occupation and indoor/outdoor air pollution (the latter requires a harmonised approach). 
 Risk-based selection of eligible participants for study entry into lung cancer CT screening 
programmes (e.g. risk prediction modelling) would be advisable. 
 The current Chinese risk models (for either individual risk or nodule malignancy 
prediction) should be validated externally, especially in an ongoing lung cancer LDCT 
screening programme, which could help to confirm the efficacy and effectiveness in the 
real world. Further optimisation may be integrated over time, i.e. integration with liquid 
biomarkers and genetic factors. 
 Development of new risk prediction models, specifically for the Chinese population, 
should be priority, utilising optimal data sources. 
 Cost-effectiveness analysis of all current CT screening programmes should be undertaken, 
taking into consideration the selection criteria/risk threshold utilised, which would achieve 
the maximum net benefits over harms. 
 Evaluation of related parameters involved in the screening programmes requires further 
research in China, e.g. screening interval, screening length, nodule management.   
 Lung cancer screening programmes should be integrated with tobacco control strategies. 
An a priori design and a detailed record on participants’ behaviours/perspectives and study 
costs including personnel cost, is required for cost-effectiveness evaluation. 
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Supplemental Materials 
Supplemental Figure  
Figure S1 Historical events associated with tobacco and tobacco control in China, the UK and the US 
Figure S2 Timeline of selected nationally/sub-nationally representative surveys or important 
historical events associating with tobacco use (above the arrow) and cancer (below the arrow), and 
development of cancer registrations in China. 
Supplemental Tables 
Table S1 Study designs in Lung cancer low-dose computerised tomography (LDCT) screening 
programmes outside China.  
Table S2 Recruitment procedures and entry criteria in lung cancer low-dose computerised 
tomography (LDCT) screening programmes  
Table S3 Baseline participant characteristics, and baseline and overall low-dose computerised 
tomography (LDCT) screening results in lung cancer screening studies  
Table S4 Lung cancer risk models from China.  
Table S5 Nodule management criteria for low-dose computerised tomography in lung cancer 
screening trials.  
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Lung cancer screening programmes in China. 
 50 
 
 
References 
1. Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency 
for Research on Cancer. 2018. [Available from: https://gco.iarc.fr/today.] 
2. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115-32. doi: 
10.3322/caac.21338. 
3. Han R, Zheng R, Zhang S, et al. [Trend analyses on the differences of lung cancer incidence between gender, 
area and average age in China during 1989-2008]. Zhongguo fei ai za zhi = Chinese journal of lung cancer. 
2013;16(9):445-51. doi: 10.3779/j.issn.1009-3419.2013.09.02. 
4. Chen W, Zheng R, Zeng H, et al. Epidemiology of lung cancer in China. Thorac Cancer. 2015;6(2):209-15. doi: 
10.1111/1759-7714.12169. 
5. Islami F, Chen W, Yu XQ, et al. Cancer deaths and cases attributable to lifestyle factors and infections in 
China, 2013. Ann Oncol. 2017;28(10):2567-74. doi: 10.1093/annonc/mdx342. 
6. Parkin DM. 2. Tobacco-attributable cancer burden in the UK in 2010. Br J Cancer. 2011;105 Suppl 2:S6-S13. 
doi: 10.1038/bjc.2011.475. 
7. Islami F, Goding Sauer A, Miller KD, et al. Proportion and number of cancer cases and deaths attributable to 
potentially modifiable risk factors in the United States. CA Cancer J Clin. 2018;68(1):31-54. doi: 10.3322/caac.21440. 
8. Chen ZM, Peto R, Iona A, et al. Emerging tobacco-related cancer risks in China: A nationwide, prospective 
study of 0.5 million adults. Cancer. 2015;121 Suppl 17:3097-106. doi: 10.1002/cncr.29560. 
9. Sisti J, Boffetta P. What proportion of lung cancer in never-smokers can be attributed to known risk factors? 
Int J Cancer. 2012;131(2):265-75. doi: 10.1002/ijc.27477. 
10. Chen G, Sun X, Ren H, et al. The mortality patterns of lung cancer between 1990 and 2013 in Xuanwei, China. 
Lung Cancer. 2015;90(2):155-60. doi: 10.1016/j.lungcan.2015.08.006. 
11. Loomis D, Huang W, Chen G. The International Agency for Research on Cancer (IARC) evaluation of the 
carcinogenicity of outdoor air pollution: focus on China. Chin J Cancer. 2014;33(4):189-96. doi: 
10.5732/cjc.014.10028. 
12. Cao J, Yang C, Li J, et al. Association between long-term exposure to outdoor air pollution and mortality in 
China: a cohort study. J Hazard Mater. 2011;186(2-3):1594-600. doi: 10.1016/j.jhazmat.2010.12.036. 
13. Tse LA, Yu IT, Qiu H, et al. Occupational risks and lung cancer burden for Chinese men: a population-based 
case-referent study. Cancer Causes Control. 2012;23(1):121-31. doi: 10.1007/s10552-011-9861-1. 
14. Wu C, Hu Z, Yu D, et al. Genetic variants on chromosome 15q25 associated with lung cancer risk in Chinese 
populations. Cancer Res. 2009;69(12):5065-72. doi: 10.1158/0008-5472.Can-09-0081. 
15. Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine 
receptor subunit genes on 15q25. Nature. 2008;452(7187):633-7. doi: 10.1038/nature06885. 
16. Hu Z, Wu C, Shi Y, et al. A genome-wide association study identifies two new lung cancer susceptibility loci at 
13q12.12 and 22q12.2 in Han Chinese. Nat Genet. 2011;43(8):792-6. doi: 10.1038/ng.875. 
17. McKay JD, Hung RJ, Gaborieau V, et al. Lung cancer susceptibility locus at 5p15.33. Nat Genet. 
2008;40(12):1404-6. doi: 10.1038/ng.254. 
18. Zhang R, Chu M, Zhao Y, et al. A genome-wide gene-environment interaction analysis for tobacco smoke and 
lung cancer susceptibility. Carcinogenesis. 2014;35(7):1528-35. doi: 10.1093/carcin/bgu076. 
19. Yamamoto H, Yatabe Y, Toyooka S. Inherited lung cancer syndromes targeting never smokers. Transl Lung 
Cancer Res. 2018;7(4):498-504. doi: 10.21037/tlcr.2018.06.01. 
20. Gou LY, Niu FY, Wu YL, et al. Differences in driver genes between smoking-related and non-smoking-related 
lung cancer in the Chinese population. Cancer. 2015;121 Suppl 17:3069-79. doi: 10.1002/cncr.29531. 
21. El-Telbany A, Ma PC. Cancer genes in lung cancer: racial disparities: are there any? Genes Cancer. 2012;3(7-
8):467-80. doi: 10.1177/1947601912465177. 
22. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth 
factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97(5):339-46. doi: 10.1093/jnci/dji055. 
23. O'Brien TD, Jia P, Aldrich MC, et al. Lung Cancer: One Disease or Many. Hum Hered. 2018;83(2):65-70. doi: 
10.1159/000488942. 
24. BRICS Joint Statistical Publication 2017: English version. Beijing: China Statistics Press; 2017. [Available from: 
http://www.gks.ru/free_doc/doc_2017/JSP-2017.pdf] 
25. Statista. Tobacco 2017. [Available from: https://www.statista.com/study/15892/tobacco-statista-dossier/] 
 51 
 
26. Giovino GA, Mirza SA, Samet JM, et al. Tobacco use in 3 billion individuals from 16 countries: an analysis of 
nationally representative cross-sectional household surveys. The Lancet. 2012;380(9842):668-79. doi: 
10.1016/s0140-6736(12)61085-x. 
27. Li S, Meng L, Chiolero A, et al. Trends in smoking prevalence and attributable mortality in China, 1991-2011. 
Prev Med. 2016;93:82-7. doi: 10.1016/j.ypmed.2016.09.027. 
28. Chen Z, Peto R, Zhou M, et al. Contrasting male and female trends in tobacco-attributed mortality in China: 
evidence from successive nationwide prospective cohort studies. Lancet. 2015;386(10002):1447-56. doi: 
10.1016/S0140-6736(15)00340-2. 
29. Han J, Chen X. A Meta-Analysis of Cigarette Smoking Prevalence among Adolescents in China: 1981-2010. Int 
J Environ Res Public Health. 2015;12(5):4617-30. doi: 10.3390/ijerph120504617. 
30. Thun M, Peto R, Boreham J, et al. Stages of the cigarette epidemic on entering its second century. Tob 
Control. 2012;21(2):96-101. doi: 10.1136/tobaccocontrol-2011-050294. 
31. ASH-Action on Smoking and Health. Smoking statistics: who smokes and how much. 2016. [Available from: 
http://ash.org.uk/wp-content/uploads/2016/06/Smoking-Statistics-Who-Smokes-and-How-Much.pdf] 
32. Cancer Research UK. Tobacco Statistics: Trends over time for tobacco statistics. [Available from: 
http://www.cancerresearchuk.org/health-professional/cancer-statistics/risk/tobacco#heading-Three] 
33. Office for National Statistics. Adult smoking habits in the UK:2017. 2018. [Available from: 
https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifeexpectancies/bulletins/
adultsmokinghabitsingreatbritain/2017#the-proportion-who-are-current-smokers-in-the-uk-its-constituent-
countries-and-local-areas-2011-to-2017] 
34. Public Health England, GOV.UK. Research and analysis: Chapter 4: European comparisons. 2017. [Available 
from: https://www.gov.uk/government/publications/health-profile-for-england/chapter-4-european-comparisons] 
35. Office for National Statistics. Likelihood of smoking four times higher in England’s most deprived areas than 
least deprived. 2018. [Available from: 
https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/drugusealcoholandsmoking/articles/
likelihoodofsmokingfourtimeshigherinenglandsmostdeprivedareasthanleastdeprived/2018-03-14] 
36. Forey B, Hamling J, Hamling J, et al. International Smoking Statistics(WEB Edition): A collection of worldwide 
historical data 2016. [Available from: http://www.pnlee.co.uk/iss3.htm] 
37. U.S. Department of Health and Human Services. The Health Consequences of Smoking—50 Years of 
Progress: A Report of the Surgeon General. 2014;Chapter 13 Patterns of Tobacco Use Among U.S. Youth, Young 
Adults, and Adults.:701-70. doi:  
38. Lopez AD, Collishaw N, Piha TA. A Descriptive Model of the Cigarette Epidemic in Developed Countries. Tob 
Control. 1994;3:242-7. doi: 10.1136/tc.3.3.242. 
39. Peto R, Lopez AD, Pan H, et al. Mortality from Smoking in Developed Countries 1950-2020 (updated 
September 2015) 2015. [Available from: http://gas.ctsu.ox.ac.uk/tobacco/] 
40. Mackay J. China: the tipping point in tobacco control. Br Med Bull. 2016;120(1):15-25. doi: 
10.1093/bmb/ldw043. 
41. Shen M. Prof. Wanqing Chen: the past, present and future of cancer registry in China. Ann Transl Med. 
2014;2(7):71. doi: 10.3978/j.issn.2305-5839.2014.04.07. 
42. Wei KR, Liang ZH, Liu J, et al. [History of Cancer Registration in China.]. Chinese Journal of Medical History. 
2012;42(1):21-5. doi: 10.3760/cma.j.issn.0255-7053.2012.01.006. 
43. Bray F, Colombet M, Mery L, et al. Cancer Incidence in Five Continents, Vol. XI (electronic version). Lyon: 
International Agency for Research on Cancer. 2017. [Available from: http://ci5.iarc.fr] 
44. Chen W, Sun K, Zheng R, et al. Cancer incidence and mortality in China, 2014. Chin J Cancer Res. 
2018;30(1):1-12. doi: 10.21147/j.issn.1000-9604.2018.01.01. 
45. Li GL, Chen WQ. Representativeness of Population-Based Cancer Registration in China - Comparison of Urban 
and Rural Areas. Asian Pac J Cancer Prev. 2009;10(4):559-64. doi:  
46. Li J, Shi L, Liang H, et al. Urban-rural disparities in health care utilization among Chinese adults from 1993 to 
2011. BMC Health Serv Res. 2018;18(1):102. doi: 10.1186/s12913-018-2905-4. 
47. Li X, Lu JP, Hu S, et al. The primary health-care system in China. The Lancet. 2017;390:2584–94. doi: 
10.1016/S0140-6736(17)33109-4. 
48. Meng Q, Xu L, Zhang Y, et al. Trends in access to health services and financial protection in China between 
2003 and 2011: a cross-sectional study. Lancet. 2012;379(9818):805-14. doi: 10.1016/s0140-6736(12)60278-5. 
 52 
 
49. Jian W, Chan KY, Reidpath DD, et al. China's rural-urban care gap shrank for chronic disease patients, but 
inequities persist. Health Aff (Millwood). 2010;29(12):2189-96. doi: 10.1377/hlthaff.2009.0989. 
50. Stone EC, Zhou C, International Association for the Study of Lung Cancer Tobacco Control C. Slowing the 
Titanic: China's Epic Struggle with Tobacco. J Thorac Oncol. 2016;11(12):2053-65. doi: 10.1016/j.jtho.2016.07.020. 
51. Li L, Liu D, Zhang L, et al. [Clinicopathological Features, Diagnoses and Treatments of 6 458 Lung Cancer 
Patients]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2017;48(3):352-8. doi:  
52. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30. doi: 
10.3322/caac.21442. 
53. Cancer Research UK: Lung cancer statistics 2018. [Available from: http://www.cancerresearchuk.org/health-
professional/cancer-statistics/statistics-by-cancer-type/lung-cancer] 
54. Pirie K, Peto R, Reeves GK, et al. The 21st century hazards of smoking and benefits of stopping: a prospective 
study of one million women in the UK. The Lancet. 2013;381(9861):133-41. doi: 10.1016/s0140-6736(12)61720-6. 
55. Jha P, Ramasundarahettige C, Landsman V, et al. 21st-century hazards of smoking and benefits of cessation 
in the United States. N Engl J Med. 2013;368(4):341-50. doi: 10.1056/NEJMsa1211128. 
56. Geneva: World Health Organization (WHO) Report On The Global Tobacco Epidemic,2017: Monitoring 
tobacco use and prevention policies 2017. [Available from: http://www.who.int/tobacco/global_report/2017/en/.] 
57. Hu TW, Zhang X, Zheng R. China has raised the tax on cigarettes: what's next? Tob Control. 2016;25(6):609-
11. doi: 10.1136/tobaccocontrol-2015-052534. 
58. Goodchild M, Zheng R. Early assessment of China's 2015 tobacco tax increase. Bull World Health Organ. 
2018;96(7):506-12. doi: 10.2471/BLT.17.205989. 
59. Field JK, Duffy SW. Lung cancer screening: the way forward. Br J Cancer. 2008;99(4):557-62. doi: 
10.1038/sj.bjc.6604509. 
60. Oken MM, Hocking WG, Kvale PA, et al. Screening by chest radiograph and lung cancer mortality: the 
Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA. 2011;306(17):1865-73. doi: 
10.1001/jama.2011.1591. 
61. Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings 
from baseline screening. The Lancet. 1999;354(9173):99-105. doi: 10.1016/s0140-6736(99)06093-6. 
62. Henschke CI, Yankelevitz DF, Libby DM, et al. Survival of patients with stage I lung cancer detected on CT 
screening. N Engl J Med. 2006;355(17):1763-71. doi: 10.1056/NEJMoa060476. 
63. Aberle DR, Adams AM, Berg CD, et al. The National Lung Screening Trial Research Team. Reduced lung-
cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409. doi: 
10.1056/NEJMoa1102873. 
64. Konning HD. NELSON Study Shows CT Screening for Nodule Volume Management Reduces Lung Cancer 
Mortality by 26 Percent in Men.  IASLC 19th World Conference on Lung Cancer (WCLC 2018); Toronto, Canada2018. 
doi:  
65. Wille MM, Dirksen A, Ashraf H, et al. Results of the Randomized Danish Lung Cancer Screening Trial with 
Focus on High-Risk Profiling. Am J Respir Crit Care Med. 2016;193(5):542-51. doi: 10.1164/rccm.201505-1040OC. 
66. Infante M, Cavuto S, Lutman FR, et al. Long-Term Follow-up Results of the DANTE Trial, a Randomized Study 
of Lung Cancer Screening with Spiral Computed Tomography. Am J Respir Crit Care Med. 2015;191(10):1166-75. doi: 
10.1164/rccm.201408-1475OC. 
67. Paci E, Puliti D, Lopes Pegna A, et al. Mortality, survival and incidence rates in the ITALUNG randomised lung 
cancer screening trial. Thorax. 2017;72(9):825-31. doi: 10.1136/thoraxjnl-2016-209825. 
68. Pastorino U, Rossi M, Rosato V, et al. Annual or biennial CT screening versus observation in heavy smokers: 
5-year results of the MILD trial. Eur J Cancer Prev. 2012;21(3):308-15. doi: 10.1097/CEJ.0b013e328351e1b6. 
69. Becker N, Motsch E, Gross ML, et al. Randomized Study on Early Detection of Lung Cancer with MSCT in 
Germany: Results of the First 3 Years of Follow-up After Randomization. J Thorac Oncol. 2015;10(6):890-6. doi: 
10.1097/JTO.0000000000000530. 
70. Blanchon T, Brechot JM, Grenier PA, et al. Baseline results of the Depiscan study: a French randomized pilot 
trial of lung cancer screening comparing low dose CT scan (LDCT) and chest X-ray (CXR). Lung Cancer. 2007;58(1):50-
8. doi: 10.1016/j.lungcan.2007.05.009. 
71. Coureau G, Salmi LR, Etard C, et al. Low-dose computed tomography screening for lung cancer in populations 
highly exposed to tobacco: A systematic methodological appraisal of published randomised controlled trials. Eur J 
Cancer. 2016;61:146-56. doi: 10.1016/j.ejca.2016.04.006. 
 53 
 
72. Sagawa M, Nakayama T, Tanaka M, et al. A randomized controlled trial on the efficacy of thoracic CT 
screening for lung cancer in non-smokers and smokers of <30 pack-years aged 50-64 years (JECS study): research 
design. Jpn J Clin Oncol. 2012;42(12):1219-21. doi: 10.1093/jjco/hys157. 
73. Moyer VA. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann 
Intern Med. 2014;160(5):330-8. doi: 10.7326/m13-2771. 
74. Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: a systematic review. 
JAMA. 2012;307(22):2418-29. doi: 10.1001/jama.2012.5521. 
75. Jaklitsch MT, Jacobson FL, Austin JH, et al. The American Association for Thoracic Surgery guidelines for lung 
cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J 
Thorac Cardiovasc Surg. 2012;144(1):33-8. doi: 10.1016/j.jtcvs.2012.05.060. 
76. Wender R, Fontham ET, Barrera E, Jr., et al. American Cancer Society lung cancer screening guidelines. CA 
Cancer J Clin. 2013;63(2):107-17. doi: 10.3322/caac.21172. 
77. Centres for Medicare & Medicaid Services (CMS). Decision Memo for Screening for Lung Cancer with Low 
Dose Computed Tomography (LDCT) (CAG-00439N). 2015. [Available from: https://www.cms.gov/medicare-
coverage-database/details/nca-decision-memo.aspx?NCAId=274.] 
78. Sun XK, Tu DH, Li JF, et al. [Mass Photofluorography in early detection of peripheral lung cancer.]. Chinese 
Journal of Oncology. 1986;8(5):370-2. doi:  
79. Shi ZT, Zhang YL. [Mass screening of lung cancer: reports in orpiment miners in Hunan.]. Chinese Journal of 
Tuberculosis and Respiratory Diseases. 1989;12(4):230-1. doi:  
80. Qin DX, Li YY, Zuo JH, et al. [Stage II test report for screening lung cancer by sputum of occult blood test.]. 
Cancer. 1991;10(2). doi:  
81. Qin DX, Xu ZJ, Sun Y, et al. [Comparison of lung cancer screening methods sputum occult blood detection 
versus chest X-ray.]. Chin J Clin Oncol Rehabil. 2009;16(2). doi: 10.13455/j.cnki. 
82. Gao G, Yao S, Sun X, et al. [Establishment of cohort to study lung cancer in Yunnan tin miners]. Zhongguo Fei 
Ai Za Zhi. 2002;5(2):87-91. doi: 10.3779/j.issn.1009-3419.2002.02.03. 
83. Guo L, Li N, Wang G, et al. [Body mass index and cancer incidence:a prospective cohort study in northern 
China]. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi. 2014;35(3):231-6. doi:  
84. Gao ZS, Ye ZX, Zhang P, et al. [Low-dose computed tomography screening for lung cancer in Tianjin: a 
preliminary clinical analysis of baseline screening and follow-up results]. Chin J Clin Oncol. 2017;44(20):1034-9. doi:  
85. Tianjin Medical University Cancer Institute and Hospital. News Centre: Initiation of Tianjin Cancer Screening 
Programme in 2018. 2018. [Available from: http://www.tjmuch.com/system/2018/03/28/011271257.shtml] 
86. Luo X, Zheng S, Liu Q, et al. Should Nonsmokers Be Excluded from Early Lung Cancer Screening with Low-
Dose Spiral Computed Tomography? Community-Based Practice in Shanghai. Transl Oncol. 2017;10(4):485-90. doi: 
10.1016/j.tranon.2017.02.002. 
87. Yang W, Qian F, Teng J, et al. Community-based lung cancer screening with low-dose CT in China: Results of 
the baseline screening. Lung Cancer. 2018;117:20-6. doi: 10.1016/j.lungcan.2018.01.003. 
88. Wang Y, Fan L, Zhou Y, et al. [Preliminary results of baseline low-dose computed tomography screening for 
lung cancer in Shanghai]. Chin J Health Manage. 2018;12(1):51-4. doi:  
89. Shanghai Changzheng Hospital. Programme declaration of Liu Shiyuan: Study on early detection and 
diagnosis of peripheral lung cancer by multi-modality imaging. 2018. [Available from: 
http://www.shcz.com/front/newOne.aspx?id=1637] 
90. Baoshan District Commission of Health and Family Planning, Shanghai Municipality. Government policy. 
Implementation of lung cancer screening programme in old people in Baoshan District. 2018. [Available from: 
http://www.baoshan.sh.cn/xxgk_website/HTML/bsxxgk/bsxxgk_zfjg_qwsjsw_gkml/2018-04-02/Detail_298737.htm] 
91. The Guangzhou Medical University First Affiliated Hospital. News report: initiation of lung cancer screening 
in Guangdong Province. 2017. [Available from: http://www.gyfyy.com/cn/list-133-7854.html] 
92. Chng B, Maclean C. Milken Institute. Financing Lung cancer screening in China: financial innovations lab 
report. 2017. doi:  
93. Zhou Q, Fan Y, Wu N, et al. Demonstration program of population-based lung cancer screening in China: 
Rationale and study design. Thorac Cancer. 2014;5(3):197-203. doi: 10.1111/1759-7714.12078. 
94. Zhou Q. MS 16.02 NELCIN-B3 SCREENING PROGRAM IN CHINA.  The IASLC 19th World Conference on Lung 
Cancer (WCLC 2018). September 23-25.; Toronto, Canada2018. doi:  
95. Dai M, Shi J, Li N. [The design and expectation of the Cancer Screening Program in Urban China]. Chin J Prev 
Med. 2013;47(02):179-82. doi: 10.3760/cma.j.issn.0253-9624.2013.02.018. 
 54 
 
96. Jincheng General Hospital. Implementation Protocol of Cancer Screening Program in Urban China. 2016. 
[Available from: http://www.jmjtzyy.com/index.php/Index/newsContent/id/1237] 
97. Liu X, Liang M, Wang Y, et al. The outcome differences of CT screening for lung cancer pre and post following 
an algorithm in Zhuhai, China. Lung Cancer. 2011;73(2):230-6. doi: 10.1016/j.lungcan.2010.11.012. 
98. Tang W, Wu N, Huang Y, et al. [Results of low-dose computed tomography (LDCT) screening for early lung 
cancer: prevalence in 4 690 asymptomatic participants]. Zhonghua Zhong Liu Za Zhi. 2014;36(7):549-54. doi:  
99. Netherlands-China Big-3 screening: NELCIN-B3. [Available from: https://cmi-nen.nl/projects/nelcin-b3] 
100. Department of Housing and Urban-Rural Development of Qinghai Province. Government news: lung cancer 
screening programme in Qinghai initiated by Shanghai Cijing Charity Fund with support of Qinghai Red Cross 
Hospital. 2017. [Available from: http://www.qhcin.gov.cn/info/1640/15629.htm] 
101. More Love Foundation. News report: cancer screening in Minhe County, Qinghai Province by Cijing Special 
Charity Fund. 2017. [Available from: http://www.morelove.org.cn/html/20170112256.html] 
102. Sheehan DF, Criss SD, Gazelle GS, et al. Evaluating lung cancer screening in China: Implications for eligibility 
criteria design from a microsimulation modeling approach. PLoS One. 2017;12(3). doi: 
10.1371/journal.pone.0173119. 
103. Zhou QH, Fan YG, Bu H, et al. China national lung cancer screening guideline with low-dose computed 
tomography (2015 version). Thorac Cancer. 2015;6(6):812-8. doi: 10.1111/1759-7714.12287. 
104. Wang Z, Han W, Zhang W, et al. Mortality outcomes of low-dose computed tomography screening for lung 
cancer in urban China: a decision analysis and implications for practice. Chin J Cancer. 2017(8):367-79. doi: 
10.1186/s40880-017-0221-8. 
105. Oudkerk M, Devaraj A, Vliegenthart R, et al. European position statement on lung cancer screening. The 
Lancet Oncology. 2017;18(12):e754-e66. doi: 10.1016/s1470-2045(17)30861-6. 
106. Ostroff JS, Buckshee N, Mancuso CA, et al. Smoking cessation following CT screening for early detection of 
lung cancer. Prev Med. 2001;33(6):613-21. doi: 10.1006/pmed.2001.0935. 
107. van der Aalst CM, van den Bergh KA, Willemsen MC, et al. Lung cancer screening and smoking abstinence: 2 
year follow-up data from the Dutch-Belgian randomised controlled lung cancer screening trial. Thorax. 
2010;65(7):600-5. doi: 10.1136/thx.2009.133751. 
108. Brain K, Carter B, Lifford KJ, et al. Impact of low-dose CT screening on smoking cessation among high-risk 
participants in the UK Lung Cancer Screening Trial. Thorax. 2017;72(10):912-8. doi: 10.1136/thoraxjnl-2016-209690. 
109. Ashraf H, Tonnesen P, Holst Pedersen J, et al. Effect of CT screening on smoking habits at 1-year follow-up in 
the Danish Lung Cancer Screening Trial (DLCST). Thorax. 2009;64(5):388-92. doi: 10.1136/thx.2008.102475. 
110. Tammemagi MC, Berg CD, Riley TL, et al. Impact of lung cancer screening results on smoking cessation. J Natl 
Cancer Inst. 2014;106(6):dju084. doi: 10.1093/jnci/dju084. 
111. Taylor KL, Cox LS, Zincke N, et al. Lung cancer screening as a teachable moment for smoking cessation. Lung 
Cancer. 2007;56(1):125-34. doi: 10.1016/j.lungcan.2006.11.015. 
112. Anderson CM, Yip R, Henschke CI, et al. Smoking cessation and relapse during a lung cancer screening 
program. Cancer Epidemiol Biomarkers Prev. 2009;18(12):3476-83. doi: 10.1158/1055-9965.Epi-09-0176. 
113. Tanner NT, Kanodra NM, Gebregziabher M, et al. The Association between Smoking Abstinence and 
Mortality in the National Lung Screening Trial. Am J Respir Crit Care Med. 2016;193(5):534-41. doi: 
10.1164/rccm.201507-1420OC. 
114. Pastorino U, Boffi R, Marchiano A, et al. Stopping Smoking Reduces Mortality in Low-Dose Computed 
Tomography Screening Participants. J Thorac Oncol. 2016;11(5):693-9. doi: 10.1016/j.jtho.2016.02.011. 
115. Joseph AM, Rothman AJ, Almirall D, et al. Lung Cancer Screening and Smoking Cessation Clinical Trials. SCALE 
(Smoking Cessation within the Context of Lung Cancer Screening) Collaboration. Am J Respir Crit Care Med. 
2018;197(2):172-82. doi: 10.1164/rccm.201705-0909CI. 
116. Wu Y, Yin D, Abbasi K. China's medical research revolution. BMJ. 2018;360:k547. doi: 10.1136/bmj.k547. 
117. Sun X, Tan J, Tang L, et al. Real world evidence: experience and lessons from China. BMJ. 2018;360:j5262. 
doi: 10.1136/bmj.j5262. 
118. McRonald FE, Yadegarfar G, Baldwin DR, et al. The UK Lung Screen (UKLS): demographic profile of first 
88,897 approaches provides recommendations for population screening. Cancer Prev Res (Phila). 2014;7(3):362-71. 
doi: 10.1158/1940-6207.CAPR-13-0206. 
119. Ali N, Lifford KJ, Carter B, et al. Barriers to uptake among high-risk individuals declining participation in lung 
cancer screening: a mixed methods analysis of the UK Lung Cancer Screening (UKLS) trial. BMJ Open. 
2015;5(7):e008254. doi: 10.1136/bmjopen-2015-008254. 
 55 
 
120. van den Bergh KA, Essink-Bot ML, van Klaveren RJ, et al. Informed participation in a randomised controlled 
trial of computed tomography screening for lung cancer. Eur Respir J. 2009;34(3):711-20. doi: 
10.1183/09031936.00098908. 
121. Tanner NT, Gebregziabher M, Hughes Halbert C, et al. Racial Differences in Outcomes within the National 
Lung Screening Trial. Implications for Widespread Implementation. Am J Respir Crit Care Med. 2015;192(2):200-8. 
doi: 10.1164/rccm.201502-0259OC. 
122. Field JK, Duffy SW, Baldwin DR, et al. The UK Lung Cancer Screening Trial: a pilot randomised controlled trial 
of low-dose computed tomography screening for the early detection of lung cancer. Health Technol Assess. 
2016;20(40):1-146. doi: 10.3310/hta20400. 
123. Duda C, Mahon I, Chen MH, et al. Impact and costs of targeted recruitment of minorities to the National 
Lung Screening Trial. Clin Trials. 2011;8(2):214-23. doi: 10.1177/1740774510396742. 
124. Ford ME, Havstad SL, Davis SD. A randomized trial of recruitment methods for older African American men in 
the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Clin Trials. 2004;1(4):343-51. doi: 
10.1191/1740774504cn029oa. 
125. Lee C. Screening for Lung Cancer: Effective Recruitment Methods. AJR Am J Roentgenol. 2018;210(3):514-7. 
doi: 10.2214/AJR.17.18755. 
126. Field JK, Marcus M, Duffy SW, et al. Liverpool Healthy Lung Programme: Preliminary report for the first three 
neighbourhoods: Everton, Picton and Speke. 2017. [Available from: 
https://www.liverpoolccg.nhs.uk/media/2665/liverpool-healthy-lung-project-report_final.pdf] 
127. Crosbie PA, Balata H, Evison M, et al. Implementing lung cancer screening: baseline results from a 
community-based 'Lung Health Check' pilot in deprived areas of Manchester. Thorax. 2018. doi: 10.1136/thoraxjnl-
2017-211377. 
128. Marcus PM, Lenz S, Sammons D, et al. Recruitment methods employed in the National Lung Screening Trial. J 
Med Screen. 2012;19(2):94-102. doi: 10.1258/jms.2012.012016. 
129. Gren L, Broski K, Childs J, et al. Recruitment methods employed in the Prostate, Lung, Colorectal, and 
Ovarian Cancer Screening Trial. Clin Trials. 2009;6(1):52-9. doi: 10.1177/1740774508100974. 
130. van Iersel CA, de Koning HJ, Draisma G, et al. Risk-based selection from the general population in a screening 
trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening 
trial (NELSON). Int J Cancer. 2007;120(4):868-74. doi: 10.1002/ijc.22134. 
131. Tammemagi MC, Schmidt H, Martel S, et al. Participant selection for lung cancer screening by risk modelling 
(the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study. The Lancet 
Oncology. 2017;18(11):1523-31. doi: 10.1016/s1470-2045(17)30597-1. 
132. Field JK, Duffy SW, Baldwin DR, et al. UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the 
screening arm provide evidence for the potential implementation of lung cancer screening. Thorax. 2016;71(2):161-
70. doi: 10.1136/thoraxjnl-2015-207140. 
133. Han SS, Ten Haaf K, Hazelton WD, et al. The impact of overdiagnosis on the selection of efficient lung cancer 
screening strategies. Int J Cancer. 2017;140(11):2436-43. doi: 10.1002/ijc.30602. 
134. National Comprehensive Cancer Network. National Comprehensive Cancer Network Clinical Practice 
Guidelines in Oncology: Lung Cancer Screening. Fort Washington, PA: National Comprehensive Cancer Network; 
version 1.2019 - June 11, 2018. [Available from: https://www.nccn.org/.] 
135. Zhou Q, Fan Y, Wang Y, et al. [China National Lung Cancer Screening Guideline with Low-dose Computed 
Tomography (2018 version)]. Zhongguo Fei Ai Za Zhi. 2018;21(2):67-75. doi: 10.3779/j.issn.1009-3419.2018.02.01. 
136. de Koning HJ, Meza R, Plevritis SK, et al. Benefits and harms of computed tomography lung cancer screening 
strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med. 
2014;160(5):311-20. doi: 10.7326/m13-2316. 
137. Dai M, Hu P, Shi J-F, et al. The China Cancer Screening Trial Feasibility Study. The Lancet. 2015;386. doi: 
10.1016/s0140-6736(15)00616-9. 
138. Chinese Clinical Trial Registry. The Feasibility Study of the Randomized Cancer Screening Trial in China 2015. 
[Available from: http://www.chictr.org.cn/showproj.aspx?proj=11888] 
139. Cassidy A, Myles JP, van Tongeren M, et al. The LLP risk model: an individual risk prediction model for lung 
cancer. Br J Cancer. 2008;98(2):270-6. doi: 10.1038/sj.bjc.6604158. 
140. Raji OY, Duffy SW, Agbaje OF, et al. Predictive accuracy of the Liverpool Lung Project risk model for 
stratifying patients for computed tomography screening for lung cancer: a case-control and cohort validation study. 
Ann Intern Med. 2012;157(4):242-50. doi: 10.7326/0003-4819-157-4-201208210-00004. 
 56 
 
141. Ten Haaf K, Tammemagi MC, Bondy SJ, et al. Performance and Cost-Effectiveness of Computed Tomography 
Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, 
Canada. PLoS Med. 2017;14(2):e1002225. doi: 10.1371/journal.pmed.1002225. 
142. Ten Haaf K, de Koning HJ. Should Never-Smokers at Increased Risk for Lung Cancer Be Screened? J Thorac 
Oncol. 2015;10(9):1285-91. doi: 10.1097/JTO.0000000000000593. 
143. Tammemagi MC, Church TR, Hocking WG, et al. Evaluation of the lung cancer risks at which to screen ever- 
and never-smokers: screening rules applied to the PLCO and NLST cohorts. PLoS Med. 2014;11(12):e1001764. doi: 
10.1371/journal.pmed.1001764. 
144. Church TR, Black WC, Aberle DR, et al. The National Lung Screening Trial Research Team. Results of initial 
low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013;368(21):1980-91. doi: 
10.1056/NEJMoa1209120. 
145. Katki HA, Kovalchik SA, Berg CD, et al. Development and Validation of Risk Models to Select Ever-Smokers for 
CT Lung Cancer Screening. JAMA. 2016;315(21):2300-11. doi: 10.1001/jama.2016.6255. 
146. Ten Haaf K, Jeon J, Tammemagi MC, et al. Risk prediction models for selection of lung cancer screening 
candidates: A retrospective validation study. PLoS Med. 2017;14(4):e1002277. doi: 10.1371/journal.pmed.1002277. 
147. Li K, Husing A, Sookthai D, et al. Selecting High-Risk Individuals for Lung Cancer Screening: A Prospective 
Evaluation of Existing Risk Models and Eligibility Criteria in the German EPIC Cohort. Cancer Prev Res (Phila). 
2015;8(9):777-85. doi: 10.1158/1940-6207.CAPR-14-0424. 
148. Tammemagi MC, Katki HA, Hocking WG, et al. Selection criteria for lung-cancer screening. N Engl J Med. 
2013;368(8):728-36. doi: 10.1056/NEJMoa1211776. 
149. Weber M, Yap S, Goldsbury D, et al. Identifying high risk individuals for targeted lung cancer screening: 
Independent validation of the PLCOm2012 risk prediction tool. Int J Cancer. 2017;141(2):242-53. doi: 
10.1002/ijc.30673. 
150. Gray EP, Teare MD, Stevens J, et al. Risk Prediction Models for Lung Cancer: A Systematic Review. Clin Lung 
Cancer. 2016;17(2):95-106. doi: 10.1016/j.cllc.2015.11.007. 
151. Sakoda LC, Henderson LM, Caverly TJ, et al. Applying Risk Prediction Models to Optimize Lung Cancer 
Screening: Current Knowledge, Challenges, and Future Directions. Curr Epidemiol Rep. 2017;4(4):307-20. doi: 
10.1007/s40471-017-0126-8. 
152. D'Amelio AM, Jr., Cassidy A, Asomaning K, et al. Comparison of discriminatory power and accuracy of three 
lung cancer risk models. Br J Cancer. 2010;103(3):423-9. doi: 10.1038/sj.bjc.6605759. 
153. Katki HA, Kovalchik SA, Petito LC, et al. Implications of Nine Risk Prediction Models for Selecting Ever-
Smokers for Computed Tomography Lung Cancer Screening. Ann Intern Med. 2018;169(1):10-9. doi: 10.7326/M17-
2701. 
154. Raji OY, Agbaje OF, Duffy SW, et al. Incorporation of a genetic factor into an epidemiologic model for 
prediction of individual risk of lung cancer: the Liverpool Lung Project. Cancer Prev Res (Phila). 2010;3(5):664-9. doi: 
10.1158/1940-6207.CAPR-09-0141. 
155. Marcus MW, Raji OY, Duffy SW, et al. Incorporating epistasis interaction of genetic susceptibility single 
nucleotide polymorphisms in a lung cancer risk prediction model. Int J Oncol. 2016;49(1):361-70. doi: 
10.3892/ijo.2016.3499. 
156. Li H, Yang L, Zhao X, et al. Prediction of lung cancer risk in a Chinese population using a multifactorial genetic 
model. BMC Med Genet. 2012;13:118. doi: 10.1186/1471-2350-13-118. 
157. Lin H, Zhong WZ, Yang XN, et al. A clinical model to estimate the pretest probability of lung cancer, based on 
1198 pedigrees in China. J Thorac Oncol. 2012;7(10):1534-40. doi: 10.1097/JTO.0b013e3182641b82. 
158. Wang X, Ma K, Cui J, et al. An individual risk prediction model for lung cancer based on a study in a Chinese 
population. Tumori. 2015;101(1):16-23. doi: 10.5301/tj.5000205. 
159. Yang D, Zhang X, Powell CA, et al. Probability of cancer in high-risk patients predicted by the protein-based 
lung cancer biomarker panel in China: LCBP study. Cancer. 2018;124(2):262-70. doi: 10.1002/cncr.31020. 
160. Yousaf-Khan U, van der Aalst C, de Jong PA, et al. Final screening round of the NELSON lung cancer screening 
trial: the effect of a 2.5-year screening interval. Thorax. 2017;72(1):48-56. doi: 10.1136/thoraxjnl-2016-208655. 
161. Sverzellati N, Silva M, Calareso G, et al. Low-dose computed tomography for lung cancer screening: 
comparison of performance between annual and biennial screen. Eur Radiol. 2016;26(11):3821-9. doi: 
10.1007/s00330-016-4228-3. 
 57 
 
162. Duffy SW, Field JK, Allgood PC, et al. Translation of research results to simple estimates of the likely effect of 
a lung cancer screening programme in the United Kingdom. Br J Cancer. 2014;110(7):1834-40. doi: 
10.1038/bjc.2014.63. 
163. Goffin JR, Flanagan WM, Miller AB, et al. Biennial lung cancer screening in Canada with smoking cessation-
outcomes and cost-effectiveness. Lung Cancer. 2016;101:98-103. doi: 10.1016/j.lungcan.2016.09.013. 
164. Horeweg N, van der Aalst CM, Vliegenthart R, et al. Volumetric computed tomography screening for lung 
cancer: three rounds of the NELSON trial. Eur Respir J. 2013;42(6):1659-67. doi: 10.1183/09031936.00197712. 
165. Patz EF, Jr., Pinsky P, Gatsonis C, et al. Overdiagnosis in low-dose computed tomography screening for lung 
cancer. JAMA Intern Med. 2014;174(2):269-74. doi: 10.1001/jamainternmed.2013.12738. 
166. Veronesi G, Maisonneuve P, Bellomi M, et al. Estimating overdiagnosis in low-dose computed tomography 
screening for lung cancer: a cohort study. Ann Intern Med. 2012;157(11):776-84. doi: 10.7326/0003-4819-157-11-
201212040-00005. 
167. Henschke CI, Boffetta P, Gorlova O, et al. Assessment of lung-cancer mortality reduction from CT Screening. 
Lung Cancer. 2011;71(3):328-32. doi: 10.1016/j.lungcan.2010.10.025. 
168. Veronesi G, Maisonneuve P, Spaggiari L, et al. Long-term outcomes of a pilot CT screening for lung cancer. 
Ecancermedicalscience. 2010;4:186. doi: 10.3332/ecancer.2010.186. 
169. Libby DM, Smith JP, Altorki NK, et al. Managing the small pulmonary nodule discovered by CT. Chest. 
2004;125(4):1522-9. doi:  
170. Henschke CI. International Early Lung Cancer Action Program: Enrollment and Screening Protocol 2011. 
[Available from: http://www.ielcap.org/sites/default/files/ielcap.pdf] 
171. Henschke CI. International Early Lung Cancer Action Program: Screening Protocol 2016. [Available from: 
http://www.ielcap.org/sites/default/files/I-ELCAP-protocol.pdf] 
172. Xu DM, Gietema H, de Koning H, et al. Nodule management protocol of the NELSON randomised lung cancer 
screening trial. Lung Cancer. 2006;54(2):177-84. doi: 10.1016/j.lungcan.2006.08.006. 
173. Baldwin DR, Duffy SW, Wald NJ, et al. UK Lung Screen (UKLS) nodule management protocol: modelling of a 
single screen randomised controlled trial of low-dose CT screening for lung cancer. Thorax. 2011;66(4):308-13. doi: 
10.1136/thx.2010.152066. 
174. Bai C, Choi CM, Chu CM, et al. Evaluation of Pulmonary Nodules: Clinical Practice Consensus Guidelines for 
Asia. Chest. 2016;150(4):877-93. doi: 10.1016/j.chest.2016.02.650. 
175. Callister ME, Baldwin DR, Akram AR, et al. British Thoracic Society guidelines for the investigation and 
management of pulmonary nodules. Thorax. 2015;70 Suppl 2:ii1-ii54. doi: 10.1136/thoraxjnl-2015-207168. 
176. Gould MK, Donington J, Lynch WR, et al. Evaluation of individuals with pulmonary nodules: when is it lung 
cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based 
clinical practice guidelines. Chest. 2013;143(5 Suppl):e93S-e120S. doi: 10.1378/chest.12-2351. 
177. Ruparel M, Quaife SL, Navani N, et al. Pulmonary nodules and CT screening: the past, present and future. 
Thorax. 2016;71(4):367-75. doi: 10.1136/thoraxjnl-2015-208107. 
178. MacMahon H, Naidich DP, Goo JM, et al. Guidelines for Management of Incidental Pulmonary Nodules 
Detected on CT Images: From the Fleischner Society 2017. Radiology. 2017;284(1):228-43. doi: 
10.1148/radiol.2017161659. 
179. Bankier AA, MacMahon H, Goo JM, et al. Recommendations for Measuring Pulmonary Nodules at CT: A 
Statement from the Fleischner Society. Radiology. 2017;285(2):584-600. doi: 10.1148/radiol.2017162894. 
180. Heuvelmans MA, Walter JE, Vliegenthart R, et al. Disagreement of diameter and volume measurements for 
pulmonary nodule size estimation in CT lung cancer screening. Thorax. 2017. doi: 10.1136/thoraxjnl-2017-210770. 
181. Henschke CI, Yip R, Yankelevitz DF, et al. Definition of a positive test result in computed tomography 
screening for lung cancer: a cohort study. Ann Intern Med. 2013;158(4):246-52. doi: 10.7326/0003-4819-158-4-
201302190-00004. 
182. Yip R, Henschke CI, Yankelevitz DF, et al. CT screening for lung cancer: alternative definitions of positive test 
result based on the national lung screening trial and international early lung cancer action program databases. 
Radiology. 2014;273(2):591-6. doi: 10.1148/radiol.14132950. 
183. Gierada DS, Pinsky P, Nath H, et al. Projected outcomes using different nodule sizes to define a positive CT 
lung cancer screening examination. J Natl Cancer Inst. 2014;106(11). doi: 10.1093/jnci/dju284. 
184. McKee BJ, Regis SM, McKee AB, et al. Performance of ACR Lung-RADS in a clinical CT lung screening program. 
J Am Coll Radiol. 2015;12(3):273-6. doi: 10.1016/j.jacr.2014.08.004. 
 58 
 
185. Pinsky PF, Gierada DS, Black W, et al. Performance of Lung-RADS in the National Lung Screening Trial: a 
retrospective assessment. Ann Intern Med. 2015;162(7):485-91. doi: 10.7326/m14-2086. 
186. American College of Radiology. Lung CT Screening Reporting & Data System: Lung-RADS™ Version 1.0. 2014. 
[Available from: https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/Lung-Rads] 
187. dos Santos RS, Franceschini JP, Chate RC, et al. Do Current Lung Cancer Screening Guidelines Apply for 
Populations With High Prevalence of Granulomatous Disease? Results From the First Brazilian Lung Cancer Screening 
Trial (BRELT1). Ann Thorac Surg. 2016;101(2):481-6; discussion 7-8. doi: 10.1016/j.athoracsur.2015.07.013. 
188. Horeweg N, van Rosmalen J, Heuvelmans MA, et al. Lung cancer probability in patients with CT-detected 
pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening. The Lancet 
Oncology. 2014;15(12):1332-41. doi: 10.1016/s1470-2045(14)70389-4. 
189. Yankelevitz DF, Yip R, Smith JP, et al. CT Screening for Lung Cancer: Nonsolid Nodules in Baseline and Annual 
Repeat Rounds. Radiology. 2015;277(2):555-64. doi: 10.1148/radiol.2015142554. 
190. Silva M, Sverzellati N, Manna C, et al. Long-term surveillance of ground-glass nodules: evidence from the 
MILD trial. J Thorac Oncol. 2012;7(10):1541-6. doi: 10.1097/JTO.0b013e3182641bba. 
191. de Hoop B, van Ginneken B, Gietema H, et al. Pulmonary perifissural nodules on CT scans: rapid growth is not 
a predictor of malignancy. Radiology. 2012;265(2):611-6. doi: 10.1148/radiol.12112351. 
192. Ahn MI, Gleeson TG, Chan IH, et al. Perifissural nodules seen at CT screening for lung cancer. Radiology. 
2010;254(3):949-56. doi: 10.1148/radiol.09090031. 
193. Schabath MB, Massion PP, Thompson ZJ, et al. Differences in Patient Outcomes of Prevalence, Interval, and 
Screen-Detected Lung Cancers in the CT Arm of the National Lung Screening Trial. PLoS One. 2016;11(8):e0159880. 
doi: 10.1371/journal.pone.0159880. 
194. Walter JE, Heuvelmans MA, de Jong PA, et al. Occurrence and lung cancer probability of new solid nodules at 
incidence screening with low-dose CT: analysis of data from the randomised, controlled NELSON trial. The Lancet 
Oncology. 2016;17(7):907-16. doi: 10.1016/s1470-2045(16)30069-9. 
195. Heuvelmans MA, Walter JE, Peters RB, et al. Relationship between nodule count and lung cancer probability 
in baseline CT lung cancer screening: The NELSON study. Lung Cancer. 2017;113:45-50. doi: 
10.1016/j.lungcan.2017.08.023. 
196. Gould MK, Fletcher J, Iannettoni MD, et al. Evaluation of patients with pulmonary nodules: when is it lung 
cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(3 Suppl):108S-30S. doi: 
10.1378/chest.07-1353. 
197. Swensen SJ, Silverstein MD, Ilstrup DM, et al. The probability of malignancy in solitary pulmonary nodules. 
Application to small radiologically indeterminate nodules. Arch Intern Med. 1997;157(8):849-55. doi:  
198. McWilliams A, Tammemagi MC, Mayo JR, et al. Probability of cancer in pulmonary nodules detected on first 
screening CT. N Engl J Med. 2013;369(10):910-9. doi: 10.1056/NEJMoa1214726. 
199. Herder GJ, van Tinteren H, Golding RP, et al. Clinical prediction model to characterize pulmonary nodules: 
validation and added value of 18F-fluorodeoxyglucose positron emission tomography. Chest. 2005;128(4):2490-6. 
doi: 10.1378/chest.128.4.2490. 
200. Al-Ameri A, Malhotra P, Thygesen H, et al. Risk of malignancy in pulmonary nodules: A validation study of 
four prediction models. Lung Cancer. 2015;89(1):27-30. doi: 10.1016/j.lungcan.2015.03.018. 
201. White CS, Dharaiya E, Campbell E, et al. The Vancouver Lung Cancer Risk Prediction Model: Assessment by 
Using a Subset of the National Lung Screening Trial Cohort. Radiology. 2017;283(1):264-72. doi: 
10.1148/radiol.2016152627. 
202. Winkler Wille MM, van Riel SJ, Saghir Z, et al. Predictive Accuracy of the PanCan Lung Cancer Risk Prediction 
Model -External Validation based on CT from the Danish Lung Cancer Screening Trial. Eur Radiol. 2015;25(10):3093-
9. doi: 10.1007/s00330-015-3689-0. 
203. Zhao H, Marshall HM, Yang IA, et al. Screen-detected subsolid pulmonary nodules: long-term follow-up and 
application of the PanCan lung cancer risk prediction model. Br J Radiol. 2016;89(1060):20160016. doi: 
10.1259/bjr.20160016. 
204. Chung K, Mets OM, Gerke PK, et al. Brock malignancy risk calculator for pulmonary nodules: validation 
outside a lung cancer screening population. Thorax. 2018. doi: 10.1136/thoraxjnl-2017-211372. 
205. Kim H, Park CM, Jeon S, et al. Validation of prediction models for risk stratification of incidentally detected 
pulmonary subsolid nodules: a retrospective cohort study in a Korean tertiary medical centre. BMJ Open. 
2018;8(5):e019996. doi: 10.1136/bmjopen-2017-019996. 
 59 
 
206. Perandini S, Soardi GA, Larici AR, et al. Multicenter external validation of two malignancy risk prediction 
models in patients undergoing 18F-FDG-PET for solitary pulmonary nodule evaluation. Eur Radiol. 2017;27(5):2042-6. 
doi: 10.1007/s00330-016-4580-3. 
207. Li Y, Wang J. A mathematical model for predicting malignancy of solitary pulmonary nodules. World J Surg. 
2012;36(4):830-5. doi: 10.1007/s00268-012-1449-8. 
208. Jin C, Cao J, Cai Y, et al. A nomogram for predicting the risk of invasive pulmonary adenocarcinoma for 
patients with solitary peripheral subsolid nodules. J Thorac Cardiovasc Surg. 2017;153(2):462-9 e1. doi: 
10.1016/j.jtcvs.2016.10.019. 
209. Zheng B, Zhou X, Chen J, et al. A Modified Model for Preoperatively Predicting Malignancy of Solitary 
Pulmonary Nodules: An Asia Cohort Study. Ann Thorac Surg. 2015;100(1):288-94. doi: 
10.1016/j.athoracsur.2015.03.071. 
210. Hu H, Wang Q, Tang H, et al. Multi-slice computed tomography characteristics of solitary pulmonary ground-
glass nodules: Differences between malignant and benign. Thorac Cancer. 2016;7(1):80-7. doi: 10.1111/1759-
7714.12280. 
211. Nguyen XV, Davies L, Eastwood JD, et al. Extrapulmonary Findings and Malignancies in Participants Screened 
With Chest CT in the National Lung Screening Trial. J Am Coll Radiol. 2017;14(3):324-30. doi: 
10.1016/j.jacr.2016.09.044. 
212. van de Wiel JC, Wang Y, Xu DM, et al. Neglectable benefit of searching for incidental findings in the Dutch-
Belgian lung cancer screening trial (NELSON) using low-dose multidetector CT. Eur Radiol. 2007;17(6):1474-82. doi: 
10.1007/s00330-006-0532-7. 
213. Pinsky PF, Dunn B, Gierada D, et al. Incidental renal tumours on low-dose CT lung cancer screening exams. J 
Med Screen. 2017;24(2):104-9. doi: 10.1177/0969141316657115. 
214. Jin GY, Lynch D, Chawla A, et al. Interstitial lung abnormalities in a CT lung cancer screening population: 
prevalence and progression rate. Radiology. 2013;268(2):563-71. doi: 10.1148/radiol.13120816. 
215. Sverzellati N, Cademartiri F, Bravi F, et al. Relationship and prognostic value of modified coronary artery 
calcium score, FEV1, and emphysema in lung cancer screening population: the MILD trial. Radiology. 
2012;262(2):460-7. doi: 10.1148/radiol.11110364. 
216. Gietema HA, Schilham AM, van Ginneken B, et al. Monitoring of smoking-induced emphysema with CT in a 
lung cancer screening setting: detection of real increase in extent of emphysema. Radiology. 2007;244(3):890-7. doi: 
10.1148/radiol.2443061330. 
217. Pompe E, de Jong PA, van Rikxoort EM, et al. Smokers with emphysema and small airway disease on 
computed tomography have lower bone density. Int J Chron Obstruct Pulmon Dis. 2016;11:1207-16. doi: 
10.2147/copd.S103680. 
218. Henschke CI, Lee IJ, Wu N, et al. CT screening for lung cancer: prevalence and incidence of mediastinal 
masses. Radiology. 2006;239(2):586-90. doi: 10.1148/radiol.2392050261. 
219. Black WC, Gareen IF, Soneji SS, et al. Cost-effectiveness of CT screening in the National Lung Screening Trial. 
N Engl J Med. 2014;371(19):1793-802. doi: 10.1056/NEJMoa1312547. 
220. Cressman S, Peacock SJ, Tammemagi MC, et al. The Cost-Effectiveness of High-Risk Lung Cancer Screening 
and Drivers of Program Efficiency. J Thorac Oncol. 2017;12(8):1210-22. doi: 10.1016/j.jtho.2017.04.021. 
221. Kumar V, Cohen JT, van Klaveren D, et al. Risk-Targeted Lung Cancer Screening: A Cost-Effectiveness 
Analysis. Ann Intern Med. 2018;168(3):161-9. doi: 10.7326/M17-1401. 
222. Prasad V, Lenzer J, Newman DH. Why cancer screening has never been shown to "save lives"--and what we 
can do about it. BMJ. 2016;352:h6080. doi: 10.1136/bmj.h6080. 
223. Young RP, Hopkins RJ. Chronic obstructive pulmonary disease (COPD) and lung cancer screening. Transl Lung 
Cancer Res. 2018;7(3):347-60. doi: 10.21037/tlcr.2018.05.04. 
224. McMahon PM, Kong CY, Bouzan C, et al. Cost-effectiveness of computed tomography screening for lung 
cancer in the United States. J Thorac Oncol. 2011;6(11):1841-8. doi: 10.1097/JTO.0b013e31822e59b3. 
225. Bunge EM, van den Bergh KA, Essink-Bot ML, et al. High affective risk perception is associated with more 
lung cancer-specific distress in CT screening for lung cancer. Lung Cancer. 2008;62(3):385-90. doi: 
10.1016/j.lungcan.2008.03.029. 
226. Brain K, Lifford KJ, Carter B, et al. Long-term psychosocial outcomes of low-dose CT screening: results of the 
UK Lung Cancer Screening randomised controlled trial. Thorax. 2016;71(11):996-1005. doi: 10.1136/thoraxjnl-2016-
208283. 
 60 
 
227. van den Bergh KA, Essink-Bot ML, Borsboom GJ, et al. Short-term health-related quality of life consequences 
in a lung cancer CT screening trial (NELSON). Br J Cancer. 2010;102(1):27-34. doi: 10.1038/sj.bjc.6605459. 
228. Gareen IF, Duan F, Greco EM, et al. Impact of lung cancer screening results on participant health-related 
quality of life and state anxiety in the National Lung Screening Trial. Cancer. 2014;120(21):3401-9. doi: 
10.1002/cncr.28833. 
229. Rasmussen JF, Siersma V, Pedersen JH, et al. Psychosocial consequences in the Danish randomised 
controlled lung cancer screening trial (DLCST). Lung Cancer. 2015;87(1):65-72. doi: 10.1016/j.lungcan.2014.11.003. 
230. McCunney RJ, Li J. Radiation risks in lung cancer screening programs: a comparison with nuclear industry 
workers and atomic bomb survivors. Chest. 2014;145(3):618-24. doi: 10.1378/chest.13-1420. 
231. Brenner DJ. Radiation risks potentially associated with low-dose CT screening of adult smokers for lung 
cancer. Radiology. 2004;231(2):440-5. doi: 10.1148/radiol.2312030880. 
232. Mascalchi M, Belli G, Zappa M, et al. Risk-benefit analysis of X-ray exposure associated with lung cancer 
screening in the Italung-CT trial. AJR Am J Roentgenol. 2006;187(2):421-9. doi: 10.2214/ajr.05.0088. 
233. Rampinelli C, De Marco P, Origgi D, et al. Exposure to low dose computed tomography for lung cancer 
screening and risk of cancer: secondary analysis of trial data and risk-benefit analysis. BMJ. 2017;356:j347. doi: 
10.1136/bmj.j347. 
234. Berrington de Gonzalez A, Kim KP, Berg CD. Low-dose lung computed tomography screening before age 55: 
estimates of the mortality reduction required to outweigh the radiation-induced cancer risk. J Med Screen. 
2008;15(3):153-8. doi: 10.1258/jms.2008.008052. 
235. Field JK, Devaraj A, Duffy SW, et al. CT screening for lung cancer: Is the evidence strong enough? Lung 
Cancer. 2016;91:29-35. doi: 10.1016/j.lungcan.2015.11.003. 
236. Zhang L, Wang H, Li Q, et al. Big data and medical research in China. BMJ. 2018;360:j5910. doi: 
10.1136/bmj.j5910. 
237. Tammemagi MC. Selecting lung cancer screenees using risk prediction models-where do we go from here. 
Transl Lung Cancer Res. 2018;7(3):243-53. doi: 10.21037/tlcr.2018.06.03. 
238. Jemal A, Miller KD, Ma J, et al. Higher Lung Cancer Incidence in Young Women Than Young Men in the 
United States. N Engl J Med. 2018;378(21):1999-2009. doi: 10.1056/NEJMoa1715907. 
239. Ferlay J, Colombet M, Bray F. Cancer Incidence in Five Continents Time Trends, CI5plus: IARC CancerBase 
No.9 [Internet]. Lyon, France: International Agency for Research on Cancer; 2018. [Available from: http://ci5.iarc.fr.] 
240. Zheng R, Zeng H, Zuo T, et al. Lung cancer incidence and mortality in China, 2011. Thorac Cancer. 
2016;7(1):94-9. doi: 10.1111/1759-7714.12286. 
241. Chen W, Zheng R, Zuo T, et al. National cancer incidence and mortality in China, 2012. Chin J Cancer Res. 
2016;28(1):1-11. doi: 10.3978/j.issn.1000-9604.2016.02.08. 
242. Zheng R, Zeng H, Zhang S, et al. Estimates of cancer incidence and mortality in China, 2013. Chin J Cancer. 
2017;36(1):66. doi: 10.1186/s40880-017-0234-3. 
243. Zhi XY, Zou XN, Hu M, et al. Increased lung cancer mortality rates in the Chinese population from 1973-1975 
to 2004-2005: An adverse health effect from exposure to smoking. Cancer. 2015;121 Suppl 17:3107-12. doi: 
10.1002/cncr.29603. 
244. World Health Organisation (WHO) International Agency for Research on Cancer (IARC): Cancer Mortality 
Database. 2016. [Available from: http://www-dep.iarc.fr/WHOdb/WHOdb.htm] 
245. Chen WQ, Zhang SW, Zou XN, et al. Cancer incidence and mortality in china, 2006. Chin J Cancer Res. 
2011;23(1):3-9. doi: 10.1007/s11670-011-0003-9. 
246. Cancer Hospital Chinese Academy of Medical Sciences. Results of project funding from the National Key 
Reseach and Development Program of China in 2017. 2017. [Available from: 
http://www.cicams.ac.cn/Html/News/Articles/2631.html] 
247. National Science and Technology Information System, Public Service Platform. Results of project funding 
from the National Key Reseach and Development Program of China in 2018. 2018. [Available from: 
http://service.most.gov.cn/2015tztg_all/index_13.html#] 
248. Shanghai Municipal Government. Progress Report of governmental programmes in September, 2018. 2018. 
[Available from: http://www.baoshan.sh.cn/xxgk_website/HTML/bsxxgk/bsxxgk_xbzfssxm_zfssxmjz/2018-10-
08/Detail_301895.htm]  
 61 
 
 
Figure 1 Trends in smoking prevalence, lung cancer incidence and mortality in China, UK and the US, 
by sex. 125x124mm (300 x 300 DPI)  
 62 
 
 
Figure 2 The landscape of lung cancer screening programmes in China since the 1990s.  
525x375mm (300 x 300 DPI)  
 63 
 
 
Figure 3 Levels of evidence for the implementation of lung cancer CT screening in China.  
90x67mm(300 x 300 DPI)  
 64 
 
Supplemental Materials 
Implementation planning for lung cancer screening in China 
Yue I. Cheng 1,2, Michael P.A. Davies 2, Dan Liu 1, Weimin Li 1, *, John K. Field 
2, * 
1 Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, 
Chengdu, 610041, China 
2 Lung Cancer Research Group, Department of Molecular and Clinical Cancer Medicine, Institute of 
Translational Medicine, University of Liverpool, William Henry Duncan Building, 6 West Derby 
Street, Liverpool L7 8TX, United Kingdom. 
* Corresponding authors:  
Weimin Li, E-mail: weimin003@163.com; John K. Field, E-mail: J.K.Field@liverpool.ac.uk. 
 
 65 
 
Supplemental Figures 
Figure S1 Historical events associated with tobacco and tobacco control in China, the 
UK and the US. ....................................................................................................................... 66 
Figure S2 Timeline of selected nationally/sub-nationally representative surveys or 
important historical events associating with tobacco use (above the arrow) and cancer 
(below the arrow), and development of cancer registrations in China. ............................ 66 
Supplemental Tables 
Table S1 Study designs in Lung cancer low-dose computerised tomography (LDCT) 
screening programmes outside China. ................................................................................. 67 
Table S2 Recruitment procedures and entry criteria in lung cancer low-dose 
computerised tomography (LDCT) screening programmes .............................................. 69 
Table S3 Baseline participant characteristics, and baseline and overall low-dose 
computerised tomography (LDCT) screening results in lung cancer screening studies . 71 
Table S4 Lung cancer risk models from China. ................................................................. 73 
Table S5 Nodule management criteria for low-dose computerised tomography in lung 
cancer screening trials. .......................................................................................................... 75 
Supplemental information  
Searching Strategies for Lung Cancer Screening Studies in China 
Lung cancer screening programmes in China  
 66 
 
Figure S1 Historical events associated with tobacco and tobacco control in China, the UK and 
the US.  
Abbreviations: UK, United Kingdom; US, United States; WW I, the First World War; WW II, the Second 
World War; CPC, The Communist Party of China; WTO, World Trade Organization; FCTC, Framework 
Convention on Tobacco Control; GYTS, Global Youth Tobacco Survey; GATS, Global Adult Tobacco Survey. 
Information excerpted from references 1-6. 
Figure S2 Timeline of selected nationally/sub-nationally representative surveys or important 
historical events associating with tobacco use (above the arrow) and cancer (below the arrow), 
and development of cancer registrations in China. 
Abbreviations: CRP, cancer registration point; NCCR, National Central Cancer Registration; IACR, 
International Agency for Research on Cancer  CI5, Cancer Incidence in Five Continents; N/A, not available.  
The first table displays the total number of CRPs at a specific time in China; the percentage in the bracket is the 
population covered by CRPs in relation to the contemporary total population from the census. The second table 
displays the number of CRPs which NCCR submitted to CI5 and CI5 included in its separate reports, the latter 
taken as an indicator of data quality. Only CRPs in mainland China have been considered here. References are 
for smoking 6-13 and cancer/cancer registrations 14-19, respectively. 
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Table S1 Study designs in Lung cancer low-dose computerised tomography (LDCT) screening programmes outside China. 
Study 
design 
Allocation 
group 
Study 
Name 
[Ref.] 
Country Initiat
ion 
year 
Cancer-
related 
mortality 
endpoint 
Study 
Power
ed 
Smoking 
cessation 
program 
No. in study/ 
control arm 
Intervention 
regimen 
Control regimen Planned 
screening 
rounds in 
LDCT arm 
Screening 
interval 
(years) 
Follow-up years 
(Median/mean 
person-years)1 
Non-
RCTs 
LDCT 
Prospective 
cohort 
I-ELCAP 20 US 1993 No No No 31567/- Annual LDCT NA 10 2 1 10 (planned for 
those LCs 
diagnosed) 
Mayo 
LDCT  21 
US 1999 No Yes No 1520/- Annual LDCT + 
sputum samples 
NA 5 1 4 (after baseline) 
COSMOS 
22 
Italy 2004 No No Yes 5201/- Annual LDCT; 
baseline spirometry 
NA 5 1 10 years 
(panned) 
PanCan 23 Canada 2008 No Yes No 2537/- LDCT at 1st , 2nd and 
4th year 
NA 3 1,2 5.5 (after 
baseline) 
BRELT1 24 Brazil 2013 No No Yes 790/- Annual LDCT NA NS 1 NA 
RCTs LDCT 
vs. 
CXR 
LSS 25 US 2000 No No No 1660/1658 Annual LDCT Annual CXR 2 1 NA (followed-up 
only LCs) 
NLST 26 US 2002 Yes Yes Yes 26722/26732 Annual LDCT Annual CXR 3 1 6.5 (after 
baseline) 
Depiscan 27 France 2002 No No No 385/380 Annual LDCT Annual CXR 3 1 NA 
JECS 28 Japan 2012 No Yes No NA 3 LDCT at 1st and 6th 
year; with CXR 
encouraged annually 
CXR at 1st year; 
with CXR 
encouraged annually 
2 5 10 (planned) 
LDCT 
vs. 
Usual Care 
DANTE 29 Italy 2001 Yes No No 1403/1408 Annual LDCT; 
baseline CXR+ 
sputum 
Annual usual care; 
baseline CXR+ 
sputum 
5 1 8.35 (after 
baseline) 
NELSON 30 Netherlands 
& Belgium 
2003 Yes Yes Yes 7915/7907 LDCT at 1st, 2nd, 4th, 
6.5th year 
Usual care 4 1,2, 2.5 10 (planned) 
ITALUNG 
31 
Italy 2004 Yes No Yes 1613/1593 Annual LDCT; 
smoking cessation 
program 
Usual care; smoking 
cessation program 
4 1 8.5 (after 
baseline) 
DLCST 32 Denmark 2004 Yes No No 2052/2052 Annual LDCT Usual care 5 1 9.80 (after 
baseline) 
MILD 33 Italy 2005 Yes No Yes 1186/1190 
/1723  4 
Biennial/annual 
LDCT 
Usual care 3; 5 2,1 4.4 (after 
baseline) 
LUSI 34 Germany 2007 Yes Yes Yes 2029/2023 Annual LDCT + 
baseline smoking 
cessation 
counselling 
Annual usual care + 
baseline smoking 
cessation 
counselling 
5 1 3-6.5 (minimum 
and maximum 
years) 
UKLS 35 UK 2011 No No Yes 2028/2027 LDCT with the 
Wald single-screen 
design 
Usual care 1 NA NA 
Abbreviations: RCT, randomised controlled trial; non-RCT, non-randomised controlled trial; LDCT, low-dose computerised tomography; CXR, chest X-ray; NA, not applicable; LC, lung cancer; yrs, years. 1 Mean person-years displayed if 
no median ones reported.  2 In the 2006 manuscript 20, only 2 screening rounds- the baseline and the 2nd screen round were reported. 3 the initial design in 2012 was to recruit 35 000 participants, and then revised to 26000 on March 2016. 4 
Data displayed as population in the biennial/annual/control arm.  
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Table S2 Recruitment procedures and entry criteria in lung cancer low-dose computerised tomography (LDCT) screening programmes  
 Recruitment procedures  Entry criteria 
Study Name 
[Ref.] 
Recruiting 
time 
Recruiting methods 
Population 
source 
Multi-
centre 
Recruitment 
Completed 
 Age Sex Smoking status Smoking exposure 
I-ELCAP 20 1993-2005 
GPs and local newspaper, radio 
and television 
Hospital/ 
volunteer-based 
Yes Yes  ≥40 Both 
Current /former 
/passive 
Varied by sites 
Mayo LDCT  
trial 21 
Jan,1999-
Dec,1999 
Local and regional television 
and newspaper coverage. 
Volunteer-
based 
Yes Yes  ≥50 Both Current /former >20 PYs, quit  <10yrs 
COSMOS 22 
Oct, 2004-
Oct, 2005 
Newspaper and television 
campaign 1 
Volunteer-
based 
No Yes  ≥50 Both Current /former ≥20 PYs, quit <10yrs 
PanCan 23 
Sep, 2008-
Dec, 2010 
Newspaper, TV radio, public 
posters, laboratories, study 
websites, friends and GPs 
Volunteer-
based 
Yes Yes  50-75 Both Current /former PanCan model: >2% lung cancer risk in 6 years 
BRELT1 24 
Jan, 2013-
Jul, 2014 
Public calls through 
communication vehicles. 
Volunteer-
based 
No Yes  55-74 Both Current /former ≥30 PYs, quit ≤15yrs 
Shanghai 
CancerHosp  36 
Aug, 2013-
Aug, 2014 
Network established In selected 
communities. 
Community-
based 
Yes Yes  50-80 Both 
≥1 of below: current or former smokers (≥20 PYs), and if former 
smoker, quit < 5yrs; or passive smokers; or never smokers with other 
risk factors of lung cancer including lung cancer family history, history 
of kitchen fume, or dust exposure. 
LSS  37 
Sep, 2000-
Nov, 2000 
primarily mass mailings; other 
including media and GPs. 
Population-
based 
Yes Yes  55-74 Both Current /former ≥30 PYs, quit <10yrs 
NLST 38 
Aug, 2002-
Apr, 2004 
primarily mass mailings; other 
including media and GPs. 
Population-
based 
Yes Yes  55-74 Both Current /former ≥30 PYs, quit ≤15yrs 
Depiscan 27 
Oct, 2002-
Dec, 2004 
GPs and occupational 
physicians 
Hospital-based Yes Yes  50-75 Both Current /former ≥15 cigs/day  for ≥20yrs, quit <15yrs 
JECS 28, 39 May,2012- Invitation letters NS Yes No  50-70 2 Both non/light <30 PYs 
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 Recruitment procedures  Entry criteria 
Study Name 
[Ref.] 
Recruiting 
time 
Recruiting methods 
Population 
source 
Multi-
centre 
Recruitment 
Completed 
 Age Sex Smoking status Smoking exposure 
DANTE 40 
Mar, 2001 
-Feb, 2006 
GPs, mass mailings, advertising 
leaflets and local media. 
Population-
based 
Yes Yes  60-74 Males Current /former ≥20 PYs, quit  <10yrs 
NELSON 30 
Sep, 2003-
2006 
Invitation letters 
Population-
based 
Yes 
 
Yes  50-75 Both Current /former 
≥15 cigs/day  for ≥25yrs or ≥10 cigs/day for 
≥30yrs, quit ≤10yrs 
ITALUNG 41 2004-2006 
Invitation letters to subjects 
registered with selected GPs 
Hospital-based Yes Yes  55-69 Both Current /former ≥30 PYs since last 10yrs, quit <10yrs 
DLCST 42 
Oct, 2004-
Mar, 2006 
Free  newspapers, weeklies or 
GPs 
Volunteer-
based 
No Yes  50-70 Both Current /former ≥20 PYs, quit <10yrs after age of 50 
MILD 33 
Sep, 2005-
Jan, 2011 
Ads, TV broadcast and articles 
in the lay press. 
Volunteer-
based 
Yes Yes  ≥49 Both Current /former ≥20 PYs, quit ≤10yrs 
LUSI 43 
Sep, 2007-
Dec, 2010 
Mass mailings 
Population-
based 
No Yes  50-69 Both Current /former 
≥15 cigs/day  for ≥25yrs or ≥10 cigs/day for 
≥10yrs,  quit ≤10yrs 
UKLS 35 
Aug, 2011-
Aug, 2012 
Mass mailings 
Population-
based 
Yes Yes  50-75 Both LLPv2 model: ≥5% lung cancer risk in 5 years 
Shanghai  
ChestHosp 44 
Nov, 2013-
Nov, 2014 
GPs and advertising leaflets in 
selected communities 
Community-
based 
No Yes  45-70 Both 
≥1 of below: current /former (≥20 PYs and/or quit ≤15yrs); or passive  
(>2h/day for ≥10yrs); or occupational; or cooking (frying >50dish-yrs); 
or family history of cancer 
China 
FeasiRCT 45 
2014-2015 NS NS Yes Yes  50-74 Both 
Current/former (>30 PYs); or passive (living with a regular daily 
smoking for >20yrs) 
Abbreviations: Non-RCTs, non-randomised controlled trials; RCTs, randomised controlled trials; PYs, pack-years; yrs, years; cigs, cigarettes; NS, not specified. 1 extracted from Pastorino et al, 2003 46. 2 aged 50-64 
years in entry criteria before March 2016.
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Table S3 Baseline participant characteristics, and baseline and overall low-dose computerised tomography (LDCT) screening results in lung cancer screening studies 
Study Name  [Ref.] 
I-ELCAP 
20 
Mayo 
LDCT 
trial 
 21, 47 
COSMOS 
 22, 48 
PanCan 
23 
BRELT1 
24 
Shanghai 
Cancer 
Hosp 36 
LSS 
25, 37 
NLST 
26, 49, 50 
Depiscan 
27 
JECS 
28, 39 
DANTE 
29, 40 
NELSON 
51-53 
ITALUNG 
31, 41, 54 
DLCST 
32, 42 
MILD 33 
LUSI 
34, 43 
UKLS 
55 
Shanghai  
Chest 
Hosp 44 
China 
FeasiRCT 
56, 57 
Baseline characteristics 
age (years)1 61 59 58 62 62 63 NR 2 61 56 NA 64 59 61 58 57 NR 3 67 60 60 
Male,% NR 52% 66% 55% 50% 54% 59% 59% 71% NA 100% 84% 65% 55% 66% 67% 75% 47% 53% 
Female,% NR 48% 34% 45% 50% 46% 41% 41% 29% NA 0% 16% 35% 45% 34% 33% 35% 53% 47% 
Smokers,% 82.8% 100% 100% 100% 100% 55.5% 100% 100% 100% NA 100% 100% 100% 100% 100% 100% 100% 28% 3 54% 
Current smokers,% NR 61% 80% 63% 55% NR 58% 58% 60% NA 57% 55% 65% 76% 77% 62% 39% 21% 46% 
Former smokers,% NR 39% 20% 37% 45% NR 42% 42% 40% NA 43% 45% 35% 24% 23% 38% 61% 7% 8% 
smoking exposure 
(PYs)1 
30 45 44 54 54 NR 54 54 NR 4 NA 45 38 39 36 39 NR NR 5 11 6 NR 7 
Baseline results at the LDCT screening arm 
LC prevalence, % 1.3% 2.0% 1.1% 5.4% 1.3% 0.2% 1.9% 1.0% 2.4% NA 2.2% 1.0% 1.5% 0.8% 
0.9% 
/0.9% 8 
1.1% 1.7% 1.6% NA 
Stage I, % 85.9% 71.0% 65.4% 74.3% 9 80.0%  81.4% 9 53.0% 57.4% 37.5% NA 57.1% 64.9% 52.3% 52.9% NS 73.9% 60.6% 94.2% NA 
Stage III/IV, % 10 NS 9.7% 29.1% 17.6% 20.0% 7.4% 30.0% 34.4% 72.5% NA 32.0% 25.7% 28.6% 41.1% NS 17.4% 15.2% 1.9% NA 
Adenocarcinoma , % 77.6% 11 74.2% 72.7%  80.9% 70.0% 88.9% 63.0% 57.8% 62.5% NA 36.0% 50.0% 47.6% 70.6% NS 68.2% 54.5% 92.3% NA 
Overall results at the LDCT screening arm 
LC incidence, % 1.5% 4.3% 1.8% 6.5% NA NA 2.4% 4.0% NA NA 8.2% 3.9% 4.8% 4.9% 
2.1% 
/2.9% 8  
3.1% 2.1% NA NA 
LC cumulative 
incidence (/10 000 
person-years) 
NA NA NA 138.1 NA 23.8 NA 64.5 NA NA NA NA 49.9 51.4 
45.7  
/62.0 8 
67.4 NA NA NA 
Stage I, % 85.1% 59.1% 66.3% 62.9% 12 NA NA 48.0% 49.1% NA NA 45.2% 69.0% 13 35.8% 13 50.0% 
70.0%/ 
62.1% 8 
69.4% 66.7% NA NA 
Stage III/IV, % 10 NS 13.6% 28.3% 22.4% 12 NA NA 40.0% 42.2% NA NA 41.3% 22.7% 13 49.3% 13 46.0% 
25.0%/ 
31.0% 8 
21.0% 14.3% NA NA 
Adenocarcinoma, % 71.4% 11 54.5% NS 74.3% 12 NA NA 60.0% 46.2% NA NA 42.3% 51.0% 13 43.3% 13 58.0% 
85.0% 
/51.7% 8 
72.6% 59.5% NA NA 
Biopsy rate, % 14 1.7% NS 1.9% 5.4% 15 3.2% 16 0.6% 16 
3.3% 
16,17 
6.5% 17 NA  NA 7.1%  15 1.2%  16,17 2.7% 13,15 1.2% 16,17 
1.8% 
15,18 
4.0% 2.0% 15 1.7% 15,16 NA 
Malignancy-to- benign 
ratio 
11.4 3.9 15,19 5.7 7.6 15 0.7 16 1.9 16 
1.5 
16,17 
1.4 17 NA NA 4.3 15 NA 8.5 13,15 3.0 16,17 10.2 15 2.5 8.8 15 11 15,16 NA 
Abbreviations: PYs, pack-years; NR, not reported; NA, not applicable; LC, lung cancer. Data are number or percentage (%); 1 mean values displayed if no median value reported. 2 68% in 55-64 years-old. 3 46% in the age of 50-54 years.  3 
passive smoking rate 24%. 4 Median pack of cigarettes per day was 1, median year of smoking history was around 30. 5 93.8% with a smoking duration of 20+ years.  6 estimated from the LDCT arm. 7 44% in the 30-39 pack-years; 47% 
were females who had passive-smoking exposure of ≥20 pack-years. 8 Data displayed as biennial arm/annual arm. 9 Including stage 0 lung cancers. 10 Including small cell lung cancers at extensive stage. 11 Only subtypes 
in stage I lung cancers were reported. 12 Percentages in lung cancers with stage 0 lung cancers (5.9%) excluded. 13 Not include clinically detected lung cancers among incompliant participants in the LDCT arm. 14 the proportion of 
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subjects undergoing invasive procedures in individuals undergoing baseline LDCT screening. 15 Calculated for those with surgeries. 16 Calculated from baseline results. 17 Any invasive procedure. 18 Overall in Biennial and annual screening 
arms. 19 Calculated from baseline, 2nd and 3rd rounds 
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Table S4 Lung cancer risk models from China. 
Author, 
year 
Dataset Study design Population Sample 
size 
Malig. 
rate 
(%) 
Formula 
displayed 
Discrimination 
(AUC or c-
statistics) 
Calibration 
(P-value) 
Prediction 
rules (risk 
threshold) 
Acc. Sen. Spe. Predictors in the model 
Risk model for high-risk population selection 
Li et al,  
2012 58 
Development Case-control 
 
Hospital-
based 
5068 NA Yes 0.637 0.154 NS 61.7% 54.2% 67.8% Smoking status (never, light, heavy); 4 candidate 
SNPs - rs2736100 (TERT), rs402710 (CLPTM1L), 
rs4488809 (TP63) and rs4083914 (RGS17). 
Internal 
validation 
5068 0.641 \ \ \ \ \ 
Internal 
validation 
3801 0.633 \ NS 61.7% 54.7% 67.5% 
Internal 
validation 
1267 \ NS 61.5% 52.6% 68.4% 
Lin et al, 
2012 59 
Development Case-control 
(cases pedigrees  
vs spouses 
pedigrees) 
 
Hospital-
based 
1198 NS Yes 0.75 \ <5; 
5-10; 
≥10 
68.3%; 
84.0%; 
91.9% 
\ \ Gender, smoking history (never, light, heavy), lung 
disease history occupational exposure, number of 
Lung cancer-affected individuals as first-degree 
relatives (0, 1, ≥ 2). 
Internal 
validation 
0.71 0.62 \ \ \ 
Wang et 
al, 2015 
60 
Development Case-control 
 
Hospital-
based 
1693 NA No 0.885 \ 0.35 \ 0.87 0.79 Age; sex; education level; family history of cancer; 
smoking cigarettes; COPD history;  BMI; pesticide 
and cooking emission exposure; dietary intake of 
specific foods (seafood, vegetables, fruits, soybean 
products and nuts, dairy products, meat) 
Yang et 
al, 2018 
61 
Development retrospective 
cohort 
Hospital-
based 
389 39.9% Yes 0.7037 
 
\ high-risk: ≥ 
0.65 
 
\ 14.9% 94.5% Age, sex, smoking status and history of cancer ; 4 
serum biomarkers progastrin-releasing peptide 
(ProGRP), carcinoembryonic antigen (CEA), 
squamous cell carcinoma antigen (SCC), and 
cytokeratin 19 fragment (CYFRA21-1) External 
validation 
(spatially) 
retrospective 
cohort 
Hospital-
based 
326 42.9% 0.7190 \ \ 13.0% 98.3% 
Risk model for nodule malignancy prediction 
Dong et 
al, 2014 
62 
Development retrospective 
cohort 
Hospital-
based 
3358 77.2% Yes 0.935 \ 0.659 \ 90.7% 81.2% Age; smoking status; family history of cancer; 
nodule diameter, spiculation, clear border, 
calcification, lobulation; satellite lesions; serum CEA 
level; serum CYFRA-21 level 
Internal 
validation 
77.7% 0.917 0.571 \ \ \ 
Hu et 
al,2016 
63 
Development Retrospective 
cohort 
Hospital-
based 
112 
(with 
GGNs) 
73.2% Yes \ \ NS 84.8% 93.9% 60.0% Solid component, vascular convergence sign, and 
diameter. 
Jin et al , 
2017 64 
Development Retrospective 
cohort 
Hospital-
based 
273 58.2% Yes 0.894 \ 0.65 80.2% 78.6% 82.5% Nodule diameter, spiculation, solid proportion; CT 
attenuation; vascular convergence; pleural tag 
Internal 
validation 
NS Excellent (in 
graph) 
\ \ \ \ 
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Author, 
year 
Dataset Study design Population Sample 
size 
Malig. 
rate 
(%) 
Formula 
displayed 
Discrimination 
(AUC or c-
statistics) 
Calibration 
(P-value) 
Prediction 
rules (risk 
threshold) 
Acc. Sen. Spe. Predictors in the model 
Li et al, 
2012 65 
Development retrospective 
cohort 
 
Hospital-
based 
 
371 61.7% Yes 0.888 \ 0.463 \ \ \ Age, diameter, spiculation, family cancer history, 
calcification, and clear border 
External 
validation 
(temporally) 
145 67.6% 0.874 \ 94.5% 70.0% 
External 
validation 
(spatially) 66 
retrospective 
cohort 
Hospital-
based 
107 72.9% 0.810 \ 0.471 \ 83.3% 75.9% 
Yang et 
al, 2017  
67 
Development retrospective 
cohort 
 
Hospital-
based 
1078 66.9% Yes 0.807 \ NS \ 85.7% 60.4% gender, age, pack-years of smoking, a previous 
history of malignancy, previous extrathoracic 
disease, nodule size, lobulated and spiculated edges, 
lobulation alone and spiculation alone, irregular 
edges, calcification 
External 
validation 
(temporally) 
344 68.6% 
 
0.784 \ NS \ 70.1% 78.6% 
Yang et 
al,2018 
61 
Development retrospective 
cohort 
Hospital-
based 
163 NS Yes 0.915 \ 0.94 \ 60.4% 94.2% Age; sex; smoking status; diameter of nodules; 
spiculation feature; and serum expression level of 
ProGRP, SCC, CYFRA21-1, and CEA. 
External 
validation 
(spatially) 
179 NS 0.584 \ \ 65.6% 77.8% 
Zhang et 
al, 2015 
68 
Development Retrospective 
cohort 
Hospital-
based 
294 59.9% Yes \ \ \ \ \ \ Age; smoking status; nodule diameter, spiculation, 
clear border; serum CYFRA-21 level 
External 
validation 
(temporally) 
120 60.0% 0.91 \ 0.5552 \ 86.8% 84.6% 
Zheng et 
al, 2015 
69 
Development Retrospective 
cohort 
Hospital-
based 
405 63% Yes (1) 0.856 \ \ \ \ \ Model 1 for SPNs with < 50% GGO: age; presence 
of symptoms; serum total protein; nodule diameter, 
lobulation; calcified nodes. 
Model 2 for SPNs with ≥ 50% GGO: sex, FEV1 %; 
nodule diameter; calcified nodes. 
(2) 0.838 
Internal 
validation 
198 (1) 0.808 \ \ \ \ \ 
(2) 0.845 
Abbreviations: Malig., malignancy; Acc., accuracy; Sen., sensitivity; Spe., specificity. GGO, ground-glass opacity; SPN, solitary pulmonary nodule. NS, not specified; NA, not applicable. \, indicates no data reported. 
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Table S5 Nodule management criteria for low-dose computerised tomography in lung cancer screening trials. 
Study Name 
[Ref.] 
Diameter 
Measurement 
Volumetric Measurement Baseline Positive def. 1 Growth def. Suspicious of LC  at baseline 2 Incidence 
positive 
def. 
Suspicious of 
LC at 
incidence 2 
I-ELCAP  20 Average of length 
and width 
Measured on conventional 
CT or 3D software. 
Largest non-calcified SNs/PSNs ≥5mm; 
largest NSNs ≥8 mm; any endo-bronchial 
SNs; No.≤ 6. 
Diameter percentage change: 
≥50% in nodules <5mm, ≥30% 
in nodules 5-9mm, ≥ 20% in 
nodules ≥ 10 mm 70; or VDT: 
30-360 days 71 
≥15 mm; or nodule growth, or 
PET-positive. 
Any new 
nodules  
Nodule 
growth or 
without 
regression, or 
PET positive. 
Mayo LDCT  
trial 21 
Average of length 
and width 
\ Any-size of non-calcified nodules, later 
changed to ≥4mm; No.≤ 6. 
NS > 20mm; or nodule growth Any new 
nodules 
As baseline 
COSMOS 22 Maximum axial 
diameter. 
Calculated on the largest 
lesion diameter using an 
electronic calliper. 
Non-calcified nodules ≥6mm, or nodules 
with benign imaging features >8 mm. 
VDT 30-400 days Nodule growth, or PET-CT 
positive SUV>2.0; enhanced CT 
delta enhancement > 20HU 
Any new 
nodules 
As baseline 
PanCan 23  Maximum axial 
diameter. 
\ ≥1 mm non-calcified or non-perifissural 
nodules or  areas of non-solid density 
\ NS As 
baseline 
As baseline 
BRELT1 24 3 Maximum axial 
diameter. 
Calculated  by semi-
automated software 
≥5mm nodules; later changed to 6mm NS in Volume threshold.  Nodule risk prediction > 60%; 
PET/CY SUV>2.5 and/or 
nodules’ morphologic 
appearance 
NA As baseline 
Shanghai 
CancerHosp  
36 
Maximum axial 
diameter. 
Measured by a computer-
aided detection software 
Largest non-calcified SNs/PSNs ≥5mm; 
largest NSNs ≥8 mm; any endo-bronchial 
SNs 
Volume percentage change ≥ 
25% 
≥15 mm; or nodule growth; or 
PET-positive. 
Any new 
nodules  
Nodule 
growth or 
without 
regression, or 
PET positive. 
LSS 25, 37 Maximum axial 
diameter. 
\ ≥4mm non-calcified nodules or masses; ≤ 3 
mm spiculated non-calcified nodules; focal 
parenchymal opacification; Endo-bronchial 
lesions. 
\ ≥4mm non-calcified nodules As 
baseline 
As baseline 
NLST 26 Maximum axial 
diameter. 
\ Non-calcified nodules Nodule(s) ≥4mm NS Non-calcified nodules >10 mm; 
or Enlarging nodules  ≥7mm; 
And PET/CT abnormal activity 
or CT enhance ≥ 15HU 
As 
baseline 
As baseline 
Depiscan 27 Average of length 
and width 
Measured on conventional 
CT or 3D software. 
Non-calcified nodules >5 mm VDT: 30-360 days ≥ 10mm, or nodule growth, or 
PET-positive. 
As 
baseline 
As baseline 
JECS 72 Average of length 
and width 
\ ≥ 5mm SN/PSNs NS (SNs) ≥ 10mm, (PSNs/NSNs) ≥ 
10mm or nodules growth 
Any new 
nodules 
New SNs ≥ 
10mm or 
nodule 
growth 
DANTE  40 Maximum axial 
diameter. 
\ ≥ 5mm,  with malignant radiological 
features, or NSNs 
NS Non‐smooth SNs/PSNs ≥ 5 mm, 
or NSNs>10mm, no regression 
As 
baseline 
As baseline 
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after antibiotics and PET-
positive 
NELSON 73 Average of length 
and width (NSNs); 
Diameter 
perpendicular to 
the costal pleura 
(PSNs and pleural-
based SNs).  
(SNs or solid component in 
PSNs) 3D volumetric 
computer assessment with 
manual adjustment. VDT 
estimation by volume in 
SNs or diameter in PNs, 
NSNs, pleural-based 
nodules. 
NOTCAT III  
SNs 50-500mm3; pleural based SNs 5-
10mm dmin; PSNs, non-solid component 
≥8mm dmean;  PSNs, solid component 50-
500mm3; NSNs  ≥8mm 
NOTCAT IV  
SNs >500mm3; pleural based SNs >10mm 
dmin; PSNs, solid component >500mm3 
All nodules measured. 
Percentage volume change 
(PVC) ≥25% after ≥ 3 months 
interval; VDT<400 days or new 
solid component in NSNs. 
SNs or PSN solid 
component >500mm3; pleural-
based SNs >10mm; nodule 
growth. 
As 
baseline 
As baseline 
ITALUNG 31 Average of length 
and width 
\ SNs ≥5mm, NSNs≥10mm, or PSNs ≥ 1mm increase in mean 
diameter of SNs or increase of 
the solid component in PSNs 
SNs ≥10mm or PET-positive, or 
nodule growth. 
Any new 
nodules 
Nodule 
growth or 
PET-positive 
in SNs/solid 
in PSNs 
≥8mm 
DLCST 42 Maximum axial 
diameter 
Measured by a computer-
aided detection software 
Non-calcified nodules ≥5mm Increase in volume of ≥25%,  
VDT <400 days 
Nodules ≥15mm, or nodule 
growth 
As 
baseline 
As baseline 
MILD 33 \ Measured by a computer-
aided detection software 
No. ≤4; non-calcified nodules ≥60 mm3 
( ≥5mm) 
Volume increase ≥25% after 3 
month interval 
Non-calcified nodules  ≥250 
mm3  (≥8mm), nodule growth 
As 
baseline 
As baseline 
LUSI 43 NS Measured by a computer-
aided detection software 
Non-calcified nodules ≥5mm VDT  ≤400 days Non-calcified nodules >10 mm, 
nodule growth, or other 
malignant features 
As 
baseline 
As baseline 
UKLS 35 Similar to 
NELSON 
Similar to NELSON CATEGORY 2 
SNs 15-49mm3 or 3-4.9mm; PSNs solid 
component <15mm3 or <3 mm; NSNs 3-
4.9mm 
CATEGORY 3 
SNs 50-500mm3 or 5-9.9mm; PSNs 
nonsolid component > 5mm, solid 
component 15-500mm3 or 3-9.9mm; NSNs 
≥5mm.  
CATEGORY 4 
SNs >500mm3 or ≥10mm; PSNs solid 
component > 500mm3   
No. ≤20. 
VDT <400days SNs >500mm3 or >10mm; PSNs 
solid >500mm3; Nodule growth. 
As 
baseline 
As baseline 
Shanghai 
ChestHosp  
44 
Maximum axial 
diameter 
\ Non-calcified nodules Nodule(s) ≥4mm Nodules <15mm: mean 
diameter increase (Average of 
length and width) ≥ 2mm in 
SNs/NSNs/solid in PSNs; 
Nodules ≥15 mm: mean 
diameter increase ≥15%  
SNs/PSNs >8mm, and PET-
positive; nodule growth. 
As 
baseline 
As baseline 
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China 
FeasiRCT 45, 
56 
NS NS NS NS NS NS NS 
Abbreviations: SN, solid nodules; PSN, partially solid nodules; NSN, non-solid nodule; NS, not specified; NA, not applicable or not yet available. 1 Individuals with LDCT positive results need to be recalled to further 
radiological or pathological examinations apart from the pre-planned rounds. For example, in an annually screening project, individuals will have a LDCT in 6 months if with nodules ≥ 5mm, but have a LDCT one 
year later if with 3-5mm nodules; we define 5mm as the positive threshold, not 3mm. We redefined the definition here due to some discordances among these studies. 2 Of which individuals undergoing invasive 
procedures directly. 3 BRELT1 applied the Mayo Clinic risk model in nodules >8mm for pre-test malignancy risk prediction. 
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Searching Strategies for Lung Cancer Screening Studies in China 
Database Query (as of 10 September 2018) Items 
Found 
Chinese Database   
Chinese Clinical 
Trial Registry 
((Target disease: lung cancer) AND (Intervention: CT))  
OR 
((Target disease: lung cancer) AND (Registered title: screening)) 
 
Use lung cancer, CT and screening associated Chinese characters. 
 
85 
Chongqing VIP 
database 
Search in Title or Keywords with using ‘lung cancer’ and 
‘screening’ associated Chinese words 
 
1412 
Wanfang Data Search in Title or Keywords with ‘lung cancer’ and ‘screening’ 
associated Chinese words  
657 
China National 
Knowledge 
Infrastructure 
database [CNKI] 
Search in Abstract with ‘lung cancer’ and ‘screening’ associated 
Chinese words 
463 
English Database   
Cochrane Library (lung cancer):ti,ab,kw AND (screening):ti,ab,kw AND 
(CT):ti,ab,kw AND (China):ti,ab,kw 
8 
PubMed ((((((((((("Tomography, X-Ray Computed"[Mesh]) OR "Mass 
Chest X-Ray"[Mesh])) OR computed tomography[Text Word]) 
OR chest X-ray[Text Word])) OR early detection[Text Word]) OR 
screening[Text Word]) OR ((((cancer screening[Text Word]) OR 
early detection of cancer[Text Word])) OR "Early Detection of 
Cancer"[Mesh]))) AND ((((China[Text Word]) OR Chinese[Text 
Word])) AND "China"[Mesh])) AND ((((lung cancer[Text Word]) 
OR pulmonary cancer[Text Word])) OR "Lung 
Neoplasms"[Mesh]) 
148 
EmBase #1  'lung cancer':ti,ab,kw 
#2  'china':ti,ab,kw OR 'chinese':ti,ab,kw 
#3  'screening':ti,ab,kw OR 'early cancer diagnosis':ti,ab,kw OR 
'computer assisted tomography':ti,ab,kw OR 'thorax 
radiography':ti,ab,kw 
#4   #1 AND #2 AND #3 
249 
Web of Science 
(Core Collection 
Library) 
#1   TS=(lung cancer) OR TS=(pulmonary cancer) 
#2   TS=(screening) OR TS=(early detection of cancer) OR 
TS=(computerised tomography) OR TS=(radiography) 
#3  TS=China OR TS=Chinese 
#4   #3 AND #2 AND #1 
549 
 
Lung cancer screening programmes in China (Table 2 & Figure 2) 
In the 1980s, the targeted population mainly focused on occupational workers 74-77, in order to identify 
the possible benefit of early screening by CXR and/or sputum examination. Later in 1992, Cancer 
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Institute and Hospital Chinese Academy of Medical Sciences (CICAMS) 78, 79 had issued a 
prospective occupational cohort with the collaboration of the US National Cancer Institute (NCI) and 
Yunnan Tin Corporation (YTC), targeting radon- and arsenic-exposed tin miners who currently 
worked in or retired from YTC in Gejiu City at Southern Yunnan (referred as the YTC cohort). The 
participants underwent annual sputum cytological examination and CXR scan. This YTC cohort had 
demonstrated moderate or severe atypia in sputum as risk indicators of lung cancer 80, 81. It was an 
important study in the Chinese lung cancer screening history since, as it has demonstrated various risk 
factors attributable to lung cancer in the occupational population. It is still under investigation with 
the aim of identifying potential early biomarkers of lung cancer 79.  
In the 2000s, two institutes - the 5th Affiliated Hospital of Sun Yat-sen University, Zhuhai in 2003 82 
and CICAMS, Beijing in 2006 83 - have participated in I-ELCAP (referring as Zhuhai I-ELCAP and 
Beijing I-ELCAP, respectively). After following the I-ELCAP protocol during 2003-2009, Zhuhai I-
ELCAP has demonstrated a higher proportion of stage I lung cancer (91% vs 67%) and 5-year all-
cause survival (94.2% vs 72.8%) than during 1994-2002 82. Lung cancers were mainly diagnosed in 
the subgroup aged 51-70 years-old 82. In Beijing I-ELCAP 83, when applying risk classification 
according to the National Comprehensive Cancer Network lung cancer screening guidelines (NCCN 
version 1.1, 2012), the lung cancer prevalence in 4690 participants at baseline were not significantly 
different among the high-risk, moderate-risk and low-risk subgroup (0.9% vs 1.1% vs 0.4%). Female 
never-smokers with second-hand smoking (SHS) exposures had a higher detection rate of lung cancer 
compared to male SHS-exposed never-smokers and the NCCN-high-risk subgroup (1.4% vs 0.4% vs 
0.9%). 76% of LDCT-detected lung cancers were at stage I 83. 
Another prospective occupational cohort, the Kailuan cohort, was undertaken by the Kailuan Hospital 
affiliated to the Kailuan Company in Tangshan, Heibei in 2006 84. The ongoing cohort targeted 
employees of the company, aged ≥ 18. These participants received biennial CXR. Its primary aim was 
to investigate risk factors and interventions for cardiovascular, cerebrovascular and other non-
communicable diseases. It provided important evidence on risk factors concerning lung cancer risk, 
including body mass index 84.       
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In around 2010s, a number of LDCT lung cancer screening programmes were instigated (Figure 2, 
Table 2).  Two national programmes granted by the Chinese Central Government were: the Rural 
Cancer Screening Programme (RuraCSP) in 2009 85 and the Cancer Screening Programme in Urban 
China (CanSPUC) in 2012 86. In RuraCSP, the high-risk definitions were different among screening 
sites. The enrolees would have annual LDCT for 3 years. RuraCSP expanded from the very first two 
sites (Tianjin and Xuanwei [Yunnan]) to ten from six provinces in 2015 (including Tianjin, Xuanwei 
[Yunnan], Gejiu [Yunan], Beijing, Sichuan, Zhejiang and Liaoning). The lung cancer detection rate at 
baseline and interval was 1.0% and 0.4%, respectively. In LDCT-detected lung cancers, 39.8% (at 
baseline) and 56.0% (at interval) were at an early stage 87. The 2015 China National lung cancer 
screening (CNS) guidelines 88 and the revised 2018 version 89 were developed upon the RuraCSP 
protocol 87. CanSPUC is a community-based project with annual LDCT screening for five rounds in 
urban residents aged 40-69 (some areas defined ages at 40-74) with high risk of lung cancer 86. 
Definition of high risk is region-dependent. Until 2016, it has covered 18 provinces/municipalities 90. 
In 2018, Hubei Province 91 and Jiangxi Province 92 have also initiated the programme. 31 
provinces/municipalities would be included if possible. The nodule management protocol followed 
that in RuraCSP 85. Both RuraCSP and CanSPUC are feasibility studies and plan to investigate health 
economics of lung cancer screening in the context of China 85-87. Following the two national 
programmes, regional programmes in several municipalities/cities have been consecutively 
conducted, most of which were funded by local government.  
Beijing Municipality 
In Beijing, another feasibility study for both lung and colorectal cancer screening was issued in 
multiple sites by CICAMS again in collaboration with US NCI in 2014 (referred as the China 
FeasiRCT) 45. It randomly allocated participants into three arms and ran for a duration of 3 years45. At 
baseline, the rate of participant appliance to LDCT was 89.0%; and the rate of LDCT results 
suspicious for lung cancer was around 6.0% 45, 93. The results were quite limited. It has been already 
completed by 2017. 
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In 2017, CICAMS has initiated another central government-funded programme, which is concerning 
lung cancer screening, intervention and investigation of management strategies 94. Again in 2018, 
there are two other programmes being funded by the central government: one is a multicentre 
screening RCT and prospective cohort of lung cancer and colorectal cancer, and the other has 
included the lung cancer screening project as a part of it (by personal communication with Professor 
Wu Ning; funding information of both have already been made public online)95  The three are referred 
as Beijing CICAMS programmes.   
Tianjin Municipality 
In Tianjin, a lung cancer screening programme has been initiated in 2012 in Tianjin Medical 
University Cancer Institute and Hospital 96 (referred as Tianjin CancerHosp programme). It is eligible 
for people who are asymptomatic, of ≥40 years-old, tolerant of possible invasive procedures and not 
screened by CT within 1 year. Participants would undergo scans at baseline and at 1 or 2 years after 
baseline. Positive nodule definition were based on NLST and NELSON, that is, non-calcified nodules 
at baseline of average diameter ≥ 4mm or volume ≥50 mm3, or new nodules at interval scans of 
average diameter ≥ 3mm or volume ≥30 mm3. The nodule growth was defined as VDT< 400days or 
percentage of volume change ≥25% based on NELSON. From Feb 2014 to Jun 2016, 650 individuals 
were enrolled for baseline screening and 548 finished interval scans. Six lung cancers (0.92%) have 
been diagnosed. When stratified risk profiles according to NCCN (v1 2016), the lung cancer detection 
rate in the high-risk subgroup (0.75%, 2/265) was lower than the moderate- and low-risk subgroup 
(1.04%, 4/385) though non-significant. Female non-smokers (1.59%, 2/126) had a non-significant 
higher detection rate of lung cancer than male smokers (1.04%, 4/383) 96. In this preliminary report, 
computer-aided detection (CAD) volume measurement was more sensitive in detecting nodule growth 
than average diameter measurement 96. The project has been completed by 2017 and undergoing 
follow-up at present. Its final results haven’t been published to date. 
In 2017, Tianjing Municipal Commission of Health and Family Planning supported a screening 
programme of four common cancers in Tianjin – lung cancer, breast cancer, liver cancer and stomach 
cancer 97 (Referred as Tianjin 4-Cancer programme ). The programme was also conducted by Tianjin 
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Medical University Cancer Institute and Hospital. Hexi District and Jinzhou District were the pilot 
sites. In last year, 52092 community residents underwent risk assessment, of which 992 were at high 
risk. 54 individuals were suspicious of lung cancer by LDCT. 14 was surgically diagnosed and the 
other 35 have been followed-up closely. The programme plans to cover up to 7 districts in 2018 97.        
Shanghai Municipality 
In Shanghai, multiple community-based screening programmes have been issued. Fudan University 
Shanghai Cancer Centre has conducted a prospective study in selected communities from Minhang 
District in 2013 to evaluate the efficacy of LDCT screening in both smokers and non-smokers (the 
Shanghai CancerHosp cohort) 36. The eligibility criteria are asymptomatic individuals aged 50-80 
years with tolerance of possible surgery, no malignancy history in the last 5 years and ≥1 risk factors 
as following: current/former smokers (≥20 pack-years, quitting <5 years if former smokers), never-
smokers with other risk factors (e.g. lung cancer family history, kitchen fume exposure, or dust 
exposure). The entry criteria is very similar to the CNS (2015/2018), except a higher stopping age (vs 
an upper age of 74 in the CNS [2015/2018]). Participants would have annual LDCT scans. The lung 
cancer prevalence at baseline was 0.2%; and the incidence rate (/100,000 person-years) was 159.06 in 
smokers and 336.97 in non-smokers, indicating a marginally significance 36.  
Shanghai Chest Hospital, Shanghai Jiaotong University, has conducted a community-based RCT in 
Xuhui District (referring as the Shanghai ChestHosp RCT) in late 2013 44. Asymptomatic participants 
aged 45-70 would be eligible if with any of the risk factors including an exposure history of smoking 
consumption (≥20 pack-years, quitting ≤ 15years if former smokers), passive smoking, cooking oil 
fumes, occupational history or family history of cancer 44. Compared to NLST criteria, it also had a 
lower age eligibility (55-74 in NLST), yet a broader entry criteria than NLST (only age and smoking 
exposure included in NLST) 44, 49. It defined nodule diameter ≥ 4mm as a positive result as NLST. The 
nodule management for positive nodules followed the National Comprehensive Cancer Network 
(NCCN 2014.V1) guidelines 44. In the LDCT arm, the baseline results were quite similar to that of 
NLST in the aspects of positive nodule rate (22.9% vs 27.3%) and lung cancer detection rate (1.5% vs 
1.0%), but the former had a higher early-stage lung cancer rate than the latter (Stage I: 94.1% vs 
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54.1%) 44, 49. In addition, only 7.1% of its participants were NLST eligible; in its NLST-ineligible 
subgroup of the LDCT arm, the lung cancer detection rate was 1.3% in males and 1.4% in females. 
The information in the baseline result suggested that individuals with passive-smoking exposures and 
other risk factors should not be ignored in Chinese lung cancer screening 44.  
Shanghai Changzheng Hospital has issued a collaborative programme with other six hospitals located 
in Shanghai in the same year 98, 99 (referred as Shanghai ChangzhengHosp programme). 
Asymptomatic participants of any age from physical examination centres in seven tertiary hospitals 
and their surrounding communities would be enrolled into the study. Positive nodule was defined as 
any nodule of any size including calcified nodules. In the preliminary report, 14 506 individuals aged 
between 26-90 years underwent LDCT scans. The positive rate of detected nodules (of any size) was 
29.89%; the overall lung cancer prevalence was 1.23%. 81.09% of the detected lung cancers were at 
stage I; 52.94% were diagnosed in nonsolid nodules 98.  
In 2016, an international collaborative, multicentre programme between China and Netherlands has 
been initiated. The programme will help to assess three diseases of the thorax (lung cancer, 
cardiovascular disease and chronic obstructive pulmonary disease) by using one-stop CT imaging 
technology in the context of LDCT screening. It has been funded by central government. There are 
three study sites in China including: Shanghai Changzheng Hospital, Shanghai General Hospital and 
Tianjin Medical University Cancer Institute & Hospital. It has been named Netherlands-China Big-3 
Screening, short for NELCIN-B3. Big-3 here stands for the ‘big’ three diseases and it will run until the 
end of the year 2020 99, 100.    
In addition, Baoshan District Commission of Health and Family Planning has supported a 
community-based screening programme to target 70 000 elderly people (≥75 years-old, or ≥65 years-
old yet with cough/expectoration ≥2 weeks and abnormal CXRs) within this district in March, 2018 
(referred as the Shanghai Baoshan programme). It will last until the end of 2018 101. As of September 
2018, 63 769 individuals have been assessed and 14 005 have undergone CT scans 102.    
Chengdu, Sichuan Province 
 84 
 
In Chengdu City, Sichuan Province, West China Hospital has conducted a retro-prospective cohort 
from 2006, to recruit a population from corporations or industry team groups (referred as the Chengdu 
WCH cohort). The participants would undergo annually physical examinations with CXR or LDCT. 
The accumulative detection rate of lung cancer was 0.06% in the CXR group and 0.89% in the LDCT 
group after five annual scans, thus demonstrating LDCT is more sensitive in detecting lung cancer. 
Researchers stratified participants into risk groups according to recommendations of the American 
Association for Thoracic Surgery (AATS) guidelines in 2012 103 or the Chinese Society of Radiology 
(CSR) in 2015 104. The detection rate of lung cancer in AATS- and SCR-eligible subgroups would be 
higher than the overall detection rate, either in the LDCT or CXR group. The results haven’t been 
published yet.  
Guangzhou, Guangdong Province 
The Guangzhou Medical University First Affiliated Hospital have conducted screening programmes 
consecutively with the support of the Guangzhou municipal government (referred as Guangzhou 
GMU-1stHosp programme) 105, 106. In Dec 2015, it initiated a lung cancer screening project by using 
LDCT scan and serum biomarkers. The programme targeted low-income citizens aged ≥ 50 years in 
Guangzhou. However, the positive response rate was low 106. In June 2017, a separate demonstration 
project was conducted to target 120 000 residents aged 50-74 with a high risk of lung cancer in 
Yuexiu District. High risk of developing lung cancer was defined as long-term smokers (20 pack-
years, quitting ≤ 5 years if former smokers) or individuals with a family history of lung cancer. Until 
Dec 2017, the programme has enrolled and scanned 808 eligible participants, of which 18 were 
suspicious of lung cancer and 5 were pathologically diagnosed 105. The Guangzhou Medical 
University First Affiliated Hospital established a collaborative group with other institutes and 
hospitals to facilitate the diagnosis and treatment of lung cancer. It also build a partnership with China 
Mobile, the biggest telco in China, to establish a digital platform in the aim of prioritizing registration, 
recruitment, follow-up and data collection 105, 106. The expenditures of the programme has been mostly 
“covered by the city government, with the rest shouldered by the hospital and the Guangzhou Charity 
Association” 106. Both low-income individuals aged ≥ 50 and high-risk participants aged 50-74 in the 
 85 
 
selected district will get free screenings. Low-income participants can also claim a pension for the 
follow-up tests if with positive screening results 105. Since Nov 2017, the programme has also 
provided a one-fifth discount on the screening costs for other residents aged ≥ 40 years in the whole 
province if they are volunteered to take part in 105.  
There would be a significant number of expenses from the screening per se, follow-up tests, public 
education, health-care specialist/staff training, limited availability of screening and data collection 
optimism; all of the factors above are barriers which would compromise “expanding the screenings to 
a wider population” in a populous and aging country 106. A working group from Milken Institute, a 
non-profit organisation aiming at improving global prosperity and advancing affordable healthcare, 
case-studied the Guangzhou GMU-1stHosp programme and recommended some innovative and 
potentially viable financing models targeting the barriers above. They proposed a comprehensive 
demonstration project to target the 40-80 year-olds in Guangzhou, by integration with financing 
considerations in population selection, price subsidies, hospital selection, awareness campaign and 
data tracking (referred as the Guangzhou Financing project). The design of the study will be further 
discussed in their subsequent working sessions 106. 
Qinghai Province 
A number of other programmes sponsored by charity groups have also been conducted, e.g. Shanghai 
Cijing Charity Fund has supported a lung cancer screening project within deprivation areas in Qinghai 
since 2016 (referred as the Qinghai SH-RenjiHosp programme) 107, 108. The programme targets  high-
risk individuals who are eligible with the criteria:  aged 50-74; or aged ≥35 but with ≥ 1 risk factors 
including long-term smokers, long-term exposure to severe air pollution, radiation, coal smoke, 
kitchen fume, with a family history of lung cancer, a personal history of cancer or pulmonary 
diseases. The programme was initiated in Shanghai Jiaotong University Affiliated Renji Hospital. It 
has also been planned to target underserved populations in other provinces including Henan, Xinjiang 
and Shandong Province 107, 108.  
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Figure S1 Historical events associated with tobacco and tobacco control in China, the UK and the US.  
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Figure S2 Timeline of selected nationally/sub-nationally representative surveys or important 
historical events associating with tobacco use (above the arrow) and cancer (below the arrow), and 
development of cancer registrations in China.  
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